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Abstract  
The aryl hydrocarbon receptor (AhR) binds a wide range of structurally diverse compounds 
such as halogenated dibenzo-p-dioxins, dibenzofurans and biphenyls which are abundant in 
the environment. Activation of AhR leads to the regulation of a battery of xenobiotic 
enzymes including cytochrome P4501A1 (CYP1A1). The purely chlorinated compounds 
feature in the World Health Organisation’s (WHO) evaluation of dioxin-like compounds 
derived from a meta-analysis of previous potency data (toxic equivalency factors; TEFs), 
which is used to calculate the total toxic equivalence (TEQ).  
The first aim of this work was to fully characterise the three most environmentally abundant 
mono-ortho-substituted polychlorinated biphenyls (PCBs; PCB 105, 118 and 156) including 
a re-evaluation of their putative antagonistic effects on AhR. Secondly, the effects of mixed 
halogenated compounds, currently not included in the TEQ estimation, were investigated as 
AhR agonists based on their environmental exposure and potency. Quantitative real-time 
PCR (qRT-PCR) was used to measure the AhR mediated induction of CYP1A1 mRNA in rat 
H4IIE and human MCF-7 cells. The three mono-ortho-substituted PCBs were shown to be 
antagonists of rat and human AhRs, an effect which is not currently included in the TEQ 
calculation. 2-bromo-3,7,8-trichlorodibenzo-p-dioxin (2-B-3,7,8-TriCDD) was found to be an 
AhR agonist that was 2-fold more potent than 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD; 
considered one of the most potent in the environment). The majority of the other tested 
compounds were found to be within 10-fold less potent than TCDD and could therefore have 
a significant impact on the TEQ. A family of putative AhR agonists from AstraZencea were 
investigated and one of the compounds was shown to be a highly potent AhR agonist, 5-fold 
more potent than TCDD at inducing CYP1A1. 
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The results indicate approximately a 15-fold higher sensitivity of the rat cell line to the AhR 
agonists compared with the human cell line. It is not currently understood what confers these 
differences whether it is a difference in the mechanism of activation or purely as a result of 
differences in the AhR sequence. The mechanism of action is thought to be the same in both 
species and the associated proteins are both comparable. The amino acid sequences of the 
AhR, in both human and rat are quite similar but may play a significant role in the differences 
observed between species. Therefore in order to directly compare the rat and human AhRs, 
two novel cell line models were created using an inducible expression system to infect an 
AhR-deficient mouse cell line with a replication-defective virus containing either the rat or 
human AhR. The AhRs were activated with various compounds to induce mouse CYP1A1. 
The CYP1A1 mRNA was measured using qRT-PCR but showed that the two AhR genes 
were not expressed enough to produce a response detectable above the background CYP1A1 
induction by the low levels of mouse AhR.  
This research has shown that these dioxin-like compounds can have very different potencies 
at AhRs in different species so it is not always possible to predict the potency in humans 
from in vitro or rat in vivo toxicity data. Furthermore, it has identified compounds, such as 
5F-203, which are significantly more potent in human compared to rat. This thesis provides 
information on the AhR species differences between human and rat that can be applied to risk 
assessment. 
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1. Introduction 
1.1 Activation of the Aryl hydrocarbon receptor (AhR) 
1.1.1 Aryl hydrocarbon receptor (AhR)  
The aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor (Okey et al., 
1994) located in the cytosol first identified by Dr Alan Poland (Poland et al., 1976). Nebert 
and co-workers first recognised a link between 3-methylchloranthrene (3-MC) and aryl 
hydrocarbon hydroxylase (AHH) induction (Nebert and Gelboin, 1969). Previous work by 
Poland and co-workers showed a correlation between some chlorinated dibenzo-p-dioxins 
(PCDDs) and the subsequent induction of AHH, showing that several of the compounds were 
potent inducers of AHH (Poland and Glover, 1972). The paper also highlighted that 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) was the most potent of the compounds tested. Further 
work showed that TCDD bound to high affinity sites in the cytosol which was later shown to 
be the AhR (Poland et al., 1976). AHH was subsequently referred to as cytochrome P450 
1A1 (CYP1A1).  
 
 
 
 
 
Figure 1.1: Structure of AhR - Adapted model of AhR structure from Denison et al. (2002). bHLH: basic helix-loop-helix, 
NLS: Nuclear localization sequence, PAS: Per-Arnt-Sim; A: Per A; B: Per B, hsp90: heat shock protein-90KDa, AhR: Aryl 
hydrocarbon receptor, Arnt: Aryl hydrocarbon Receptor Nuclear Translocator, DRE: Dioxin responsive element. 
The structure of the AhR, which is shown in Figure 1.1, comprises of a basic-helix-loop-helix 
domain (bHLH) located at the n-terminus of the protein. This is followed by the Per-Arnt-
Transformation 
A B 
bHLH PAS Domain Q-rich 
Transactivation 
AhR:Arnt:DRE Complex 
formation 
NLS Ligand and Hsp90 
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Sim protein domain (PAS). The PAS domain is made up of three protein domains, known as 
Per (period circadian protein), Arnt (aryl hydrocarbon receptor nuclear translocator protein) 
and Sim (single-minded protein). A protein domain is a part of a protein sequence that can 
form and fold independently of the main protein sequence. The three domains which make up 
PAS have been individually identified in a variety of other proteins in several different 
organisms but together they function as a RedOx signal sensor (Taylor and Zhulin, 1999). 
AhR is part of the (bHLH/PAS) family of transcription factors (Gu et al., 2000). The bHLH 
and PAS domains are associated with ligand binding, binding to the chaperone proteins and 
formation of the transcription binding complex with Aryl hydrocarbon Receptor Nuclear 
Translocator (Arnt).  
 Rat Human Mouse 
    Chromosome location 6q16 7p15 12a3 
mRNA length 2538 bp 2547 bp 2418 bp 
Amino acid length 845 aƗ 848 aƗ 805 aƗ 
Location of LBD 234 – 401 aƗ2 236 – 403 aƗ2 230 – 397 aƗ1 
Table 1.1: Comparison of the three AhR proteins of rat, human and mouse – Data was taken from the NCBI website 
(www.ncbi.nlm.nih.gov), accessed on 28/06/2012. 1location based on research by Fukunaga et al., 1995. 2Theroetical 
position based on comparison with the mouse AhR LBD location. DƗDPLQRDFLGUHVLGXH (stop codon not included). 
Table 1.1 shows some of the basic comparisons between rat, human and mouse AhR proteins 
(a more detailed AhR comparison is shown in section 1.1.2 and comparison of the homology 
of AhR and its chaperone proteins is shown in Table 4.6). The data shows that all of the 
proteins are similar size with binding domains in similar locations demonstrating the high 
homology between the three species. In rats, the AhR has been found in most tissues with the 
highest concentrations found in the thymus, liver, lung and kidney (Carlstedt-Duke, 1979; 
Carver et al., 1994a). In humans, high concentrations of AhR can be found in the placenta, 
lung, spleen and heart, with limited levels in liver, pancreas and kidney (Dolwick et al., 1993; 
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Yamamoto et al., 2004). The AhR has been found in a wide range of mammalian and non-
mammalian species and is highly conserved (section 1.1.2; Reviewed by Hahn, 1998). 
Several attempts have been made to ascertain the structure of the AhR ligand binding domain 
(LBD) either practically (Helaly, 2011), with limited success, by computer modelling of the 
binding domain (Bisson et al., 2009; Denison et al., 2002; Jacobs et al., 2003; Pandini et al., 
2007; Procopio et al., 2002) or by ligand binding prediction studies (Lo Piparo et al., 2006; 
Petkov et al., 2010; Waller and McKinney, 1995) to estimate binding affinity and/or efficacy 
of compounds based on their structure. Helaly (2011) attempted to express the 
Caenorhabditis elegans (C. elegans) AhR LBD in several expression systems such as yeast 
and bacteria, but was either unable to obtain enough protein in its ligand-bound form or 
produced soluble protein yields too low for structural studies. Lo Piparo et al. (2006) did a 
virtual screening to predict AhR binding and produced a model, based on the dibenzo-p-
dioxin structure, of which parts of the ligand are important for receptor binding. They 
wrongly identified 2,3,7-tribromodibenzo-p-dioxin as the most toxic compound, as the 
experimental data set was based on binding affinity not actual potency. However the model 
did show that positions 4, 6 and 7 had an important role in the potency of the compound 
(Figure 1.2A). They also showed that the dibenzo-p-dioxin structure of TCDD was strongly 
related to the toxicity of the compound. The mouse AhR LBD has been identified as located 
approximately between amino acid residues 230-421 (Coumailleau et al., 1995) or 230-397 
(Fukunaga et al., 1995) which is just less than 25% of the total size of the AhR protein 
(Coumailleau et al., 1995). Denison et al. (2002) and Procopio et al. (2002) developed 
theoretical models of the mouse AhR LBD based on the structures of other proteins 
belonging to the PAS family. This theoretical mouse AhR LBD is shown in Figure 1.2B 
(Denison et al., 2002). 
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Figure 1.2: Computer generated prediction of ligand interaction and the AhR – (A) The putative individual 
contributions of one of the more toxic compounds, 2,3,7-tribromodibenzo-p-dioxin. Simplified figure taken from Lo Piparo 
et al. (2006). The colours at the red end of the spectrum reflect poor contributions whereas those at the green end (yellow, 
green-blue, and green) reflect favourable contributions (grey has no effect). (B) The predicted LBD of mouse AhR (with 
TCDD interaction) based on the structures of various PAS related proteins taken directly from Denison et al. (2002). 
The AhR has been shown to exist in ancient invertebrate evolution demonstrating its 
importance for the immune system, further established by its effect on the liver and immunity 
when removed from the animal system (Fernandez-Salguervo et al., 1995; Hahn et al., 1997; 
Schmidt et al., 1996). 
1.1.2 Species differences in the AhR 
Ligands tend to interact with the AhR in the same way regardless of the species with only a 
few exceptions. The most significant difference is the level of potency of a ligand between 
species. For example, previous research has shown that most compounds are significantly 
more potent at activating rat AhR than human AhR (Budinsky et al., 2010; Silkworth et al., 
2005; Xu et al., 2000), with the exception of a few atypical compounds (Bazzi et al., 2009, 
Bucklund and Ingelman-Sundberg, 2004).  
1 
4 6 
7 
8 
9 
3 
2 
A B
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Figure 1.3: Complete amino acid sequences of mouse, rat and human AhR– Sequences were taken from the National 
Centre for Biotechnology Information website on 22/9/2011. The average PAS domain was estimated to be around 100-200 
aƗ from the start. The green highlighted area indicates the ligand binding domain (Burbach et al., 1992; Coumailleau et al., 
1995; Crews et al., 1988; Ema et al., 1994; Fukunaga et al., 1995; Hahn et al., 1997).  
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The mechanism of action is thought to be the same in all mammalian species and the 
associated proteins such as Hsp90 and Arnt are thought to be very similar (Chen et al., 2006; 
Hord and Perdew, 1994). The amino acid sequences of human and rat AhR share a high 
idenity with the ligand binding domain and the chaperone protein interacting domains being 
particularly similar (Table 4.6). What small differences are left may play a significant role in 
the differences in ligand potency observed between different species (Denison et al., 2002; 
Hahn et al., 1997). Figure 1.3 compares the amino acid sequences of mouse, rat and human 
showing that there is significant conservation between species. The bHLH domains are 
highly conserved with 100% between rat and mouse as well as 98% between rodent and 
human. Also highlighted are the LBDs (based on the mouse AhR LBD; Fukunaga et al., 
1995), which show that the two rodents share 97% conservation of amino acids, with both 
species sharing 85-87% idenity with the human LBD (Hahn et al., 1997). The AhR protein 
can be found in other non-mammalian species such as the nematode C. elegans where it still 
shares up to 46% identity (Powell-Coffman et al., 1998). 
1.1.3 Mechanism of action 
When AhR is not bound to a ligand, chaperone proteins keep the binding site of the receptor 
open and in the correct shape ready for activation. This AhR complex exists as a tetrameric 
complex consisting of a heat-shock protein 90 (Hsp90) dimer, immunophilin-like associated 
protein 2 (XAP2: X-associated protein 2 or AIP: Aryl hydrocarbon receptor interacting 
protein) and a 23KDa co-chaperone protein which appears to interact more with the Hsp90 
called the Hsp90 accessory protein (p23; PTGES3: Prostaglandin E synthase 3; Bell and 
Poland, 2000; Carver et al., 1994b; Carver and Bradfield, 1997; Kazlauskas et al., 1999; Ma 
and Whitlock, 1997; Meyer et al., 1998; Perdew, 1988; Petrulis and Perdew, 2002; Shetty et 
al., 2003). Hsp90 is one of the most abundant proteins expressed in cells and shows 
significant conservation between species (Table 4.6; Chen et al., 2006; Southworth and 
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Agard, 2008). The AhR complex resides in the cytoplasm of the cell until it is activated by an 
AhR ligand. Successful activation of the AhR leads to translocation of the AhR:ligand 
complex to the nucleus.  
 
 
 
 
 
Figure 1.4: Mechanism of ligand-dependant activation of the AhR – 1. Ligand binds to the AhR complex in the 
cytoplasm. 2. AhR:ligand complex translocates to the nucleus. 3. Chaperone proteins dissociate from AhR, allowing it to 
bind to Arnt. 4. AhR:Arnt:ligand complex binds to DRE binding sites on DNA, transcribing several xenobiotic enzymes. 
Once inside the nucleus, the chaperone proteins dissociate from the AhR:ligand complex and 
are replaced by the Arnt protein (Hankinson, 1994). This new AhR:Arnt:ligand complex then 
binds to specific locations on the DNA known as the dioxin responsive elements (DREs) or 
xenobiotic responsive elements (XREs). These are specific locations mainly upstream of the 
site of transcription and have the sequence of 5’-TNGCGTG-3’ (Denison et al., 1988). 
Successful binding at these sites leads to the transcription of a battery of xenobiotic 
metabolism genes including CYP1A1, CYP1A2 and glutathione s-transferase (Denison and 
Whitlock, 1995; Hankinson, 1995; Nebert et al., 1981, 2004; Whitlock, 1999). Figure 1.4 
demonstrates a simplified mechanism of action of the AhR. The AhR is activated by a variety 
of endogenous and exogenous compounds with the most characterised being TCDD. There 
are no known endogenous ligands of significant potency (based on their concentration), but 
there are a number of naturally occurring compounds that interact with the receptor as well as 
exogenous environmental pollutants such as dibenzo-p-dioxins, dibenzofurans and biphenyls.  
1. 2. 
3. 
4. 
Cytoplasm Nucleus 
= AhR ligand 
= Chaperone proteins 
= AhR 
= Arnt 
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1.1.4 Cytochrome P4501A1 (CYP1A1) 
Cytochrome P450 is a super-family of hemoproteins responsible for the metabolism of 
thousands of endogenous and exogenous compounds (Guengerich, 1991; Nebert and 
Gonzalez, 1987; Whitlock, 1999). Only activation of the AhR will induce the transcription of 
certain P450 enzymes such as CYP1A1 (Behnisch et al., 2001; Nebert et al., 2000, 2004; 
Schmidt et al., 1996; Vanden Heuvel et al., 1994). The human and rat CYP1A1 genes are 
located on chromosome 15 (15q24.1) and chromosome 8 (8q24), respectively, which encodes 
the P450 enzyme CYP1A1. CYP1A1 is found at low basal levels in most tissues in mammals 
(Benedict et al., 1973). Induction of xenobiotic enzymes, in the presence of xenobiotics, is an 
adaptive process facilitating the detoxification of the xenobiotics. CYP1A1 induction does 
not necessarily imply a toxic response but is nevertheless a useful marker of AhR activation 
(Gonzalez et al., 1996). Increased activation of the AhR would imply a more efficacious 
agonist so can therefore be used to estimate the toxic potency of AhR agonists. It can be 
assumed that increased activation of the AhR would lead to an increased induction of 
CYP1A1 which can be detected by a variety of methods. CYP1A1 induction is one of the 
most characterised endpoints of AhR activation and is a highly inducible marker allowing 
detection of either the CYP1A1 mRNA or protein (Whitlock, 1999; Whyte et al., 2004). 
TCDD has been shown to increase induction of CYP1A1 mRNA by up to 500-fold above 
basal levels (Bazzi, 2008; Wall, 2008). CYP1A has been identified in a variety of species, 
including rat and human, although some significant interspecies differences in concentration 
have been noted (Ikeya et al., 1989; Martignoni et al., 2006). CYP1A1 binds to TCDD, with 
high affinity, although it does not metabolise it, which could be the reason that TCDD has a 
long half life in humans, in addition to its chemical stability (Inouye et al., 2002).  
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1.1.5 Other xenobiotic metabolism genes (CYP1B1 and CYP1A2) 
Activation of the AhR leads to the induction of a gene battery which includes CYP1B1 and 
CYP1A2 (Hankinson, 1995; Iwanari et al., 2002; Walker et al., 1999; Whitlock, 1999). In the 
same way as CYP1A1, CYP1B1 is regulated solely by the AhR and is induced upon 
successful AhR activation although it is not as highly induced as CYP1A1 (Santostefano et 
al., 1997; Walker et al., 1998, 1999). The gene and its connection with AhR activation was 
only identified relatively recently and encodes the protein CYP1B1 which is involved in 
phase 1 drug metabolism (Bhattacharyya et al., 1995; Lewis et al., 1999; Sutter et al., 1994; 
Walker et al., 1995). CYP1B1 is normally expressed at high levels in the adrenal gland 
(Walker et al., 1995) although CYP1B1 and CYP1A2 are expressed in various tissues at low 
basal levels (Drahushuk et al., 1996; Edwards et al., 1998; Iwanari et al., 2002). CYP1A1 
and CYP1A2 only share a 40% identity with CYP1B1 therefore the protein was assigned to a 
new CYP1 subfamily (Murray et al., 2001; Nelson et al., 1996). CYP1B1 is highly expressed 
in human tumours; thus, it may have important implications in the development of anti-
cancer drugs (Liehr and Ricci, 1996; McFadyen et al., 2001; Murray et al., 2001). CYP1A2 
is not exclusively induced by the AhR showing that it would be a non-specific biomarker of 
AhR activation. A wide variety of compounds have been shown to induce CYP1A2 but not 
CYP1A1 (or presumably activate the AhR). Caffeine was shown to induce CYP1A2, which 
in turn is responsible for metabolising caffeine as the presence of CYP1A2 increased the 
elimination of caffeine from the blood of wild-type mice, 7-fold above CYP1A2 knock-out 
mice (Buters et al., 1996; Chen et al., 1996). CYP1A2 mRNA has been found at significantly 
higher basal levels (2- to 30-fold) compared with CYP1A1 but is less inducible which 
reduces its sensitivity as a biomarker for AhR activation (Drahushuk et al., 1996; Schweikl et 
al., 1993). There is also a suggestion that TCDD binds to CYP1A2 but the enzyme does not 
metabolise it (Olson et al., 1994). The protein has been found at very high levels in the liver 
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compounding the reasons why TCDD is also found at high concentrations in the liver 
(Diliberto et al., 1997). There is also suggestion that the levels of CYP1A2 are significantly 
different between rat and human, which binds TCDD thus reducing the availability of the 
compound to bind to the AhR possibly explaining some of the potency differences witnessed 
between these species (Ikeya et al., 1989; Shinkyo et al., 2003). 
1.2 Toxicity and AhR-mediated response 
1.2.1 Toxic effects 
Activation of the AhR is required to instigate the toxic effects of AhR agonists. This is 
demonstrated in AhR-null mice, which are resistant to the acute toxicity of TCDD (Gonzalez 
and Fernandez-Salguero, 1998; Lin et al., 2002; Stohs and Hassoun, 2011). TCDD-like AhR 
agonists all undergo the same mechanism of AhR activation and thus have similar toxic 
effects. TCDD induces the transcription of a diverse battery of xenobiotic enzymes including 
CYP1A1 and CYP1A2 as well as their dependant activities, glutathione s-transferase and 
NAD(P)H quinine oxidoreductase (Safe, 1986). Nevertheless, CYP1A1 and CYP1A2 have 
only minimal effect on TCDD metabolism (Olson et al., 1994). Some of the most notable 
endpoints of TCDD toxicity include chloracne, which is an acne-like eruption of blackheads 
(Tindall et al., 1985; Schulz, 1968), as well as carcinogenesis (NTP TR-521, 2006; Manz et 
al., 1991; Huff, 1992). TCDD is described as a reproductive toxicant (Mann, 1997) in 
addition to causing hepatotoxicity, which is drug induced damage of the liver and thymic 
atrophy, which inhibits the development of the immune system in rat offspring (Gupta et al., 
1973; Vos et al., 1974). Wasting syndrome, where the body weight is drastically reduced 
including muscle and fatty tissue mass, has been found as an effect of various concentrations 
of TCDD (Max and Silbergeld, 1987; Pohjanvirta and Tuomisto, 1994).  
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1.2.2 Structure-activity relationships 
AhR agonists have been shown to increase the risk of cancer, cause long-term reproductive 
issues and liver damage (Pohjanvirta and Tuomisto, 1994). Although not necessarily as a 
direct result of AhR interaction, it has been shown that several different families of AhR 
agonists can cause these illnesses and that generally only successful activation of the AhR 
can lead to increased bioaccumulation and health problems (Brown et al., 1994; Gonzalez 
and Fernandez-Salguero, 1998; Lin et al., 2002; Stohs and Hassoun, 2011). The most 
characterised of these compounds is TCDD and it is generally accepted that compounds with 
a similar shape and polarity (at least where it binds to the receptor) will have similar TCDD-
like effects. Research has shown that the most persistent and prevalent compounds such as 
PCDDs, polychlorinated dibenzofurans (PCDFs) and polychlorinated biphenyls (PCBs) can 
have very different affinity and efficacy depending on the number and location of the 
chlorine atoms. 
 
 
 
 
 
Figure 1.5: Overlay of TCDD, TCDF and PCB 126 – Demonstration of the similarities between the three most 
characterised families of AhR agonists, TCDD (black), 2,3,7,8-tetrachlorodibenzofuran (TCDF; red) and 3,3’,4,4’,5-
pentachlorobiphenyl (PCB 126; blue). 
Figure 1.5 shows the overlay of the three most potent compounds in their families; TCDD, 
2,3,7,8-tetrachlorodibenzofuran (TCDF) and 3,3’,4,4’,5-pentachlorobiphenyl (PCB 126). 
TCDD and TCDF both have four chlorine atoms positioned equally on the compounds at 
positions 2, 3, 7 and 8. However TCDD is estimated to be about 10-fold more potent than 
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TCDF (Haws et al., 2006), which is likely due to the reduced size of the dibenzofuran 
backbone as it only has one ether group (R-O-R). The most potent PCB congener is PCB 126 
which has five chlorines positioned 3, 3’, 4, 4’ and 5. Despite the increase in chlorine 
substituents, the compound has the same potency as TCDF. This may be due to the reduced 
size of the biphenyl backbone structure due to the complete lack of oxygen between benzene 
rings and therefore an extra chlorine atom is required for the molecule to match the shape and 
size of TCDD. 
1.2.3 Describing agonism and antagonism 
 
The initial activation of the AhR depends on two important qualities of the ligand; affinity 
and intrinsic efficacy. The affinity is the property of attraction between a ligand and the 
receptor. Intrinsic efficacy is used to describe the property of agonism and relates receptor 
occupancy with receptor activation (Kenakin, 1997). A potent agonist is a compound which 
binds to the receptor and activates it meaning it has both a strong affinity and a high efficacy. 
A compound can have a good binding affinity for the receptor but a low efficacy resulting in 
no activation of the receptor. This type of compound is known as an antagonist and due to the 
relatively high affinity, can prevent an agonist from binding to the same receptor complex, 
reducing the agonist’s ability to produce a response, known as its potency. Potency is the 
measure of the activity of the ligand required, in relation to concentration, to produce an 
observable effect (Jenkinson et al., 1995). A partial agonist has both agonistic and 
antagonistic properties. This means that some of the molecules of the compound will bind to 
the receptor and activate it, whereas other molecules will bind but the receptor will remain 
dormant. One possible reason to account for this lack of activation is the orientation of the 
molecule as it binds to the receptor as activation requires a perfect fit which may not occur 
with a partial agonist/antagonist. The effective concentration that gives 50% of the maximal 
response (EC50) can be used as a measure of the potency of a compound. 
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1.2.4 Measuring agonism and antagonism 
The putative agonism and antagonism of various compounds can be tested using bioassays 
that measure a particular end-point to produce a concentration-response curve. Figure 1.6A 
shows a concentration-response curve of a potent agonist. The EC50 was calculated as the 
concentration of agonist giving 50% of the maximal induction and can be used as a method 
of comparing between compounds. In order to determine any putative antagonistic properties 
of the compound, a concentration which produces 20% of the maximum induction (Figure 
1.6A) was treated simultaneously with various concentrations of pure agonist. Figure 1.6B 
shows the pure agonist in the presence and absence of a putative partial agonist. At lower 
concentrations of pure agonist, the partial agonist has agonistic properties which induce a 
20% response (as shown in Figure 1.6A). At higher concentrations of pure agonist, the 
antagonistic properties of the partial agonist are easier to identify. The antagonist (partial 
agonist) forces the pure agonist concentration-response curve to the right, reducing the 
potency of the pure agonist to induce a response. 
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Figure 1.6: Calculating agonism and antagonism – Examples of A) agonism and B) partial agonism. VC: vehicle control, 
TC: maximal response of TCDD, AC: antagonist only (partial agonist) control (concentration that gives 20% response). 
Graphs are examples and therefore do not represent real data or give an accurate representation of the agonism by TCDD. 
The exact method of calculating the EC50s is discussed in more detail in the method (section 
2.4.5) but is essentially the concentration of agonist that gives 50% of the maximal response. 
However in the presence of a partial agonist, this EC50 estimation is slightly different. The 
A B 
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EC50 is then calculated as the halfway point between the background induction (which in 
Figure 1.6B is 20%) and the maximal response (100%). All of the antagonism assays in this 
thesis are calculated in this way. This method will also be used to identify a pure antagonist, 
which is a compound that binds to the receptor but not activate it simultaneously preventing a 
pure agonist from binding and therefore reducing the overall potency of that pure agonist. 
1.3 Ligands of the AhR 
1.3.1 Dibenzo-p-dioxins 
1.3.1.1 TCDD 
TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) is a potent agonist of the AhR belonging to a 
family of halogenated dibenzo-p-dioxin agonists, which are environmental pollutants and are 
colloquially known as dioxins. In the 1970s, TCDD was a by-product of plastic production 
and general industrial manufacture, although this unintentional production has now reduced 
due to regulations (Reviewed by Schecter, 1994). Today, the main source of TCDD is from 
incomplete burning of waste, which is more difficult to control. The environmental levels of 
TCDD have decreased over the last 20 years (Figure 1.7; Aylward and Hays, 2002; Lorber, 
2002).  
 
Figure 1.7: (A) Mean lipid-adjusted TCDD levels from the general population and (B) Predicted lipid-adjusted 
TCDD levels from 1980 onwards – Figures taken from Aylward and Hays (2002). 
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Nevertheless, due to its potency, tight controls of the levels found in food are still required. 
Low concentrations of TCDD are found in fat-containing food, and TCDD can accumulate in 
humans due to a half life of 6-7 years (Aylward and Hays, 2002; Päpke, 1998; Pirkle et al., 
1989; Poiger and Schlatter, 1986). TCDD is lipophilic and accumulates in adipose tissue 
hence the main concentration of TCDD is located in the fatty tissue. Diliberto et al. (1995) 
investigated the distribution of TCDD in rats over a time course of 35 days. The results 
showed that the majority of the TCDD was concentrated in the liver and the adipose tissue 
followed by minor quantities in the adrenal glands and the skin (Diliberto et al., 1995). 
TCDD is the most characterised and amongst the most potent ligands of the AhR, thus 
making the compound ideal as a reference compound (Van den Berg et al., 1998, 2006).  
1.3.1.2 Mixed halogenated dibenzo-p-dioxins (PXDDs) 
Development of Gas Chromatography/Mass Spectrometry (GC/MS) techniques for the 
identification of dibenzo-p-dioxins, dibenzofurans and biphenyls, has lead to the discovery of 
a variety of mixed halogenated compounds in various food samples (Fernandes et al., 2011). 
Table 1.2 shows the concentration of several mixed halogenated compounds in several food 
items, taken from Fernandes et al. (2011), which were calculated using GC/MS. The table 
also gives the structure of dibenzo-p-dioxin and relative potencies (REPs; see section 1.4.2.1) 
calculated by other authors. Several mixed halogenated dibenzo-p-dioxins have been tested 
previously, producing a wide range of REPs for each compound (Behnisch et al., 2003; 
Olsman et al., 2007; Samara et al., 2009). These REPs were calculated in rat H4IIE cells 
using ethoxyresorufin-O-deethylase (EROD) and Dioxin-Responsive-Chemical Activated 
LUciferase gene eXpression (DR-CALUX) techniques. The data suggest that several of the 
compounds, 2-B-3,7,8-TriCDD, 2,3-DiB-7,8-DiCDD and 2-B-1,3,7,8-TetraCDD, could have 
equal or increased potency compared with TCDD. 
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Concentration Milk Soft Cheese 
Marine 
fish 
River 
fish 
Offal - 
Liver 
Shellfish 
(oysters) 
Composite 
vegetables 
 
       
2-B-7,8-DiCDD 0.007 0.021 0.123 0.066 0.045 21.634 0.078 
2-B-3,7,8-TriCDD 0.007 0.008 0.008 0.751 0.056 0.143 0.069 
2,3-DiB-7,8-DiCDD 0.005 0.005 0.005 0.565 0.058 0.468 0.044 
1-B-2,3,7,8-TetraCDD 0.006 0.005 0.007 0.225 0.022 0.031 0.066 
2-B-1,3,7,8-TetraCDD 0.005 0.009 0.007 0.033 0.025 0.037 0.134 
 
       
 
Structure 
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dibenzo-p-dioxin (DD) 
Potency Behnisch et 
al., 2003 
Olsman et 
al., 2007 
Samara et 
al., 2009 
    
2,3,7-TriBDD 0.033 0.081 0.0006 
2-B-7,8-DiCDD - 0.061 - 
2,3,7,8-TetraCDD 1 1 1 
2-B-3,7,8-TriCDD 0.67 1.93 0.72 
2,3-DiB-7,8-DiCDD 0.86 1.00 0.43 
1-B-2,3,7,8-TetraCDD 0.28 - - 
2-B-1,3,7,8-TetraCDD 0.37 1.52 - 
    
Table 1.2: Examples of concentration and potency data for mixed halogenated dibenzo-p-dioxins –The table shows 
concentration data (in ng/kg fat) from food tested for mixed halogenated compounds (Fernandes et al., 2011 supplementary 
data) and potency data shown as REPs (their potency in comparison to TCDD; see section 1.4.2.1; Behnisch et al., 2003; 
Olsman et al., 2007; Samara et al., 2009) was gathered from the literature. Chemical names are organised as follows; 2-B-
7,8-DiCDD = 2-bromo-7,8-dichlorodibenzo-p-dioxin: C = Chlorine (Cl), B = Bromine (Br). 
1.3.2 Mixed halogenated dibenzofurans (PXDFs) 
Previous work had characterised the agonistic properties of TCDF and 2,3,4,7,8-
pentachlorodibenzofuran (PeCDF) in rat H4IIE cells (Bandiera et al., 1984; Wall, 2008). The 
data showed they are strong-medium potency agonists of the AhR with EC50s of 2.02 nM and 
0.13 nM (Bandiera et al., 1984), respectively and neither of the two compounds have any 
antagonistic properties (Wall, 2008). There is evidence of carcinogenic activity of PeCDF 
(NTP TR-525, 2006) especially in a mixture with TCDD (NTP TR-526, 2006) in rats. 
Human exposure to dibenzofurans has been identified in a variety of food samples (Huwe 
and Larsen, 2005; Theelen et al., 1993) and even in human samples (Shen et al., 2009). As of 
the 1st January 2012 (European Commission, 2011), the toxic equivalency factors (TEFs; see 
section 1.4.2.1) for TCDF and PeCDF are 0.1 and 0.3, respectively (Haws et al., 2006; Van 
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den Berg et al., 2006). This project looked at several mixed halogenated dibenzofurans 
(PXDFs), based on the structures of TCDF and PeCDF but with bromine substitutions. There 
is only limited potency data currently available in the literature for PXDFs. Concentration 
data from various food groups (Fernandes et al., 2011) and REPs for several PXDFs, 
calculated using rat cell based bio-assays (Behnisch et al., 2003; Olsman et al., 2007; Samara 
et al., 2009) are shown in Table 1.3. 
Concentration Milk Soft Cheese 
Marine 
fish 
River 
fish 
Offal - 
Liver 
Shellfish 
(oysters) 
Composite 
vegetables 
 
       2-B-7,8-DiCDF 0.005 0.012 0.018 0.045 0.024 0.878 0.579 
3-B-2,7,8-TriCDF 0.005 0.007 0.023 0.346 0.068 0.173 0.077 
2-B-6,7,8-TriCDF 0.005 0.009 0.03 1.031 0.016 0.605 0.075 
2,3-DiB-7,8-DiCDF 0.007 0.009 0.011 0.08 0.147 0.558 0.056 
1-B-2,3,7,8-TetraCDF 0.013 0.005 0.005 0.034 0.052 0.049 0.078 
4-B-2,3,7,8-TetraCDF 0.014 0.012 0.022 0.044 2.454 2.585 0.072 
1,3-DiB-2,7,8-TriCDF 0.007 0.011 0.006 0.023 0.045 0.043 0.004 
 
       
 
Structure 
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Dibenzofuran (DF) 
Potency Behnisch et 
al., 2003 
Olsman et 
al., 2007 
Samara et 
al., 2009 
    
2-B-7,8-DiCDF - 0.000037 - 
2,3,7,8-TetraCDF 0.32 - 0.07 
3-B-2,7,8-TriCDF 0.74 - 0.38 
2-B-6,7,8-TriCDF - - - 
2,3-DiB-7,8-DiCDF - - - 
2,3,4,7,8-PentaCDF 0.5 - 0.46 
1-B-2,3,7,8-TetraCDF - - - 
4-B-2,3,7,8-TetraCDF - - - 
1,3-DiB-2,7,8-TriCDF - - - 
    
Table 1.3: Examples of concentration and potency data for mixed halogenated dibenzofurans –The table shows 
concentration data (in ng/kg fat) from food tested for PXDFs (Fernandes et al., 2011 supplementary data) and potency data 
shown as REPs (their potency in comparison to TCDD; see section 1.4.2.1; Behnisch et al., 2003; Olsman et al., 2007; 
Samara et al., 2009) was gathered from the literature. Chemical names are organised as follows; 2-B-7,8-DiCDF = 2-bromo-
7,8-dichlorodibenzofuran: C = Chlorine (Cl), B = Bromine (Br). 
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1.3.3 Mixed halogenated biphenyls (PXBs) 
1.3.3.1 Non-ortho-substituted PCBs and PXBs 
Non-ortho-substituted PXBs (including PCBs), which can be described as biphenyls that do 
not have a halogenated atom on the ortho-substituted positions on the compound (i.e. 
2,2’,6,6’), have the same mechanism of action as dibenzo-p-dioxins. As with most PCBs, the 
non-ortho-substituted PCBs are associated with an increased risk of cancer (Hemming et al., 
1995). Many PCBs had widespread applications, used as coolants and additives, before they 
were banned in the 1970s once their toxicity and ability to bioaccumulate were identified. In 
this study PCB 126 will be tested as a comparison for the other, less studied PCBs. PCB 126 
is the most potent and well characterised of the PCBs. Previous work has shown that this 
compound is a potent agonist of the AhR and has no antagonistic properties (Haws et al., 
2006; Wall, 2008). Based on the TEF guidelines produced on the potency of dioxin-like 
compounds, PCB 126 has a value of 0.1 (Haws et al., 2006; Van den Berg et al., 2006), 
suggesting it is approximately 10-fold less potent at inducing TCDD-like effects but is still a 
very potent AhR agonist (Peters et al., 2004; Sanderson et al., 1996; Silkworth et al., 2005). 
Levels of PXB 126 compounds have been found in a variety of food samples which, 
depending on their potency, may have a significant effect on the TEQ in food (Fernandes et 
al., 2011); for example, river fish had levels of 4’-B-3,3’,4,5-TetraCB (PXB 126B; 1.681 
ng/kg), 3’,4’-DiB-3,4,5-TriCB (PXB 126H; 0.19 ng/kg) and 3’,4’,5-TriB-3,4-DiCB (PXB 
126V; <0.076 ng/kg). The structure of biphenyl is shown in Table 1.4.  
1.3.3.2 Mono-ortho-substituted PCBs and PXBs 
Mono-ortho-substituted PXBs (including PCBs) can be described as biphenyls that contain at 
least on halogenated atom on the ortho-substituted positions on the compound (i.e. 2,2’,6,6’) 
and have been well studied in the past due to their abundance in the environment (Ahlborg, 
1992; Fernandes et al., 2008; Larebeke et al., 2001; Kalantzi et al., 2004; Polder et al., 
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2008a, 2008b; Safe, 1990; Safe, 1994). Research has shown that several mono-ortho-
substituted PCBs possess both agonistic and antagonistic properties (Chen and Bunce, 2004; 
Clemons et al., 1998; Suh et al., 2003). The compounds have been tested in rat H4IIE cells 
(Clemons et al., 1998), trout RTL-W1 cells (Clemons et al., 1998) and fish PLHC-1 cells 
(Hesterman et al., 2000).  
Composite 
sample 
PCB 
105 
PCB 
114 
PCB 
118 
PCB 
123 
PCB 
156 
PCB 
157 
PCB 
167 
PCB 
189 
Ortho- PCBs 
TEQ (ng/kg) 
         
 
Sprat 7.99 0.37 28.27 1.89 2.86 1.01 1.97 0.41 0.55 
Sea Bass 13.03 0.60 51.17 2.15 6.24 1.92 4.32 0.81 0.76 
Wild Turbot 12.95 0.65 50.97 2.26 5.92 2.02 4.39 0.73 0.28 
Wild Dogfish 21.95 1.67 80.44 2.95 10.01 3.12 5.77 1.04 1.32 
Wild Greenland 
Turbot 5.28 0.35 16.16 0.62 1.71 0.56 0.89 0.16 0.37 
Wild halibut 6.49 0.49 22.79 0.68 2.57 0.73 1.45 0.30 0.22 
Wild Whitebait 16.77 0.59 73.85 6.18 8.91 2.28 5.56 1.17 0.71 
Wild Pilchard/ 
Sardines 10.68 0.32 44.77 2.61 5.09 1.69 3.71 0.76 1.20 
Wild Hake 6.80 0.29 23.47 1.29 3.08 1.11 2.13 0.44 0.13 
Fresh Crab 5.16 0.18 18.59 0.87 2.44 1.09 2.03 0.42 0.26 
Farmed Turbot 14.96 0.69 56.62 2.89 6.36 2.10 4.62 0.55 0.18 
Farmed Halibut 12.66 0.44 40.65 1.46 4.63 1.33 2.96 0.48 0.37 
         
 
 
3,3’,4,4’,5-PentaCB (PCB 126) 
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4’-B-3,3’,4,5-TetraCB (PXB 126B) 
 
3’,4’-DiB-3,4,5-TriCB (PXB 126H) 
 
3’,4’,5-TriB-3,4-DiCB (PXB 126V) 
 
3,3’,4,4’,5-PentaBB (PBB 126) 
 
2,3,3’,4,4’-PentaCB (PCB 105) 
 
4’-B-2,3,3’,4-TetraCB (PXB 105) 
 
2,3’,4,4’,5-PentaCB (PCB 118) 
 
4’-B-2,3’,4,5-TetraCB (PXB 118) 
 
2,3,3’,4,4’,5-HexaCB (PCB 156) 
 
4’-B-2,3,3’,4,5-PentaCB (PXB 156) 
 
 
 
 
 
Table 1.4: GC/MS analysis of fish samples detecting mono-ortho-substituted PCBs – GC/MS was used to measure the 
concentrations of a variety of PCBs. Only the data for the most potent mono-ortho-substituted PCBs are included in this 
table. Amounts are in µg/kg fat. The TEQ values have been published previously (Fernandes et al., 2008), individual PCB 
concentrations were taken from supplementary data. Chemical names are organised as follows; 4’-B-3,3’,4,5-TetraCB = 4’-
bromo-3,3’,4,5-tetrachlorobiphenyl: C = Chlorine (Cl), B = Bromine (Br). 
Risk assessment requires both potency and exposure data to fully understand the associated 
risk of the specific compound. A compound with a high potency can be harmless if there is 
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no environmental exposure of that compound so it was important to identify which of the 
more potent mono-ortho-substituted PCB congeners were abundant in the environment. As 
part of a project for the Food Standards Agency, the levels of AhR ligands including mono-
ortho-substituted PCBs were measured in several species of fish from around the UK 
(Fernandes et al., 2008). The analysis used GC/MS to measure the concentration of 
contaminants in the fish samples with the data presented as µg contaminant/kg fat (Table 
1.4). A shortlist of samples, which gave the highest levels of PCB contamination, was 
selected (Fernandes et al., 2008 supplementary data). The data shows that 2,3,3',4,4'-
pentachlorobiphenyl (PCB 105), 2,3',4,4',5-pentachlorobiphenyl (PCB 118) and 2,3,3',4,4',5-
hexachlorobiphenyl (PCB 156) are the most abundant of the PCBs measured suggesting they 
would have the biggest impact on the total toxic potency of a mixture (section 1.4.2.1). Table 
1.4 also shows the structures of all of the biphenyls used in this project. 
 
 
 
Figure 1.8: Distribution of REP values based on previous research – The REPs calculated from a variety of research was 
plotted as a meta-analysis to allow identification of the most appropriate TEF values. Figure was taken from the literature 
(Van den Berg et al., 2006). The red line indicates the current TEF for all of the mono-ortho-substituted PCBs included in 
the TEQ system. 
TEF = 0.00003 
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Figure 1.8 is taken from Van den Berg et al. (2006) and shows the range of REP values from 
the meta-analysis of the seven main mono-ortho-substituted PCBs spans several orders of 
magnitude. The mean REP from each compound was used to calculate the total mean of all 
of the compounds to produce a TEF of 0.00003 (van den Berg et al., 2006). The figure shows 
that there is as much as a 100,000-fold difference in REP estimation depending on the 
reference data it was derived from (PCB 156). There are several explanations for this but the 
most likely explanation is that some of the samples were contaminated with more potent 
PXBs or dioxin-like compounds (Koistinen et al., 1996) as even a trace amount would have 
an effect compared with the weaker PCB agonists. Koistinen et al. (1996) found that when 
conducting potency experiments to calculate the REP, some of the PCB congeners were 
contaminated with more potent compounds such as PCB 126 and TCDD. In order to confirm 
that only the PCB congener in question is inducing CYP1A1 and not any contamination, the 
composition of the compound solution used in this project will be tested using gas-
chromatography with a mass spectrometer attached. This will identify any impurities in the 
compound solutions as even a 1% contamination can have an effect on the potency of these 
compounds (DeVito, 2003).  
1.3.4 Other AhR ligands 
1.3.4.1 CH223191 
An example of a potent AhR antagonist is CH223191 
or 2-methyl-2H-pyrazole-3-carboxylic acid (2-
methyl-4-o-tolylazo-phenyl)-amide (Bazzi, 2008; 
Choi et al., 2012; Kim et al., 2006; Veldhoen et al., 
2008; Zhao et al., 2010). CH223191 has previously been shown to have no agonistic activity 
up to a concentration of 10 µM and inhibited the induction of CYP1A1 by TCDD at 
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nanomolar concentrations in human hepatoma (HepG2) cells (Kim et al., 2006). Zhao and 
co-workers further investigated the antagonistic properties and showed that the compound is 
actually a halogenated aromatic hydrocarbon (HAH) specific antagonist and did not have the 
same properties in polycyclic aromatic hydrocarbon (PAH)-like compounds such as beta-
naphthoflavone (ȕ-NF; Zhao et al., 2010). 
1.3.4.2 5F 203  
2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole 
(5F 203) was part of a group of chemically similar 
compounds that were synthesised as antitumor 
agents (Hutchinson et al., 2001). The compounds 
were expected to interact with the AhR and inhibit cancer cell line (MCF-7) growth as 
previously shown by 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610 or PMX 
610). Amongst the fluorinated versions of these drugs, 5F 203 was shown to have very 
positive results and is subsequently involved in phase 1 clinical trials (Aiello et al., 2008, 
Hutchinson et al., 2002). The compound was shown to be a partial agonist in rat H4IIE cells 
and a pure agonist in human MCF-7 cells (Bazzi et al., 2009). One of the more interesting 
characteristics of this compound was that it was found to be more potent in human cells than 
rat. This compound was therefore identified as a useful compound when studying the species 
differences in AhR activation. 
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1.3.5 Putative AhR ligands 
1.3.5.1 AZFMHCs 
Several compounds received from AstraZeneca were thought 
to have a higher potency than TCDD when inducing CYP1A1 
based on routine measurement of CYP1A1 protein induction 
conducted on the compounds by AstraZeneca (Furber, 
Personal communication). At least one of the compounds was 
thought to have comparable potency to activate the AhR based 
on CYP1A1 protein measurement (EROD; data not shown). 
This family of fused mesoionic heterocycle compounds (AZFMHCs) was originally 
developed as part of a programme by AstraZeneca researching Th2 selective immune-
suppressive agents (Abbott et al., 2002) but are no longer in development as pharmaceuticals. 
Compounds with a similar structure to these have been shown to cause chloracne (Mackenzie 
and Brooks, 1998; Scerri et al., 1995), which is a characteristic of dioxin-like toxicity 
(Tindall, 1985), which suggests they undergo the same mechanism of action. 
1.3.5.2 2-Amino-isoflavones (Chr) 
Several compounds, similar to isoflavones, but with an 
amino group on position 2, were shown in preliminary 
tests, using a luciferase based assay, to have some 
unusual agonistic and antagonist properties (Full 
structures are shown in Table 4.5; Wall et al., 2012b). 
The initial screening data was conducted using two recombinant AhR-responsive luciferase 
cell culture models, mouse H1L6.1c2 and human HG2L6.1c3 cells (Figure 4.2). The 
recombinant mouse (Hepa1c1c7) and human hepatoma (HepG2) cell lines (H1L6.1c2 and 
HG2L6.1c3, respectively) contain a stably transfected plasmid (pGudLuc6.1) which has the 
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firefly luciferase gene (Photinus pyralis) under AhR-responsive control of four DREs 
immediately upstream of the mouse mammary tumour virus (MMTV) viral promoter and 
luciferase gene (Aarts et al., 1995; Garrison et al., 1996; Han et al., 2004). The screening 
data showed that Chr-15 was the most potent of the ligands tested and displayed a significant 
difference in induction between mouse and human however it was decided instead to focus 
on agonism/antagonism-related species differences rather than purely potency. 2-amino-3-(4-
chlorophenyl)-7-methoxychromen-4-one (Chr-13) was shown in the preliminary work to be 
an agonist of AhR in mouse Hepa6.1.1 cells but an antagonist of AhR in human HepG26.1.1 
cells (Wall et al., 2012b). The other compound which was more intensely investigated was 6-
chloro-3-(4’-methoxy)phenylcoumarin (Chr-19). The compound was a precursor in the 
production of a group of anticoagulants and was shown in the preliminary data to be an 
agonist of mouse AhR and a partial agonist of human AhR (Wall et al., 2012b). Compounds 
from the coumarin family, which are similar in chemical structure, have considerable uses 
including anticoagulants such as warfarin (coumadin) and edema modifiers (coumarin) and 
can still be found in tobacco despite being a banned additive. This leads to the hypothesis that 
these compounds may also exhibit AhR activation ability.  
1.4 Risk assessment 
1.4.1 Food contamination  
Accurately measuring the levels of dioxin-like HAH compounds (PCDDs, PCDFs and PCBs) 
is very important for the food industry and regulators, costing several millions of dollars to 
properly regulate (Vanden Heuvel and Lucier, 1993). Over the last decade many countries 
have monitored the levels of dioxin-like compounds in food on an ad hoc basis. The EU 
became the first body to set extensive and comprehensive limits for these compounds which 
first came into force in 2002 (Van den Berg et al., 1998; European Commission, 2002b). 
There are three tiers of risk assessment levels in place: Maximum levels are set at ‘a strict but 
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feasible level in food’ in order that manufactures make continued effort to minimise the 
presence of dioxin-like compounds in food and feed. Action levels are used as an ‘early 
warning’ of potentially higher levels of dioxin-like compounds in food or feed allowing local 
authorities to identify potential contamination and eliminate it prior to the maximum level 
being reached. Target levels are in place to gradually reduce the levels of dioxin-like 
compounds in food and feed to more acceptable levels as recommended by scientific 
committees (European Commission, 2001, 2002a). There have been several cases where 
higher than normal levels have been detected causing the food to be recalled before sale to 
the general public. There have been several high profile exposures to dioxin-like HAHs such 
as the rice oil contamination in Yusho, Japan in 1968. Rice bran oil was found to be 
contaminated with PCBs and PCDFs affecting over 1000 people who had symptoms of 
chloracne (Kuratsune et al., 1972; Schecter, 1994; Yoshimura, 2003). More recently in 
December 2008, routine sampling of pork and beef samples revealed levels up to 200-times 
higher than the legal limits of dibenzo-p-dioxins and PCBs (Casey et al., 2010). The Irish 
pork industry is worth approximately £400 million a year exporting 50% abroad so the 
impact of these findings had a significant effect on the industry (Dixon, 2009; Kennedy et al., 
2010). Once the dibenzo-p-dioxin has been consumed by the animal, it accumulates in the 
fatty tissue until consumed by the general public or is removed from the animal’s body as 
waste which may be used as fertiliser for crops.  
1.4.2 Prediction of risk in humans 
1.4.2.1 TEF estimation 
The current internationally recognised method of calculating the TCDD-like toxicity of a 
mixture based on experimental data for individual compounds has been devised by the World 
Health Organisation (WHO; Van den Berg et al., 2006) in 2005 and was officially initiated 
on the 1st January 2012 (European Commission, 2011). However, there have been various 
Richard Wall 
 
26 
 
versions of this method in the past that utilise a similar methodology to estimate risk, such as 
NATO I-TEFs (International toxicity equivalency factors; NATO/CCMS, 1988a, 1988b), 
WHO-ECEH TEF (WHO-European Centre for Environment and Health TEF; Ahlborg et al., 
1994) and the original WHO TEQ methodology devised in 1998 (Van den Berg et al., 1998) 
which was revised to form the current WHO 2005 version. This data has been collected from 
various sources each using slightly different methodology (Haws et al., 2006). The relative 
potency (REP) of a compound is a measure of its ability to bind and activate the AhR 
allowing direct comparison between compounds and different data sets. REPs are also 
calculated in relation to TCDD, which is set at 1, using the EC50s gathered from 
concentration-response curves (Equation 1.1). The use of different experimental methods (i.e. 
in vitro and in vivo) as well as different data analysis, to calculate the REP makes it more 
difficult to compare between different data sets. The REP is calculated either in vivo or in 
vitro and is measured by a variety of methods such as PCR and EROD. This data was used to 
calculate toxic equivalency factors (TEFs), which are normalised REPs based on a meta-
analysis of all of previous data from the literature producing an average of all of the (suitable) 
REPs found in the literature. TCDF, for example, has a TEF of 0.1 because it is 10-fold less 
potent at activating the AhR than TCDD (based on a variety of REPs found in the literature).  
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Compound WHO 1998 TEF WHO 2005 TEF 
      Chlorinated dibenzo-p-dioxins 
    
 
2,3,7,8-TCDD 
 
1 
 
1 
 
1,2,3,7,8-PeCDD 
 
1 
 
1 
 
1,2,3,4,7,8-HxCDD 
 
0.1 
 
0.1 
 
1,2,3,6,7,8-HxCDD 
 
0.1 
 
0.1 
 
1,2,3,7,8,9-HxCDD 
 
0.1 
 
0.1 
 
1,2,3,4,6,7,8-HpCDD 
 
0.01 
 
0.01 
 
OCDD 
 
0.0001 
 
0.0003 
      Chlorinated dibenzofurans 
    
 
2,3,7,8-TCDF 
 
0.1 
 
0.1 
 
1,2,3,7,8-PeCDF 
 
0.05 
 
0.03 
 
2,3,4,7,8-PeCDF 
 
0.5 
 
0.3 
 
1,2,3,4,7,8-HxCDF 
 
0.1 
 
0.1 
 
1,2,3,6,7,8-HxCDF 
 
0.1 
 
0.1 
 
1,2,3,7,8,9-HxCDF 
 
0.1 
 
0.1 
 
2,3,4,6,7,8-HxCDF 
 
0.1 
 
0.1 
 
1,2,3,4,6,7,8-HpCDF 
 
0.01 
 
0.01 
 
1,2,3,4,7,8,9-HpCDF 
 
0.01 
 
0.01 
 
OCDF 
 
0.0001 
 
0.0003 
      Non-ortho-substituted PCBs 
    
 
3,3',4,4'-TCB (PCB 77) 
 
0.0001 
 
0.0001 
 
3,4,4',5-TCB (PCB 81) 
 
0.0001 
 
0.0003 
 
3,3',4,4',5-PeCB (PCB 126) 
 
0.1 
 
0.1 
 
3,3',4,4',5,5'-HxCB (PCB 169) 
 
0.01 
 
0.03 
      Mono-ortho-substituted PCBs 
    
 
2,3,3',4,4'-PeCB (PCB 105) 
 
0.0001 
 
0.00003 
 
2,3,4,4',5-PeCB (PCB 114) 
 
0.0005 
 
0.00003 
 
2,3',4,4',5-PeCB (PCB 118) 
 
0.0001 
 
0.00003 
 
2',3,4,4',5-PeCB (PCB 123) 
 
0.0001 
 
0.00003 
 
2,3,3',4,4',5-HxCB (PCB 156) 
 
0.0005 
 
0.00003 
 
2,3,3',4,4',5'-HxCB (PCB 157) 
 
0.0005 
 
0.00003 
 
2,3',4,4',5,5'-HxCB (PCB 167) 
 
0.00001 
 
0.00003 
 
2,3,3',4,4',5,5'-HpCB (PCB 189) 
 
0.0001 
 
0.00003 
         
Table 1.5: List of WHO TEF values - Shows several examples of TEF values for a selection of chlorinated dibenzo-p-
dioxins, dibenzofurans and PCBs. Values were calculated by the world health organisation (Haws et al., 2006; Van den Berg 
et al., 2006). The table was taken from Van den Berg et al. (2006). T: Tetra; Pe: Penta; Hx: Hexa; Hp: Hepta. 
Table 1.5 demonstrates all of the current TEF values for dibenzo-p-dioxins, dibenzofurans 
and PCBs. The TEFs were recorded as half order of magnitude estimates demonstrating the 
high variability in TEF estimation (as shown in Figure 1.8). Environmentally, these dioxin-
like compounds are found in complex mixtures therefore in order to predict the total toxicity, 
it is necessary to calculate the contribution of each compound in the mixture. The TEF-
weighted concentration of each compound in the mixture is added together to calculate the 
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total toxic equivalency (TEQ; total TCDD-like toxicity) of the mixture (Equation 1.1). The 
estimate can then be compared between laboratories, although full analysis of the underlying 
data is usually required to understand the full impact of the TEQ. 
[TCDD] ECହ଴
[Agonist] ECହ଴ = REP  
REPଶ + REPଶ+  . . .
REP#
= TEF 
(TEFଵ x Conc.ଵ )  +  (TEFଶ x Conc.ଶ )  +    =  TEQ of mixture  
 
Equation 1.1: TEQ equation for a mixture of HAHs – REPn: Relative potency for compound n; REP#: Total number of 
Relative potencies for compound; TEFn: Toxic equivalency factor for compound n; Concn: Concentration of compound n in 
the mixture; TEQ: Total TCDD-like toxicity of the mixture. Equation is discussed further by the world health organisation 
(Haws et al., 2006; Van den berg et al., 2006).  
Obviously in terms of risk assessment, it is better to overestimate the risk to human health 
rather than under estimate it; however, tight regulations and low environmental pollutant 
limits in food means an increase in the costs to regulate it. It is therefore crucial that these 
levels are correctly established. 
1.4.2.2 Advantages of the TEQ method 
The TEQ method employs an additivity approach that predicts the total TCDD-like toxicity 
of a mixture of TCDD-like compounds. The approach sums the potencies of all the 
compounds within the mixture in a dose dependent fashion and includes PCDDs, PCDFs and 
PCBs. This additivity approach assumes two important points, firstly, that TCDD-like 
toxicity is achieved by the same mechanism for each compound, and secondly that the 
toxicity of each compound can be added together and would therefore not affect the ability of 
another agonist from activating the receptor (Van den Berg et al., 2006). Additivity between 
TCDD-like compounds has been shown by several authors performing their own mixture 
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experiments, confirming the total toxicity experimentally after prediction by the additivity 
method (Brown et al., 1994; Fattore et al., 2000; Hamm et al., 2003; Walker et al., 1996). 
Walker et al. (1996) tested a mixture of 14 TCDD-like and non TCDD-like compounds in 
rainbow trout. They showed that although the mixture was not completely additive, the 
method was more accurate than current toxicity predictions applied in ecology (Walker et al., 
1996).  
The benefits of the TEQ system are that it is a simple method to calculate a potentially 
complicated subject. It incorporates potency data from a huge data set of in vitro and in vivo 
studies allowing confidence in the TEFs used. The TEQ method incorporates individual 
potency and prevalence data when calculating the TEQ allowing a more accurate estimate of 
toxicity. Having a universal table of TEF values allows for comparison between international 
regulatory bodies and makes it easier for governmental agencies to measure and compare risk 
from international sources. 
1.4.2.3 Disadvantages of the TEQ method 
There are several disadvantages with this method of prediction which could limit the 
accuracy of the method and reduce confidence in the estimation obtained. Firstly, the REP 
data used to derive the TEFs is, in some cases, highly variable (Figure 1.8), which reduces 
the confidence in the TEFs used for this assessment and highlights the uncertainty in 
estimating the TEQ. This uncertainty between laboratories is mostly like due to 
contamination of stock solutions with more potent AhR agonists such as TCDD, TCDF or 
PCB 126, which would give a higher response. Secondly, if an agonist with antagonistic 
properties (partial agonist; section 1.2.3) is in the presence of a pure agonist, the overall 
toxicity would decrease and the TEQ calculated by the additivity method would be higher 
than the actual risk (Howard et al., 2010; Safe, 1994; Toyoshiba et al., 2004; Walker et al., 
2005). Walker et al. (2005) followed work by Toyoshiba et al. (2004) and concluded that the 
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additivity method does not accurately predict potency despite considerable statistical power 
but instead requires a potency adjusted dose-additivity approach to be used, due to the lack of 
dose additivity and differences in the shape of dose-response curves (Toyoshiba et al., 2004; 
Walker et al., 2005). Compounds already included within the additivity scheme may be 
partial agonists (Clemons et al., 1998). Certain PCBs have been found to possess both 
agonistic and antagonistic properties in the presence of TCDD which would ultimately 
reduce the overall TCDD-like toxicity of the mixture (Chu et al., 2001; Clemons et al., 
1998). Clemons et al. (1998) showed that several PCB ligands had a less-than-additive 
interaction and concluded that the H4IIE bioassay could lead to lower TCDD-equivalent 
concentration than would be determined empirically (Clemons et al., 1998). This problem 
could also extend to other exogenous AhR agonists found in the environment, which are not 
currently included within the TEQ method, such as polybrominated diphenylethers (PBDEs; 
Darnerud et al., 2001) and mixed halogenated dioxin-like HAHs which, may further impact 
risk assessment of a mixture (Peters et al., 2004).  
The method does not consider the interaction between the exogenous mixture of 
environmental pollutants and naturally occurring AhR ligands found in the body and foods. 
Natural AhR ligands include; resveratrol (Casper et al., 1999; Ciolino et al., 1998, Ciolino 
and Yeh, 1999a), bilirubin (Phelan et al., 1998), indirubin (Adachi et al., 2001), indole-3-
carbinol (Bjeldanes et al., 1991) and flavones (Henry et al., 1999). Suitable concentrations of 
these compounds may seriously affect the TCDD-like toxicity of further AhR agonists by 
acting as antagonists or partial agonists of the AhR. Furthermore, the presence of a natural 
antagonist may reduce the overall toxicity of an exogenous mixture. Additionally, even if 
natural agonists were taken into account, this assumes that the levels of natural AhR agonists 
will be the same between different people. If intra-species differences were high it would be 
very difficult to take these compounds into account when making a prediction.  
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1.5 Background of techniques used 
1.5.1 Ligand binding assay 
The ability of a compound to compete with tritiated 
TCDD ([3H]-TCDD) for binding to the AhR was 
measured using a ligand binding assay (Bazzi et al., 
2009; Bradfield and Poland, 1988). The assay used 
[3H]-TCDD which competes with the compound of interest for binding to the rat cytosolic 
protein containing cytosolic AhR. Two assays were conducted for each compound; (1) total 
binding of [3H]-TCDD to all protein and (2) non-specific binding of [3H]-TCDD to cytosolic 
proteins other than AhR. A high affinity AhR ligand, TCAOB (3,4,3',4'-
tetrachloroazoxybenzene) was used as the competitor (Bazzi, 2008, Poland et al., 1976). The 
[3H]-TCDD is a low-energy beta emitter which was measured using liquid scintillation 
counter. The [3H]-TCDD sample was suspended in scintillation fluid which, upon emission 
of beta radiation, emits light that can be measured by the scintillation counter. 
1.5.2 Quantitative real-time PCR (qRT-PCR) 
1.5.2.1 Overview 
In order to measure the activation of the AhR, measurement of the induction of CYP1A1 was 
conducted in mRNA from rat liver cells (H4IIE) and human carcinoma cells (MCF-7) using 
quantitative real-time PCR (qRT-PCR). Measurement of the induction of CYP1A1 mRNA by 
a particular compound then allows the construction of a concentration-response curve. A 
method which can detect both the agonistic and antagonistic properties of a compound was 
formulated. A standard concentration-response curve will give the agonistic potency of the 
compounds. Antagonism was measured by treating cells with TCDD along with a set 
concentration of the antagonist. 
N+
N
O-Cl
Cl
Cl
Cl
 
TCAOB 
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1.5.2.2 Cell lines 
The H4IIE cell line has several important advantages making it the most appropriate cell 
system to use for the measurement of CYP1A1 mRNA induction. One of the key features of 
H4IIE cells are their low basal AHH (CYP1A1) levels (Benedict et al., 1973) and their high 
responsiveness to CYP1A1 mRNA induction by TCDD-like compounds. In addition, they 
have excellent growth characteristics allowing a high through-put (Whyte et al., 2004). 
CYP1A1 induction was measured as it is a good indication of TCDD-like toxicity (Whitlock, 
1999), however high CYP1A1 RNA induction does not imply high toxicity (Whyte et al., 
2004). Measurement of CYP1A1 RNA can be very robust with a high signal to noise ratio 
(Whitlock, 1999). There is a significantly large quantity of research of dioxin-like 
compounds in rat H4IIE cells with the majority of the data collected to calculate the TEFS 
derived from treatment of these cells allowing comparison with the literature (Haws et al., 
2006 supplementary data). MCF-7 cells have been widely used for the measurement of AhR 
activation (Bazzi et al., 2009; Ciolino et al., 1998; Coumoul et al., 2001; Krishnan and Safe, 
1993; Loaiza-Pérez et al., 2002; Pang et al., 1999; Peters et al., 2004; Van Duursen et al., 
2003). Human MCF-7 cells were used in this project because they have been shown to be 
more sensitive at detecting AhR antagonism than other human cell lines (Zhang et al., 2003). 
Iwanari et al. (2002) showed that several of the most characterised AhR ligands, such as 
TCDD and 3-methylchloranthrene (3-MC), showed a comparable pattern of induction of 
CYP1A1 mRNA in human HepG2 and human MCF-7 cells. The similar pattern of induction 
observed with a variety of flavonoids in both human HepG2 and human MCF-7 cells 
indicated that there were minimal inter-tissue differences in response (Zhang et al., 2003). 
Human cells derived from human liver (to compare against rat liver H4IIE cells) were not 
used as human liver has been shown to have low levels of AhR (Dolwick et al., 1993; 
Yamamoto et al., 2004). 
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1.5.2.3 Taqman vs SYBR green 
There are two methods of using qRT-PCR to measure gene expression, Taqman (uses a target 
specific probe) and SYBR green (binds non-specifically to all DNA) which are illustrated in 
Figure 1.9.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Comparison of Taqman and SYBR green methodologies – (A) Taqman: 1) A fluorescent reporter (R) dye 
and a quencher (Q) are attached to the 5’ and 3’ ends of a Taqman probe respectively. 2) When the probe is intact, the 
reporter dye emission is quenched. 3) During each extension cycle, the DNA polymerase cleaves the reporter dye from the 
probe. 4) Once separated from the quencher the reporter dye emits its characteristic fluorescence. (B) SYBR green: 1) The 
SYBR green II dye fluoresces when bound to double-stranded DNA. 2) When the DNA is denatured the SYBR green dye is 
released and the fluorescence is drastically reduced. 3) During extension, primers anneal and PCR product is generated. 4) 
When polymerisation is complete, SYBR green dye binds to the double-stranded product, resulting in a net increase in 
fluorescence detected by the machine. Figure from ‘Absolute Quantitation using Standard Curve’ (Applied Biosystems). 
1. Reaction setup 
2. Denaturation 
3. Polymerisation 
4. Polymerisation 
(B) SYBR 
PROBE 
Reverse primer 
Forward primer 
(A) TAQMAN 
R Q 
R Q 
R Q 
R Q 
2. Strand 
3. Cleavage 
4. Polymerisation 
1. Polymerisation 
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The Taqman method of qRT-PCR utilises a probe which is initially quenched to restrict 
fluorescence. Both the primers and probe bind to specific sites on the mRNA during the 
polymerisation step. As the polymerase is synthesising a copy of the mRNA, it breaks down 
the probe. The probe consists of a nucleotide sequence with a fluorescent reporter dye on one 
end and a light quencher on the other. In the probe’s natural state, the fluorescent reporter is 
quenched so only a faint background level of fluorescence is detected. Once the probe is 
broken apart by the polymerase, the fluorescence reporter is released and in the absence of 
the quencher, is detectable by the qRT-PCR fluorescence readers. SYBR green dye binds 
non-specifically to double stranded DNA and therefore does not require a specific probe. The 
method is much cheaper than Taqman but is less specific. Only a single gene (primer pair) 
can be analysed in one reaction reducing the accuracy of the method over Taqman. A 
diagram showing the process of Taqman and SYBR green qRT-PCR is shown in Figure 1.9. 
For both Taqman and SYBR green, the point at which the level of fluorescence is 
significantly different from the background (fluorescence threshold) is used to compare 
between samples. This point is called the cycle threshold (Ct) and is the point at which the 
signal passes the fluorescence threshold. The lower the Ct at which the sample can be 
identified above the background, the more mRNA is present and hence the more induced the 
gene is. For example, a sample treated with a high concentration of TCDD would have 
CYP1A1 mRNA levels at a higher level producing a lower Ct than a vehicle control. In this 
project, two reference genes will be run alongside CYP1A1 to allow normalisation between 
samples. Unlike CYP1A1, these genes are unaffected by the treatment of the AhR activating 
compounds so are expected to give approximately the same Ct in every experiment.  
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1.5.3 Viral infection 
In this project a retroviral expression assay was used to allow creation of a target cell line 
expressing an exogenous gene. The gene of interest is isolated and cloned into a pRevTRE 
vector (via subcloning into pGEM-T). The vector is then transfected into a specialised 
packaging cell (PT67) which contains all of the genes required to synthesise a virus. The cell 
line is specifically designed for easy vector transfection and has all of the genes required to 
produce a virus (containing the vector DNA). The cell then produces a replication-defective 
virus which can be used to infect the target cell line. This virus can then infect other cells but 
does not contain the genes necessary to replicate itself and re-infect after the initial infection 
(Figure 1.10A). For successful transcription of the gene of interest, the assay requires dual 
vectors, one containing the gene of interest and the other containing the initiator sequence 
that would begin transcription from the first vector. Transcription of the gene of interest in 
the host cell requires both vectors. Initially a tTA (transactivator) regulatory element is 
encoded from the pRevTet-Off vector which binds to the Tet-response element (TRE) on the 
pRevTRE vector in the absence of tetracycline (Tc) or its derivative doxycycline (Dox). 
Binding of the tTA to this TRE site induces transcription of the gene of interest and is 
reduced in a dose dependent manner as Tc or Dox is added to the medium (Figure 1.10B). 
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Figure 1.10: Summary of viral production and expression – (A) Mechanism of packaging of infectious, replication 
incompetent, retroviral particles. The vector is transfected into the cell1, where it integrates into the DNA of the packaging 
cell2, which contains the necessary genes required to produce a virus (pol: reverse transcriptase, integrase; gag: core 
structural proteins; env: coat glycoproteins) and transcription begins3. Viral proteins in the cell recognise the packaging 
VLJQDOȥIURPWKHYHFWRUDQGEHJLQYLUDOSDUWLFOHIRUPDWLRQ4. This produces an infectious but replication incompetent virus 
which will be used to infect the target cell line5. (B) Mechanism of pRevTet-Off gene expression. Both vectors, pRevTet-
Off and pRevTRE are required to be successfully integrated into the target cell line before transcription of the gene of 
interest can occur. The TRE is located upstream of the viral promoter which is silent when not activated by pRevTet-Off. 
The tTA (pRevTet-Off) binds the TRE and initiates transcription (in the absence of doxycycline). Both figures were taken 
from the RevTet System User Handbook. 
A 
B 
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1.5.4 Measurement of concentration 
1.5.4.1 Gas Chromatography (GC) 
The concentration of compounds can be measured using Gas chromatography (GC)/Mass 
spectrometry (MS). Sample (in nonane vehicle) introduction into the GC is carried out by 
injection into a PTV (programmed temperature volatilisation) injector which is initially held 
a little above ambient temperature (50oC) and programmed for constant helium flow. This 
combination of temperature and pressure forces the nonane to vaporise, leaving the 
compounds bound to the glass insert inside the injector. After removing the nonane (~3 min), 
the injector is heated to 330oC-350oC to volatilise the dioxin-like compounds. Under the 
pressurised flow of helium gas the compounds are transferred to the front of the GC column 
which is initially held at 60oC, a relatively cool temperature which allows focussing of the 
compounds for enhanced separation. When this process is completed, the temperature is 
increased in programmed stages in order to allow the compounds to traverse the length of the 
GC column. The rate at which the compounds move down the column depends on the 
interaction of each compound with the mobile phase of the GC column and on their 
individual boiling points. Even compounds of the same molecular weight will have a slightly 
different boiling point depending on their molecular arrangement therefore it is possible to 
separate the compounds for individual analysis by MS. 
1.5.4.2 Mass spectrometry (MS) 
Once leaving the GC, the compounds, separated by time, are sequentially introduced into the 
MS via a GC/MS interface which allows transfer into the ionisation source. The MS is in a 
vacuum so that the compounds can be detected without interference from molecules in the 
atmosphere. The compounds enter the ionisation chamber where they are bombarded by 
electrons produced by a special filament. The electrons produced are energised using an 
anion located on the opposite side of the chamber and collide with the compounds of interest 
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ionising them. Once an electron collides with a molecule of the compound, it breaks it, 
producing a range of different sized fragments of different polarities depending on the energy 
imparted to the electrons. In the current application, only positively charged ions are of 
interest and must therefore be selectively progressed through the mass analyser. In the initial 
stage this is done using a positively charged lens called a repeller which deflects positive ions 
away toward the next stage of the machine, attracting negative ions in the process (Figure 
1.11). 
 
Figure 1.11: Mass spectrometer –Volatilised compound (positive ion) is bombarded by electrons then accelerated around 
the spectrometer, filtering out any fragments. The chamber of a mass spectrometer has been expanded: the sample enters the 
chamber, bombarded with electrons producing positive ions which are then deflected away towards the recorder. 
After leaving the ionisation chamber the positive ions are directed through a series of 
focussing lenses and pass though a narrow slit into the mass analyser. Here, under the 
influence of electrostatic and magnetic fields, the ions accelerate through the analyser and 
separate based on their individual masses and mass to charge (m/z) ratios. The energies 
required to focus these ions are measured in order to allow computation of the accurate mass 
of each fragment. When the identity of the compound is known, as in the present case, a more 
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selective measurement process called selected ion recording is used. In this technique the MS 
is programmed to isolate and measure only the specified ions (which are derived from the 
compounds of interest). This results in a tremendous increase in measurement sensitivity. 
Selected ions collide with the recording unit, a photomultiplier, which magnifies the primary 
signals from the ion fragments before detection on a photosensitive plate. The response per 
retention time and molecular weight is recorded.  
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1.6 Aims 
The main aim of this work is to improve our overall understanding of the mechanism of AhR 
activation by environmental pollutants and then apply this understanding to risk assessment. 
This includes further understanding of the structure-activity relationships of AhR ligands, 
species differences in the potency of AhR ligands and how risk assessment can be applied to 
other environmentally abundant AhR compounds. 
Calibration of a qRT-PCR-based method to detect either agonism or antagonism - 
Measurement of the agonistic properties of a putative highly potent AhR ligand (AZ1) and 
characterisation of a known AhR antagonist (CH22319) will allow full calibration the 
measurement methods. 
Measurement of the potency of newly identified dioxin-like compounds - Measure the 
potency and investigation of the structure-activity relationships of a range of mixed 
halogenated dibenzo-p-dioxins, dibenzofurans and biphenyls, in rat and human. 
Accurate measurement of the agonistic and antagonistic properties of putative partial 
agonists - The agonistic and antagonist properties of three environmentally abundant mono-
ortho-substituted PCBs will be determined as well as their effect on the TEQ.  
Investigating structure activity relationships of AhR ligands between rat and human - 
The species-specific difference in the agonistic and antagonistic properties of novel 2-amino-
isoflavones will be investigated.  
Investigating species differences between rat and human with respect to agonism and 
antagonism - The AhR of rat and human will be isolated and transfected into an AhR 
deficient mouse cell line to directly compare between the two receptors. The new cell lines 
will then be treated with TCDD and 5F 203 to illustrate any differences from wild-type cells. 
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2. Method  
2.1 Materials 
2.1.1 Reagents and kits 
x pGEM®-T Vector system (Promega; #A3600) 
 
x RevTet-off™ System (Clontech; #631020) 
 
x Absolutely RNA® Miniprep Kit (Stratagene #400800) 
 
Lysis buffer-ȕ-ME:  RNase-Free DNase I: 
- ȝOȕ-ME  - ȝORI'1DVH'LJHVWLRQ%XIIHU 
- ȝO/\VLV%XIIHU - ȝORIUHFRQVWLWXWHG51DVH-Free DNase I 
 
x High capacity RNA-to-cDNA kit (Applied Biosystems; #4387406) 
 
x Extensor Hi-Fidelity PCR Master Mix (ABgene; AB-0792) 
x Taqman® gene expression master mix (Applied Biosystems; #4369016) 
x Brilliant SYBR Green QPCR master mix (Stratagene; #600548) 
 
x Microamp fast optical 96-well plates (0.1 ml) with covers (Applied Biosystems 
#4346906 and #4360954) 
 
x GeneJuice (Novagen; #70967-5) 
 
x QIAquick gel extraction kit (Qiagen; #28704) 
 
Buffer PE: Buffer PB: 
- 10 ml Buffer PE - 30 ml Buffer PB 
- 40 ml 100% Ethanol - 120 µl pH indicator I 
 
x QIAprep Spin Miniprep kit (DNA isolation; Qiagen; #27104) 
 
Buffer P1: Buffer PE: 
- 20 ml Buffer P1 - 6 ml Buffer PE 
- 200 µl RNase A - 24 ml 100% Ethanol 
- 20 µl LyseBlue reagent  
 
x SalI HF (Biolabs; #R3138S)  
x HindIII (Biolabs; #R0104S) 
x 10x T4 ligase (Biolabs; #M0202S) 
 
x Quick-load®1 kbp DNA ladder (Biolabs; #N0468L) 
x Quick-load®100 bp DNA ladder (Biolabs; #N0467L) 
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2.1.2 Solutions, buffers and medium 
 
x JM109 E. coli bacterial cells (glycerol stock, Promega; #P9751)  
x H4IIE rat liver cell line (ATCC; #CRL-1548) 
x PT67 cell line (Clontech; #631510) 
x Tao BpRc1 cell line (ATCC; #CRL-2218) 
x Cell freezing medium-DMSO 1x (Sigma-Aldrich; #C6164)  
x Dulbecco’s phosphate buffered saline (Sigma #D8537) 
 
x Complete minimum essential medium (cMEM) 
- 440 ml Minimum essential medium (Sigma #M2279) 
- 50 ml Fetal bovine serum (Sigma #F7524) 
- 5 ml 200 mM L-glutamine, 10,000 U/ml Pencillin and 10,000 µg/ml Streptomycin 
solution (Final conc. 2 mM, 100 U/ml and 100 µg/ml, respectively; Sigma #G1146) 
- 5 ml Non-essential amino acids (Sigma #M7145) 
 
x Complete Dulbecco’s modified Eagle’s medium (cDMEM) 
- 435 ml Dulbecco’s modified Eagle’s medium (High glucose 4.5 g/L; Sigma #D5671) 
- 50 ml Tet system approved fetal bovine serum (Clontech #631101) 
- 5 ml 200 mM L-glutamine, 10,000 U/ml Penicillin and 10,000 µg/ml Streptomycin 
solution (Final conc. 2 mM, 100 U/ml and 100 µg/ml, respectively; Sigma #G1146) 
- 5 ml 200 mM L-glutamine (2 mM final concentration; Sigma #G7513) 
- 5 ml 100 mM Sodium pyruvate (1 mM final concentration; Sigma #S8636)  
 
x 1x Trypsin-EDTA solution (trypsin) 
- 1 ml 10X Trypsin-EDTA solution (Sigma #T4174) 
- 9 ml Dulbecco’s phosphate buffered saline (Sigma #D8537) 
 
x De-proteinated water (DEPC treated water):  
- 1 ml Diethyl Pyrocarbonate 
- 9 ml Ethanol 
- Distilled water to make up to 1 Litre (autoclaved after mixing to neutralise) 
 
x TfbI: 
- 0.588 g Potassium acetate (30 mM) 
- 2.42 g Rubidium chloride (100 mM) 
- 0.294 g Calcium chloride (10 mM) 
- 2.0 g Manganese chloride (50 mM) 
- 30 ml Glycerol (15% v/v) 
- Distilled water up to 200 ml 
 
(pH 5.8 with dilute acetic acid) 
 
x TfbII: 
- 0.21 g MOPS (10 mM) 
- 1.1 g Calcium chloride (75 mM) 
- 0.121 g Rubidium chloride (10 mM) 
- 15 ml Glycerol (15% v/v) 
- Distilled water to make volume up 
to 100 ml  
 
(pH 6.5 with dilute sodium 
hydroxide) 
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x ALP Solution I: 
- 50 mM Glucose 
- 25 mM Tris. Cl (pH 8) 
- 10 mM EDTA (pH 8) 
 
- Kept at 4oC 
 
x ALP Solution III: 
- 60 ml Potassium acetate  
- 11.5 ml Glacial acetic acid 
- 28.5 ml dH2O 
(5 M acetate, 3 M potassium) 
 
x ALP Solution II: 
- 0.2 M NaOH 
- 1% SDS 
 
x Orange G 10x 
- 30 ml glycerol 
- 1 ml 1 M Tris pH 7.6 
- 0.05 ml 1 M EDTA 
- 200 mg Orange G 
 
x TNES buffer (DNA extraction) 
- 18.1 mg Tris, pH 7.5 (10mM) 
- 350.6 mg NaCl (400mM) 
- 3 ml 0.5 M EDTA (100mM) 
- 900 µl 10% SDS (0.6%) 
- Distilled water up to 15 ml 
 
x 50 mg/ml Hygromycin B 
antibiotic  
- 0.5 g Hygromycin B powder (Sigma 
#H3274) 
- 10 ml DMEM (sigma #D5671 – 
without supplements) 
 
     (Filter sterilised, 0.2 µM filter) 
 
x 10 mg/ml G418 antibiotic 
- 0.5 g G418 powder (Clontech #80561)  
- 35 ml DMEM (Sigma #D5671 – 
without supplements) 
 
(Note: The effective weight is 0.7 g per 1 
g of powder (Clontech Revtet 
manual); Filter sterilised, 0.2 µM 
filter) 
 
x 1 mg/ml Hexadimethrine 
bromide (Polybrene®) 
- 20 mg Hexadimethrine bromide 
powder (Sigma #H9268) 
- 18 mg NaCl 
- 20 ml distilled water 
 
Autoclaved 
 
x 50 mg/ml Doxycycline hyclate 
- 0.5 g Doxycycline hyclate powder 
(Sigma #D9891) 
- 10 ml distilled water 
(Filter sterilised, 0.2 µM filter) 
 
x MEN stock buffer  
- MN buffer 
- 1 mM EDTA. 
(pH 7.5 at 4ºC) 
 
x MN stock buffer  
- 25 mM MOPS 
- 0.02 % Sodium Azide. 
(pH 7.5 at 4ºC) 
x 1x Agarose gel 
- 0.3 g Agarose 
- 0.3 ml 10% SDS 
- 30 ml 1x TBE buffer 
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x MDENG stock buffer (pH 7.5, 4oC) 
- MEN buffer 
- 10 % (w/v) glycerol 
- 1 mM dithiothreitol (DTT).  
(DTT is freshly supplemented to the 
buffer before the protein preparation).  
 
x 5x Bradford dye concentrate 
- 100 mg Coomassie brilliant blue 
G-250 
- 50 ml 95% Ethanol 
- 100 ml Phosphoric acid 
- Distilled water up to 200 ml 
 
x 10x TBE buffer 
- 108 g Tris 
- 55 g Boric Acid 
- 40 ml 0.5 M EDTA pH 8 
- Distilled water to make up to 1 L 
(Working concentration was 1x 
dilution) 
 
x LB plates with ampicillin 
- 1 L LB medium 
- 15 g agar 
- 100 µg/ml (final) Ampicillin 
 
Cool below 50oC before addition of 
Amp. 
x LB medium 
- 10 g Bacto-tryptone 
- 5 g Bacto-yeast extract 
- 5 g NaCl 
- 1 L distilled water 
 
pH adjusted to 7.0 with NaOH 
 
x SOC medium 
- 2 g Bacto-tryptone 
- 0.5 g Bacto-yeast extract 
- 1 ml 1M NaCl 
- 0.25 ml 1M KCl 
- 1 ml 2M Mg2+ stock, filter 
sterilised 
- 1 ml 2M glucose, filter sterilised 
- 97 ml distilled water 
 
2.1.3 Compounds 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD; purity 99%) was purchased from Cerilliant 
Cambridge Isotope Laboratories (Middlesex, UK). A 155 µM top stock of TCDD was made 
with dimethyl sulfoxide (DMSO) which was kept at room temperature and protected from 
light. Further dilution of TCDD was done in DMSO to 10 µM which was aliquoted into 
eppendorf tubes and stored at -20oC. All further dilutions of TCDD were made using 
conditioned medium (See section 2.4.1), giving a final DMSO concentration of <0.02%. 
2,3,3’,4,4’-pentachlorobiphenyl (PCB 105; purity 98%), 2,3’,4,4’,5-pentachlorobiphenyl 
(PCB 118; purity 98%), 2,3,3’,4,4’,5-hexachlorobiphenyl (PCB 156; purity 98%) was 
purchased from Cambridge Isotope Laboratories (Massachusetts, USA). A 10 mM top stock 
was made by dissolving the PCB in DMSO. The solution was then stored at -20oC.  
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The mixed halogenated compounds were a kind gift from Dr Alwyn Fernandes and Dr. 
Martin Rose (The Food and Environment Research Agency, UK). They were previously 
obtained either from Wellington Laboratories Inc. (Ontario, Canada) or from Cambridge 
Isotope Labs (Massachusetts, USA). Where required the standards were solvent exchanged to 
DMSO and the concentrations verified. The chemical names for the 3,3’,4,4’,5-substituted-
mixed halogenated biphenyls have been published previously (Falandysz et al., 2012). The 
compounds were dissolved in DMSO up to a concentration of 100 µM or 1 mM. 
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH223191; 
purity 95.71%) was purchased from Calbiochem (Nottingham, UK). A 10 mM top stock was 
made by dilution into DMSO. The solution was stored at -20oC and protected from light.  
The AZFMHCs were a kind gift from Dr. Mark Furber (AstraZeneca Mölndal, Sweden). The 
full synthesis of the compounds has been published previously (Abbott et al., 2002). AZ1 
was dissolved in DMSO to make a concentration of 1 µM. AZ2, 3 and 4 were dissolved in 
purified water at concentrations of 3 µM – 10 µM.  
- 3-Hydroxy-2-[4-(trifluoromethyl)phenyl]-[1,2,3]-triazolo[1,5-a]quinolinium hydroxide (AZ1) 
- 4-Methyl-3-hydroxy-2-[4-(trifluoromethyl)phenyl]-[1,2,3]triazolo[1,5-a]quinoxalinium hydroxide (AZ2) 
- 4-Methyl-3-hydroxy-2-[4-(methyl)phenyl]-[1,2,3]-triazolo[1,5-a]quinolinium hydroxide (AZ3) 
- 4-Amine-3-hydroxy-2-[4-(trifluoromethyl)phenyl]-[1,2,3]triazolo[1,5-a]quinoxalinium hydroxide (AZ4) 
2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203) was synthesised at the Cancer 
Research Laboratories, University of Nottingham with the full synthesis published previously 
(Hutchinson et al., 2001). 5F 203 was dissolved in DMSO to a concentration of 10 mM. 
2-Amino-3-(4-chlorophenyl)-7-methoxychromen-4-one (Chr-13) and 6-chloro-3-(4’ 
methoxy)phenylcoumarin (Chr-19) were a kind gift from Prof. Gianfranco Balboni 
(University of Cagliari, Italy). Chr-13 can be purchased from Life Chemicals (Braunschweig, 
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Germany) and Chr-19 was synthesised as reported by Quezada et al. (2010). Chr-13 and Chr-
19 were prepared as 100 mM and 30 mM solutions, respectively, in DMSO. 
The radio-ligand [3H]-2,3,7,8-tetrachlorodibenzo-p-dioxin ([3H]-TCDD) was purchased from 
ChemSyn Laboratories (Kansas, USA) and had a specific activity of 29.7 Ci/mmol. 3,4,3',4'-
Tetrachloroazoxybenzene (TCAOB) was purchased from AccuStandard, USA and dissolved 
to 3 mM in MDENG buffer. It may be important to note that the [3H]-TCDD is 
approximately 70% of the original specific activity as the compound was purchased at least 5 
years ago. Therefore the compound now has a specific activity of ~20.79 Ci/mmol. 
2.1.4 Gas Chromatography/Mass Spectrometry (GC/MS) analysis 
Research from other authors regarding the agonistic and antagonist properties of the three 
PCBs has given widely different estimates of potency (Van den Berg et al., 1998, 2006). One 
possible reason for this discrepancy is that the compounds were actually contaminated by 
other, more potent AhR agonists. Therefore the stock aliquots of the three PCBs used were 
tested to confirm that they contained no contamination. Gas chromatography/mass 
spectrometry (GC/MS) was conducted at FERA (Sand Hutton, York). Samples were 
transferred from DMSO into Acetone then diluted again in Nonane. An aliquot was taken 
from this for analysis along with the addition of 13C containing dibenzo-p-dioxins, 
dibenzofurans and PCBs to allow identification and quantitation. 10 µl of the samples (with 
13C compounds) was added into the injector by an automated dispensing robot. The gas 
chromatograph (HRGC, Agilent) was fitted with a 60m x 0.25mm i.d. DB5-MS column 
which was temperature programmed from 60oC to 330oC in 3 stages and the compounds were 
separated (see section 1.5.4.1 for more details). Compounds were then transferred to the high 
resolution mass spectrometer (HRMS; Autospec Premier Series, Micromass, UK) which 
characterises molecules based on their exact molecular weight and structure (see section 
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1.5.4.2). The HRMS used electron ionisation (EI) mode with selected ion monitoring (SIM). 
An internal control of perfluorokerosene (PFK; Fluka), which splits into known fragments, 
was used to calibrate the mass axis of the instrument. The raw data from the HRMS was 
analysed with MassLynx software to allow more accurate identification and quantitation of 
the contaminants as well as the compound itself. Toluene and nonane were run through after 
the samples to remove any residual material and ensure that the GC/MS system was free of 
any carryover between injections. The actual work was carried out by staff at FERA (Sand 
Hutton, UK) in the presence of the author. 
 
Figure 2.1: Graphical representation of the ratio of compounds in the PCB 156 stock – The data was collected using a 
gas chromatograph with attached mass spectrometer. The graph shows a magnified view of the levels of PCB 105 and PCB 
118 compared against PCB 156. 
The graph in Figure 2.1 shows the comparison of the amount of PCB 156 against the levels 
of contaminants: PCB 105 and PCB 118. It shows that although there is contamination 
present, the levels are insignificant in comparison to PCB 156. The results of this analysis 
can be seen in Table 2.1 with an example of the graphical representation of the data peaks 
shown in Figure 2.1. 
PCB 118 
PCB 105 
PCB 156 
Richard Wall 
 
48 
 
Contaminant 
(pg/µl) PCB 105 PCB 118 PCB 156 
    PCB 77 <0.05 0.69 <0.05 
PCB 81 - - - 
PCB 126 - - <0.05 
PCB 169 <0.05 <0.05 - 
PCB 123 <0.05 - - 
PCB 118 0.57 121.42 0.26 
PCB 114 <0.05 0.10 <0.05 
PCB 105 116.93 <0.05 0.34 
PCB 167 <0.05 <0.05 <0.05 
PCB 156 0.10 0.24 188.84 
PCB 157 0.14 <0.05 - 
PCB 189 - <0.05 <0.05 
    
 
Table 2.1: GC/MS analysis of the three PCB stock aliquots – Analysis was conducted using gas chromatography with 
mass spectrometry. The table shows the concentration of the most common PCBs including confirmation of the 
concentration of the actual PCB. Concentrations are shown in pg/µl. In most cases no compound could be found or only a 
small trace. 
The main source of contamination that was found in the samples was actually PCB 105, PCB 
118 and PCB 156. Further to this, the PCB 156 stock was found to contain trace levels of 
PCB 126 (<3777-fold less than PCB 126) which, according to the WHO TEF values, is more 
than 3000-fold more potent than PCB 156 (Van den Berg et al., 2006). This could therefore 
have a small impact on the potency of PCB 156, inducing CYP1A1 mRNA above the normal 
levels achievable by this compound. The other two compounds were found to be clean of 
highly potent AhR agonists however the trace amounts of PCB 77, PCB 156 and PCB 157 
could still have an agonist effect at the higher concentrations if they exhibit an additive 
response. No detectable trace of any of the most potent compounds such as TCDD, or any of 
the other potent PCDD/PCDF congeners was observed during this analysis. 
The two 2-amino-isoflavone compounds, Chr-13 and Chr-19, were also tested. The same 
protocol was used but with the addition of a clean-up step before conducting the GC. The 
Richard Wall 
 
49 
 
dibenzo-p-dioxin and PCB 13C standards were added to the two samples. The solutes were 
then passed through mini-columns consisting of silanised glass wool, sodium sulphate, acid 
modified silica gel topped with another thin layer of sodium sulphate. Samples were rinsed 
through the column using hexane. Concentrated samples were then run through the GC. The 
purpose of this step was to remove any reactants from the mixture which may bind and 
damage the GC coil. Chr-19 was found to be free of contamination (or at least traces of 
contamination were below the level of detection). However, a small trace of PCB 118 
contamination (120 ng/ml; 0.3 nM) was found at the highest concentration of Chr-13 (100 
µM). Based on the data collected on this compound (Figure 3.19) it was concluded that <0.3 
nM PCB 118 would have no effect on the potency of Chr-13 to agonise or antagonise. 
2.1.5 Gene identification 
The GenBank mRNA numbers for the genes used in this study are shown in Table 2.2.  
 Rat Mouse Human 
    
AhR NM_013149.2 NM_013464.4 NM_001621.4 
Arnt NM_012780.1 NM_001037737.2 NM_001668.3 
ȕ-actin NM_031144 NM_007393 NM_001101 
CYP1A1 NM_012540 NM_009992 NM_000499 
CYP1A2 NM_012541 - - 
CYP1B1 NM_012940 - - 
Hsp90 NM_175761.2 NM_010480.5a NM_005348.3 
p23 NM_001130989.1 NM_019766.4 NM_006601.5 
XAP2 NM_172327.2 NM_016666.2 NM_003977.2 
Table 2.2: GenBank reference numbers of all the genes discussed in this project – Reference numbers were last 
accessed on the 27/5/12. aMouse Hsp90 alpha was used for comparison. 
2.1.6 Cell Culture 
2.1.6.1 Cell culture maintenance 
Cells (described below) were passaged every 2-3 days into a new 25 cm2 flask with fresh 
cMEM or cDMEM. To passage the cells, the old medium was removed and the cells were 
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washed with 2.5 ml PBS. The PBS was then removed and 1.5 ml 1x trypsin-EDTA was then 
added to the cells and incubated for 2 min at 37oC, 5% CO2 to separate the cells from the 
base of the flask. After the allotted time, 3.5 ml fresh complete medium was added to the 
trypsin/cell mixture to neutralise the trypsin. A 1 ml aliquot of this was transferred to 9 ml of 
fresh complete medium in a new flask. Cells were incubated at 37oC, 5% CO2 in an incubator 
(Sanyo). All work was done in a class II Microbiological safety cabinet (Walker, 
Derbyshire), using sterile equipment with work surfaces cleaned with 1% Trigene to prevent 
contamination of the cells.  
2.1.6.2 Freezing cells for storage 
Cells were processed as discussed in section 2.1.6.1, however, instead of being transferred to 
a new flask after neutralisation of the trypsin, the cell mixture was added to a 15 ml 
centrifuge tube and centrifuged for 5 min at room temperature (RT; 20 - 25oC) and maximum 
speed (Max; 14,000 rpm) in an eppendorf 5417R centrifuge (used in all experiments unless 
otherwise stated), to form a cell pellet. The medium was removed and the cells were re-
suspended in 1 ml 1x cell freezing medium-DMSO. This cell mixture was added to a 
cryotube, frozen in a Nalgene Cryo 1oC freezing container at -80oC (-1oC/min rate of 
freezing; to prevent cell damage) and then stored at -196oC until required. 
2.1.6.3 H4IIE Rat liver cells 
Cells reached complete confluence within 6 days with a concentration of ~2 x 105 cells/well 
from a starting concentration of 1 x 102 cells/well (Wall, 2008). Cells were grown in cMEM 
and incubated at 37oC, 5% CO2. The cells were passaged every 3 days as described in section 
2.1.6.1. 
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2.1.6.4 MCF7 Human breast carcinoma cells 
The MCF7 human breast carcinoma cells were a kind gift from Dr Tracey Bradshaw (Centre 
for Biomolecular Science, University of Nottingham). Cells have been previously show to 
reach confluence after 7 days starting from a concentration of 2.5 x 103 cells/well with total 
confluence providing 1 x 105 cells/well (Bazzi, 2008). Cells were grown in cMEM and 
incubated at 37oC, 5% CO2. The cells were passaged every 3 days as described in section 
2.1.6.1.  
2.1.6.5 RetroPack PT67 packaging cell line 
The packaging cell line, PT67, was derived from the NIH/3T3 cell line. It contains three viral 
genes from the Moloney murine leukaemia virus (MoMuLV); pol, gag and env, integrated 
into its genome which are necessary for virus replication and packaging. A virus packaged by 
these cells can enter the host cell in two different ways, either through the RAM1 or GALV 
receptors. The cells were purchased from Clontech Laboratories Inc, USA and upon receipt, 
were grown (section 2.1.6.1), separated into aliquots and stored in liquid nitrogen (-196oC) 
for future use as previously discussed in section 2.1.6.2. Cells were passaged as described 
previously in section 2.1.6.1. The cell line does not normally demonstrate any significant 
hygromycin or G418 antibiotic resistance. The cells were grown in cDMEM and kept in a 5% 
CO2 atmosphere at 37oC. 
2.1.6.6 Taoc1BPrc1 AhR-defective cell line 
The AhR-defective Taoc1BPrc1 cell line (BpRc1; AhR-defective clone, AhR-D) was created 
in the lab of Whitlock and co-workers (Miller et al., 1983). The clones were created using 
Hepa1c1c7 mouse cells which in turn were derived from the Hepa-1 cell line (Hankinson, 
1979). TCDD treated hepa1c1c7 cells were shown to be induced by 127-fold over vehicle 
control. The BpRc1 cells have a basal CYP1A1 level of 10-fold less than wild-type 
Richard Wall 
 
52 
 
Hepa1c1c7 cells and an induced level of CYP1A1 (by TCDD) which is 20-fold less than 
wild-type cells (Miller et al., 1983). The cell line was purchased from ATCC (LGC 
standards). The cells were grown in cDMEM (section 2.1.6.1) and kept in a 5% CO2 
atmosphere at 37oC. Before experimentation, several aliquots of cells were frozen in liquid 
nitrogen (-196oC) in cell freezing medium-DMSO (1x). Pilot experiments using the two 
antibiotics used for selection of vector-integrated cells, G418 and hygromycin, were 
conducted on the cell line before exposure to the viruses to establish the optimal 
concentrations (See section 2.5.6.2).  
2.1.6.7 NIH/3T3 mouse embryonic fibroblast cell line 
The cells were first isolated from desegregated NIH Swiss mouse embryo fibroblast cell line. 
The cells were a kind gift from Dr Andrew Johnson (School of Biology, University of 
Nottingham). The cells were grown in cDMEM. It was recommended by the Johnson lab that 
the cells should be grown in medium containing 1% non-HVVHQWLDO DPLQRDFLGV DQGȕ-ME. 
Research into the cell line showed that these additional additives were not required (ATCC 
cell lines). To confirm this, cells were grown in cDMEM with the addition and absence of 
non-essential amino acids and ȕ-mercaptoethanol (ȕ-ME) over a period of 9 days (3 
passages). Visual inspection showed no difference in cell growth or health. It was therefore 
concluded that the additional additives were not required. ATCC encourage the use of calf 
bovine serum (CBS; serum taken from <20 day old calves) as opposed to fetal bovine serum 
(FBS; serum taken from unborn fetus) (ATCC cell lines), however the Johnson lab 
recommended FBS. Therefore the cells could be grown in exactly the same medium as the 
BpRc1 cells and the PT67 packaging cells. The cells were used to estimate the titer of the 
viruses produced by the stable PT67 virus producing cell lines reducing variables between 
the three cell lines. 
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2.1.6.8 JM109 E.coli cells 
In order to identify successful AhR containing plasmids, JM109 Escherichia coli (E. coli) 
chemically competent cells were transformed with the vector:insert. Lysogeny broth (LB 
medium) is a nutritionally rich media used for the growth of the bacteria (Bertani, 1951). The 
medium contains vitamins and minerals necessary for successful bacteria growth and is made 
by adding 25 g LB to 1 L of purified water followed by autoclaving. The JM109 cells do not 
normally demonstrate ampicillin resistance. Chemically competent cells were created using 
the method shown in section 2.1.6.9. 
2.1.6.9 Producing chemically competent JM109 bacterial cells 
A single bacteria colony (grown from stock, Promega; #P9751) was grown in 1 ml LB 
medium at 37oC overnight with aeration. This was then added to 100 ml of fresh LB medium 
and incubated until the optical density (O.D.) at 595 nm was ~0.6 which took about 2-3 
hours. All the reagents were kept on ice and the procedure was done a quickly as possible. 
The cells were centrifuged (4000 g, 5 min, 4oC) to obtain a pellet of the bacterial cells. The 
cells were re-suspended in 40 ml of ice cold TBF1 solution and incubated for 5 min on ice. 
The cells were then centrifuged a second time (4000 g, 5 min, 4oC). The resulting pellet was 
re-suspended in 4 ml of TBF2 solution then incubated on ice for 1 hour. Aliquots of 150 µl 
were flash frozen in liquid nitrogen and stored at -80oC for future use.  
2.2 General molecular biology techniques 
2.2.1 Gel electrophoresis 
End-point PCR was conducted using a PCR thermocycler with the specific conditions and 
primer sequences of each reaction discussed in each section or figure legend (section 2.2.8). 
The 1x agarose gel was made as described in the materials (section 2.1.2). Generally a single 
gel would be run however two gels were run simultaneously for extraction work, one for gel 
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extraction and one for taking a photo. This was to avoid DNA damage to the PCR fragments 
caused by the UV from the camera. The RNA was loaded on the gel with 1x Orange G 
loading dye and compared against a 100 bp or 1 kbp DNA ladder (BioLabs, USA). The gels 
were run for 70 min at 90 V. After electrophoresis, the gel was briefly washed then stained 
with 5 µl ethidium bromide for 20 min then washed again for 30 min in distilled water. A 
photo of the gel was taken using BioRad chemdoc UV camera. 
2.2.2 Purification of DNA from mammalian cells 
The cell DNA was isolated using the following DNA extraction method which uses a high 
salt buffer and proteinase K. The cells were pelleted by removing the conditioned medium 
after treatment and washing the cellVZLWKȝO3%6&HOOVZHUHWKHQWUHDWHGZLWKȝO[
trypsin-EDTA and left to incubate for 1 min at 37oC, 5% CO2ȝORIFRQGLWLRQHGPHGLXP
was then added immediately to each well to dilute and neutralise the trypsin. The contents of 
each individual well was transferred to an eppendorf tube and centrifuged (5 min; RT, 6000 
rpm), forming a cell pellet (remove supernatant). 300 µl TNES buffer and 17.5 µl proteinase 
K (10 mg/ml) were added to the cell pellet which was then left to incubate overnight at 55oC. 
The following day, 100 µl 5M NaCl was added and the mixture was vortexed for 15 sec. The 
cell mixture was centrifuged (5 min, RT, Max). The supernatant was transferred to a new 
eppendorf tube with 420 µl 95% ethanol. This was then centrifuged (10 min, 4oC, Max). The 
supernatant was removed and the remaining pellet (DNA) was washed with 100 µl 70% 
ethanol, centrifuged (1 min, RT, Max), then re-suspended in 50 µl of filtered UHP water.  
2.2.3 RNAse treatment 
The isolated DNA was incubated at 37oC for 30 min with 2 µl of 10 µg/ml RNAse A. After 
incubation 4 µl of 3 M sodium acetate and 80 µl of 95% ethanol were added. This solution 
was incubated on ice for 10 min then centrifuged (5 min, RT, Max). The supernatant was 
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removed and the remaining pellet was washed with 70% ethanol. This was then centrifuged 
again (1 min, RT, Max) and the remaining DNA pellet was re-suspended in DEPC-treated 
water. The samples were frozen at -20oC.  
2.2.4 Gel extraction 
The product was run on a 1x agarose gel (section 2.2.1) then the band of interest was 
identified using a UV transilluminator UVP, extracted and purified using a QIAquick gel 
extraction kit (Qiagen). Briefly, the gel fragment was dissolved in buffer QG. Once bound to 
the filter membrane, the DNA was washed with 0.75 ml of buffer PE and centrifuged (1 min, 
RT, Max) before being eluted into an eppendorf tube. Finally 40 µl of elution buffer was 
added directly to the filter, left for 1 min then centrifuged (1 min, RT, Max). 
2.2.5 Ethanol precipitation of DNA 
The volume of the DNA sample was measured. A volume of half the original sample volume 
of 10 M NH3Acetone was added to give a final concentration of 3.3 M. Then two times the 
sample original volume of 100% ethanol was added and vortexed thoroughly. This was then 
left at -20oC overnight. The following day, the sample was centrifuged (10 min, 4oC, Max) to 
form a pellet and the liquid was aspirated. 175 µl of 70% ethanol was then added and the 
samples were centrifuged again at (1 min, 4oC, Max). The liquid was then aspirated again and 
the sample was centrifuged (1 min, 4oC, Max) and any remaining ethanol was removed. The 
samples were left to air dry for 5 min then re-suspended in dH2O and frozen at -20oC for 
further use.  
2.2.6 DNA isolation (alkaline lysis protocol) from bacteria 
Successful colonies were picked from the plate with a pipette tip and grown in 10 ml LB 
medium overnight in an aeration incubator (37oC). In order to perform the alkaline lysis 
protocol (ALP), an aliquot of 1.5 ml this bacteria was centrifuged (4 min, RT, 9000 rpm). 
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The supernatant was aspirated and the cell pellet was re-suspended in 100 µl of ALP solution 
I. Then 200 µl of ALP solution II was added and the sample was mixed by inverting the 
eppendorf tube 5 times. 150 µl of ALP solution III was added to the sample. The formulation 
of the three ALP solutions is shown in section 2.1.2. The tubes were then instantly inverted to 
mix the sample leaving a white curdled precipitate of protein and cellular membrane. This 
mixture was centrifuged (5 min, RT, Max) and the supernatant was decanted into a new 
eppendorf tube. 350 µl isopropanol was added to the supernatant and mixed. This was 
centrifuged (5 min, RT, Max) forming a white DNA pellet. The supernatant was removed 
and the pellet was washed with 175 µl of 70% ethanol then centrifuged again (1 min, RT, 
Max). The supernatant was removed and the remaining pellet was left to dry for 5 min. 
Finally the pellet was re-dissolved in 40 µl of DEPC treated water and frozen at -20oC. This 
method was taken from Sambrook et al. (1989). 
2.2.7 DNA isolation (Qiagen) from bacteria 
Once a positive colony (containing the vector) was identified using the ALP method, a 
method that provides a more purified sample of DNA was used, so that sequencing could be 
conducted on the DNA. The vector needed to be sequenced to confirm that the vector 
contains the correct insert. The QIAprep kit was used for a better quality of isolation of DNA. 
Firstly, 1.5 ml of the bacterial overnight culture (see section 2.2.6) was centrifuged (4 min, 
RT, 9000 rpm) then the supernatant was removed and the pellet was re-suspended in 100 µl 
P1 buffer. Following this 250 µl of buffer P2 was added to the sample and mixed by 
inverting the tube 5 times. 350 µl of buffer N3 was then added and again the sample was 
mixed by inverting the tube. A white precipitate was formed after this step. The sample was 
centrifuged (10 min, RT, Max) forming a white pellet at the bottom of the tube. The 
supernatant was carefully decanted from the eppendorf tube into a spin column and 
centrifuged (1 min, RT, Max). 0.5 ml of buffer PB was then added to clean the sample of 
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nuclease activity. A further wash was conducted by adding 0.75 ml of buffer PE. The sample 
was then centrifuged (1 min, RT, Max) and the supernatant removed. Finally 40 µl of buffer 
EB was added directly to the filter and left for 1 min before centrifugation (1 min, RT, Max). 
The isolated samples were then frozen at -20oC ready for sequencing. 
2.2.8 End-point PCR 
PCR was conducted using an Eppendorf thermocycler (Germany). Specific primers are 
shown in each section. The method used is the same as for the qRT-PCR discussed in section 
2.4.4.3. Briefly, a master mix containing: 21 µl of 2x Taqman master mix, 1 µl of each of the 
primers (10 µM), 150-200 µg cDNA, all made up to 42 µl (20 µl per well; allowing for 
error). The protocol used was 1 cycle (2 min at 50oC; 10 min at 95oC) followed by 40 cycles 
(20 sec at 95oC; 90 sec at 59oC) unless otherwise stated in the section text. 
2.3 Ligand binding assay 
2.3.1 Overview 
The method of ligand-binding was adapted from Bradfield and Poland (1988) but used 
3,4,3',4'-tetrachloroazoxybenzene (TCAOB; section 2.1.3) as a competitor because it binds 
with high affinity to the AhR (Poland et al., 1976). The method has been fully validated 
previously (Bazzi et al., 2009, Fan et al., 2009, Fried et al., 2007; Jiang et al., 2009). Bazzi 
(2008) validated many of the key elements of the experiment so the method used here applied 
the same controls and calculations. All of the experiments were conducted at 4oC. Once the 
[3H]-TCDD and compound were added to the rat liver cytosol, they were incubated at 4oC for 
16 hrs. All the experimental parameters were obtained from Bazzi (2008). The methods are 
explained in more detail in section 2.3.2 and 2.3.3.  
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2.3.2 Protein separation and calculation of dissociation constant 
2.3.2.1 AhR protein preparation 
The AhR protein was prepared from a rat liver of a recently culled female Charles River 
Wistar rat. The liver was a kind gift from Tim Smith (IBIOS Laboratory, University of 
Nottingham, UK). Every care was taken to ensure the liver was kept at 4oC to avoid 
degradation by proteases. The liver was weighed, shredded using scissors then homogenised 
in MDENG buffer at 4oC using a Potter-elvehjem glass homogeniser fitted with a Teflon 
pestle. The homogenate was centrifuged (20 min, 4oC, 12,000x g) using a Beckman J21-21 
centrifuge. The supernatant was then carefully removed and centrifuged (25 min, 4oC, 
440,000x g) in an Optima Max ultracentrifuge. Care was taken not to disturb the lipid layers 
on the top of the supernatant before removal. Aliquots of the supernatant were frozen down at 
-80oC until required. 
2.3.2.2 Determination of total protein concentration 
A Bradford assay was performed to measure the concentration of protein in the rat liver 
cytosol. A Bradford assay is a colorimetric protein assay based on absorbance shift of a dye. 
Initially protein standards were prepared from 0 to 100 µg of bovine serum albumin (BSA) in 
20 µl from a 10 mg/ml stock. The hepatic cytosol prepared in section 2.3.2.1 was diluted 
several times, to give several 10-fold dilutions. The 5x Bradford dye was diluted to 1x with 
distilled water and filtered with a 0.45 µm syringe. 1 ml of the 1x Bradford dye was added to 
each 20 µl sample and allowed to develop for 5 min. The absorbance at 595 nm was 
measured. The concentration of the BSA versus absorbance at 595 nm was plotted and the 
protein concentration of the hepatic cytosol was extrapolated. 
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2.3.2.3 [3H]-TCDD binding standard 
The equilibrium dissociation constant (Kd) was required for [3H]-TCDD to allow the 
calculation of the inhibition constants for the competitors. This was done slightly differently 
to the normal binding assay as instead of a fixed concentration of [3H]-TCDD, various 
concentrations were used. This was done in the presence and absence of 200 nM TCAOB to 
calculate the total binding and the non-specific binding. The protein samples were incubated 
at 4oC for 16 hours upon which the reaction was terminated by the addition of 30 µl of 10 
mg/ml dextran-coated charcoal. After centrifugation (10 min; 4oC; Max), the supernatant was 
transferred into scintillation vials. The radiation produced by this supernatant was measured 
using liquid scintillation spectroscopy. The data was converted from dpm into nM [3H]-
TCDD binding (Bazzi, 2008) then plotted with Graphpad Prism 5 using the ‘One site – Total 
and nonspecific binding’ option. This option then calculated the Kd and the maximum 
concentration of specific binding (Bmax). 
2.3.3 Competitive [3H]-TCDD binding assay 
2.3.3.1 Total binding 
The total binding was calculated by adding 1 µl 1 nM [3H]-TCDD to 200 µl of cytosolic 
protein along with various concentrations of the compound to be tested. The assay was done 
in triplicate then the average total binding of [3H]-TCDD was plotted against log 
concentration. A positive control of 1 nM [3H]-TCDD and 200 µl rat liver cytosol was used 
to show full binding of TCDD to the AhR protein. The samples were incubated at 4oC for 16 
hours upon which the reaction was terminated by the addition of 30 µl of 10 mg/ml dextran-
coated charcoal. After centrifugation (10 min; 4oC; Max), the supernatant was transferred 
into scintillation vials. The radiation produced by this supernatant was measured using liquid 
scintillation spectroscopy. 
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x Control: Total binding = cytosol + 1 nM [3H]-TCDD 
x Assay: Total binding = cytosol + 1 nM [3H]-TCDD + various concentrations of 
compound 
2.3.3.2 Non-specific binding 
Non-specific binding was determined in a similar way to the total [3H]-TCDD binding. 1 µl 1 
nM [3H]-TCDD was added to 200 µl of cytosol in the presence of various concentrations of 
the compound to be tested. In addition to this 200 nM TCAOB was added which is 200-fold 
more than the [3H]-TCDD so competitively binds to the AhR completely displacing [3H]-
TCDD. The non-specific binding assay was performed in triplicate. A positive control 
consisting of cytosol, 1 nM [3H]-TCDD and 200 nM TCAOB was used to show complete 
displacement of [3H]-TCDD. The samples were incubated at 4oC for 16 hours upon which the 
reaction was terminated by the addition of 30 µl of 10 mg/ml dextran-coated charcoal. After 
centrifugation (10 min; 4oC; Max), the supernatant was transferred into scintillation vials. 
The radiation produced by this supernatant was measured using liquid scintillation 
spectroscopy. 
x Control: Non specific binding = cytosol + 1 nM [3H]-TCDD + 200 nM TCAOB 
x Assay: Non specific binding = cytosol + 1 nM [3H]-TCDD + 200 nM TCAOB + 
various concentrations of compound 
2.3.3.3 Specific binding and analysis of binding data 
The specific binding was calculated as total binding of [3H]-TCDD minus the non-specific 
binding of [3H]-TCDD. This was plotted against log concentration of test compound. A 
positive control of [3H]-TCDD without test compound was included as a positive control and 
to indicate maximum binding. 
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x Control: Specific binding = Total – Non specific  
x Assay: Specific binding = Total – Non specific 
The total binding data obtained from each concentration of compound was averaged and the 
non-specific binding was taken away from this average to give the specific binding for each 
concentration. This data was plotted with Graphpad Prism 5. The IC50 (half maximal 
inhibitory concentration) was calculated by plotting the [3H]-TCDD specific binding (% of 
maximal response of vehicle control) vs. the concentration of the competitor (nM), then using 
the ‘log(inhibitor) vs, response’ option. The equilibrium inhibition constant (Ki) was 
calculated using the ‘one site – fit Ki’ option where the concentration of [3H]-TCDD was 1 
nM, and the Kd of the [3H]-TCDD was calculated as 1.24 nM (95% CI = 0.58 nM – 1.90 nM; 
calculated in Figure 3.28). 
2.4 Measurement of mRNA using quantitative real time-PCR 
2.4.1 Cell Treatment 
The investigation utilised two different types of assay which measure two different properties 
of the compounds tested. Firstly, an agonist assay was performed on each compound to 
confirm that it is an agonist of the AhR and that it induces CYP1A1. Secondly, the 
antagonistic property of the compound was tested by treating cells with a combination of the 
putative partial agonist/antagonist and TCDD. The induction of CYP1A1 was used as a 
measure of AhR activation by treating cells with various compounds for 4 hours. The 
compounds were diluted in medium to minimise the concentration of DMSO/solvent. Two 
flasks were prepared for each curve. The first was used purely to seed the 96-well plate and 
the second was for conditioning the medium. The cells were prepared several days in 
advance to allow approximately 90% confluence to occur. Research has shown that the fetal 
bovine serum contains known agonists including indirubin which has been shown to affect 
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the background levels of CYP1A1 mRNA (Adachi et al., 2001; Bazzi, 2008). It was therefore 
necessary to condition the medium to remove any pre-existing AhR agonists from the 
medium. The cells were transferred in a volume of 150 µl medium per well. The 96-well 
plate and flask containing the conditioned medium were left for 24 hours to allow for ~90% 
confluence. Agonist curves used 9 different concentrations of agonist with three biological 
replicates for each concentration. Antagonist curves also used 9 concentrations as well as an 
‘antagonist only’ control. The controls consisted of a vehicle control which was always 
included, as well as an antagonist only control (antagonism assay only) and a 10 nM TCDD 
control. After 4 hours of treatment, the conditioned medium (with compound) was removed 
and the cells were pelleted exactly as described in section 2.2.2. Briefly, the contents of each 
individual well was transferred to an eppendorf tube (using 1x trypsin-EDTA) and 
centrifuged (5 min; RT, 6000 rpm), forming a cell pellet. The supernatant was removed and 
the cell pellet was frozen at -20oC for further processing. 
Several of the compounds were originally dissolved in different solvents before being 
transferred into DMSO. The final concentrations of these compounds was <0.1% after 
dilution in conditioned medium. Behnisch et al. (2003) transferred mixed halogenated 
compounds from their original solvents (including nonane and toluene) to DMSO and found 
no loss of test compound or effects from the original solvents. Iso-octane has been previously 
shown not to interact with the AhR or affect the growth of the cells during treatment 
(~0.02%; Villeneuve et al., 1998). In this study, DMSO was used up to a maximum 
concentration of <0.02% whereas it has been previously used up to concentrations of >0.04% 
with no effect on the induction of the AhR or cell growth (Behnisch et al., 2003; Wahl et al., 
2008; Zeiger et al., 2001). 
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2.4.2 RNA purification 
RNA purification was carried out using an ‘Absolutely RNA® Miniprep Kit’ (Stratagene, The 
Netherlands) but due to the small sample size several changes were made to the method to 
UHGXFHPDWHULDO ORVV ,QLWLDOO\ȝl of the lysis buffer-ȕ-ME was added to each sample, 
PL[HGWKRURXJKO\WKHQȝO(WKDQROZDVDGGHGZLWKIXUWKHUPL[LQJXVLQJWKHSLSHWWH
This mixture was then added to a white spin cup and centrifuged (1 min, RT, Max). The 
‘Appendix I: Protocol Modifications for small sample’ was followed which omitted the pre-
ILOWUDWLRQVWHS7KHILOWUDWHZDVGLVFDUGHGDQGȝOORZVDOWZDVKEXIIHUZDVWKHQDGGHGDQG
centrifuged (2 min, RT, Max) until the filter was dry. The filtrate was once again discarded 
then 55 ȝO51DVH-free DNase I was added and incubated at 37oC, 5% CO2 for 15 min. The 
RNA was centrifuged (1 min, RT, MaxZLWKȝOKLJKVDOWZDVKEXIIHUIROORZHGE\ȝO
then ȝOORZVDOWZDVKEXIIHUWRUHPRYHWKH'1DVH,2QFHWKHILOWHUZDVGU\ȝOHOXWLRQ
buffer was added and left to incubate for 2 min before the sample was centrifuged in a fresh 
eppendorf tube. The sample was then immediately frozen at -20oC ready for cDNA synthesis. 
Quantitative analysis of the average amount of RNA purified in each sample was conducted 
using a NanoDrop 1000 spectrophotometer (Thermo Scientific, USA). A concentration of 20 
QJȝOP51$ZDVUHFRUGHGDOWKRXJKWKLVDQDO\VLVZDVQRWFRQGXFWHGRQHYHU\VDPSOH$[
agarose gel was run to confirm the quality of the extracted RNA. The protocol for running a 
gel is discussed in section 2.2.1. RNA is refered to mRNA in later sections for simplicity. 
2.4.3 cDNA synthesis 
cDNA was then synthesised using a ‘High capacity RNA-to-cDNA Kit’ (Applied 
%LRV\VWHPV86$E\DGGLQJȝO51$ to ȝORI51$-to-cDNA master mix (including 1 
ȝO57HQ]\PHPL[. Samples were then incubated for 60 min at 37oC followed by 5 min at 
95oC using an Eppendorf thermocycler (Germany). A ‘no RevT’ containing no reverse-
transcriptase and a ‘no RNA’ control were also conducted to measure for contamination in 
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the reagents. cDNA samples were then immediately frozen at -20oC ready for PCR analysis 
(section 2.4.4). 
2.4.4 Quantitative Real Time-PCR 
2.4.4.1 Overview 
The quantitative real-time polymerase chain reaction (qRT-PCR) was conducted using an 
ABI 7500fast RT-PCR machine. The method was adapted from previous work which used a 
Stratagene MX4000 RT-PCR machine using reagents from Stratagene (Wall, 2008). This 
new machine required the same level of calibration as the original machine to confirm PCR 
efficiency and accurate measurement of mRNA levels. CYP1A1 mRNA was measured and 
QRUPDOLVHG DJDLQVW WZR UHIHUHQFH JHQHV ȕ-actin and AhR. This method meant that even if 
there was a slight variation in RNA concentration or reagent quantities, the CYP1A1 mRNA 
could still be normalised against other samples as the m51$ OHYHOV RI ȕ-actin and AhR 
would always remain the same in every sample. An internal normalisation dye, 5(6)-carboxy-
X-rhodamine (ROX) dye, was used, VR WKH G\H RQ WKH ȕ-actin probe was changed to CY5 
from previous work (Bell et al., 2007; Bazzi, 2008; Wall, 2008). The probe and primer 
sequences for rat and human (Table 2.3) IRU &<3$ ȕ-actin and AhR were designed 
previously (Bell et al., 2007) with the exception of the CY-G\HXVHG IRU WKH WZRȕ-actin 
probes. The primers and probes for the mouse genes, rat CYP1A2 and CYP1B1 were 
designed using the NCBI database (http://www.ncbi.nlm.nih.gov) and Primer3 software. 
2.4.4.2 Primers and probes 
Bell et al., (2007) found that the three pairs (CYP1A1, AhR and ȕ-actin) of primers for rat or 
human could be run in the single multiplex reaction. To measure the efficiency of the primers 
and probes used, stand curves were conducted. Standard curves were constructed for all of 
the primer pairs to confirm that they worked at ~100% efficiency.  
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Gene Sequence Dye 
 
 
 
 Rat CYP1A1 Primer (f)   CCACAGCACCATAAGAGATACAAG 
 
 
Primer (r)   CCGGAACTAGTTTGGATCAC 
 
 
Probe     ATAGTTCCTGGTCATGGTTAACCTGCCAC FAM-BH1 
    Rat AhR Primer (f)   GCAGCTTATTCTGGGCTACA 
 
 
Primer (r)   CATGCCACTTTCTCCAGTCTTA 
 
 
Probe     TATCAGTTTATCCACGCCGCTGACATG HEX-BH1 
    5DWȕ-Actin Primer (f)   CTGACAGGATGCAGAAGGAG 
 
 
Primer (r)   GATAGAGCCACCATCCACA 
 
 
Probe     CAAGATCATTGCTCCTCCTGAGCG CY-5-BH2 
    Rat CYP1A2 Primer (f)   CTCAACCTCGTGAAGAGCAG 
 
 
Primer (r)   CTCCTGAGGGATGAGACCAC 
 
    Rat CYP1B1 Primer (f)   AGGATGTGCCTGCCACTATT 
 
 
Primer (r)   TGACGTATGGTAAGTTGGGTTG 
 
    Human CYP1A1 Primer (f)   GTTGTGTCTTTGTAAACCAGTG 
 
 
Primer (r)   CTCACTTAACACCTTGTCGATA 
 
 
Probe     CAACCATGACCAGAAGCTATGGGT FAM-BH1 
    Human AhR Primer (f)   ATACAGAGTTGGACCGTTTG 
 
 
Primer (r)   CTTTCAGTAGGGGAGGATTT 
 
 
Probe     TCAGCGTCAGTTACCTGAGAGCCA HEX-BH1 
    +XPDQȕ-Actin Primer (f)   GACATGGAGAAAATCTGGC 
 
 
Primer (r)   AGGTCTCAAACATGATCTGG 
 
 
Probe     ACACCTTCTACAATGAGCTGCGTGT CY-5-BH2 
    Mouse CYP1A1 Primer (f)   TCACCATCCCCCACAGCACCA 
 
 
Primer (r)   CGCTTGTCCAGAGTGCCGCT 
 
 
Probe     CCATGACCGGGAACTGTGGGG FAM-BH1 
    Mouse AhR Primer (f)   GGATTTGCAAGAAGGAGAGTTC 
 
 
Primer (r)   TTGTGCAGAGTCTGGGTTTAGA 
 
 
Probe     GCTGGTTGTCACAGCAGATG HEX-BH1 
    0RXVHȕ-Actin Primer (f)   AGATGACCCAGATCATGTTTGA 
 
 
Primer (r)   CGTGAGGGAGAGCATAGCC 
 
 
Probe     GTCGTACCACAGGCATTGTG CY-5-BH2 
    
Table 2.3: Sequences of rat, human and mouse primers and probes – Forward (f) and Reverse (r) primers and probes are 
indicated. Sequences are shown from 5’ to 3’. FAM: iscarboxy fluorescein, HEX: hexachlorofluorescein and CY-5: 3'-
deoxy-5-(cyanine dye 3)uridine 5'-trisphosphate. The reporter dye is located at the 5’ end of the probe, and the quencher dye, 
Black Hole-1 or -2 (BH1 or BH2), is found at the 3’ end. The nucleotide sequences for rat and human: CYP1A1, AhR and ȕ-
actin were obtained from Bell et al., 2007 (with the exception of the CY-5 dye used for ȕ-actin). Primers and probes for the 
mouse genes and for rat CYP1A2 and CYP1B1 were designed using the NCBI database (http://www.ncbi.nlm.nih.gov) and 
Primer3 software 
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The efficiency of all of the primers and associated probe (for each species) to bind and 
transcribe the target gene was calculated for each primer set. RNA and cDNA were produced 
from untreated cells as described earlier. Five dilutions were then determined (1, 0.5, 0.25, 
0.125, 0.062) then measured using qRT-PCR. Each dilution should shift the PCR curve a set 
distance to the right, indicating that there is one cycle worth of RNA less than the previous 
dilution.  ܧ݂݂݅ܿ݅݁݊ܿݕ =  10ቀ ିଵ௦௟௢௣௘ቁ െ  1 
Equation 2.1: Calculation of the PCR efficiency 
The PCR efficiency was calculated using Equation 2.1 and are presented in the results 
(Figure 3.3). The slope was calculated using Graphpad Prism 5. The rat CYP1A1 primers 
produced a product of 124 bp, the AhR priPHUVSURGXFHGDSURGXFWRIESDQGWKHȕ-actin 
primers produced a product of 107 bp. The PCR product size of the CYP1B1 and CYP1A2 
primers was 192 bp and 264 bp, respectively. The human CYP1A1 primers produce a PCR 
product of 122 bp, the AhR primers proGXFHGDSURGXFWRIESDQG WKHȕ-actin primers 
produce a product of 139 bp. The PCR product size for mouse was: CYP1A1 was 175 bp, for 
ȕ-actin it was 168 bp and for AhR it was 233 bp. The primer and probe sequences for mouse 
&<3$$K5DQGȕ-actin genes are shown in Table 2.3. 
2.4.4.3 Measurement of mRNA induction with Taqman probes 
qRT-PCR was conducted using an ABI 7000fast PCR machine. A previously calibrated 
method (Wall, 2008) was adapted for use with this machine. The Taqman® master mix used 
in this new method requires the activation of Uracil-DNA Glycosylase (UDG) and AmpliTaq 
Gold® DNA polymerase; Ultra Pure (UP) enzyme activation before cycling and real-time 
measurement takes place. UDG prevents the re-amplification of previously synthesised PCR 
products by removing any uracil incorporated in the amplicons (Taqman master-mix 
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protocol, 2007). The master mix also contains a ROX™ passive reference dye (ROX) which 
is used to normalise between cycles. A complete master mix was prepared containing; 21 µl 
2x Taqman master mix, set concentrations of primers and probes as indicated in Table 2.4, 
150-200 µg cDNA, all made up to 42 µl (20 µl per well; allowing for error). Each sample 
was first mixed in an eppendorf tube before being transferred to the qRT-PCR plate.  
  Rat Human Mouse 
     CYP1A1 Primers 100 nM 200 nM 200 nM 
 
Probe 50 nM 100 nM 100 nM 
Actin Primers 200 nM 100 nM 100 nM 
 
Probe 100 nM 50 nM 50 nM 
AhR Primers 300 nM 300 nM 300 nM 
 
Probe 150 nM 150 nM 150 nM 
     
Table 2.4: Primer and probe concentrations for qRT-PCR – The required concentrations of all the probes and primers in 
order to create the complete master mix. The initial concentration of the probes and primers was  ȝ0 DQG  ȝ0
respectively and are shown in Table 2.3.  
Taqman Time Temperature 
    
1 cycle UDG activation 2 min 50oC 
 AmpliTaq gold, UP enzyme activation 10 min 95oC 
    
40 cycles Denature 20 sec 95oC 
 Anneal/Extension 90 sec X1 
    
SYBR green Time Temperature 
    
1 cycle Denature 10 min 95oC 
    
40 cycles Denature 30 sec 95oC 
 Anneal 1 min 58oC 
 Extension 1 min 72oC 
    
Table 2.5: Thermal cycling conditions for qRT-PCR – Shows the times and temperatures for each step of the qRT-PCR 
protocol for the 7500fast RT-PCR machine when using Taqman gene expression master mix. X1: 58oC for rat, 59oC for 
human, 60oC for mouse and 63oC for rat AhR (section 3.2.7). 
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 For UDG activation, 2 min at 50oC is required followed by 10 min at 95oC for AmpliTaq 
gold UP enzyme activation. These two stages are critical for accurate PCR results. The full 
cycling conditions are described in Table 2.5. Addition conditions for other primer pairs will 
be described when stating the primer nucleotide sequences. 
2.4.4.4 Measurement of mRNA induction with SYBR green dye 
SYBR green dye allows the quantition of a single gene without requiring a probe. The dye 
binds non specifically to double stranded DNA which is the reason only a single gene can be 
measured per reaction. CYP1B1 and CYP1A2 were run separately using: 20 µl Brilliant 
SYBR Green QPCR master mix, CYP1B1 or CYP1A2 primers (10 µM) and 150 ng cDNA, 
made up to 40 µl with DEPC treated water (providing 2 x 20 µl reactions). The genes were 
then normalised against AhR and ȕ-actin which were run separately as a multiplex. A 20 µl 
of each sample was added to each well of a 96-well qRT-PCR plate. The PCR analysis was 
conducted using an Applied Biosystems 7500fast RT-PCR machine and used the protocol 
shown in Table 2.5. 
2.4.5 Data Analysis and controls 
The EC50 was used to compare between compounds and was calculated as 50% of the 
maximal induction with the error used being the 95% confidence interval (95% CI). As well 
as the cDNA synthesis controls (No RevT and No RNA), each run conducted contained 
several important inter-run controls for normalising the data against other curves. Firstly, a 
known positive control from cells treated with a 10 nM TCDD only and a vehicle control 
cDNA was used in every experiment. These are from pre-existing batches of cDNA so 
should be the same for each experiment by removing the inter-experiment error. These two 
samples will be used to normalise between curves. The next control used was 10 nM TCDD 
only control which was treated the same time as the other samples in the experiment. This 
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control is used to normalise the data within a particular run so that the normalised data can be 
graphically depicted with 10 nM TCDD as 100% of the maximal response. Finally, a no 
template control (NTC) was performed to confirm that the complete master mix was free of 
cDNA contamination. 
The software associated with the ABI 7500fast collected all of the raw fluorescence data 
from each run and provided the Ct at which the level of RNA crossed the fluorescence 
threshold. As discussed previously, the master mix contains ROX fluorescent dye which is 
used to normalise between wells in a plate and removes some of the error associated with 
sample volume. The next stage of the data analysis uses qBasePlus (Hellemans et al., 2007; 
Vandesompele et al., 2002) which normalises the CYP1A1 RNA levels against the two 
reference genes (normalisation genes)ȕ-actin and AhR. ȕ-actin mRNA was chosen because 
it is in high abundance in the genome and AhR mRNA was chosen to confirm that it was 
present. Furthermore, both genes were unaffected by the treatments (Head and Kennedy, 
2007; Laupeze et al., 2002; Walker et al., 1999; Wu et al., 2002). An excel worksheet was 
used to sort the data in to the correct format for qBasePlus by removing errors and correcting 
the certain jargon words and columns titles. The data was then normalised in qBasePlus, 
which assumes that the PCR efficiency for all three genes is always 100%. The normalised 
data is transferred to another excel worksheet where it is initially normalised against the two 
reference cDNA samples; 10 nM TCDD control and vehicle control. The same cDNA is used 
on each curve reducing the error of inter-experiment differences. This allows normalisation 
between curves in the same experiment. Finally, each curve has a 10 nM TCDD only control 
which is automatically assigned as 100% of the maximal response for each curve. This data is 
then plotted on to an XY graph using GraphPad Prism 5 as % maximum response against 
log[agonist]. The % maximal response data was plotted using the standard deviation of the 
data derived from the three replicates after qBasePlus analysis. GraphPad Prism allows the 
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estimation of the EC50 of each of the curves as well as providing the 95% confidence interval 
of this estimation. The EC50 can then be used to calculate the TEF by dividing the EC50 of the 
agonist by the EC50 for TCDD alone. Curves were generated using the settings: ‘log[agonist] 
vs. normalised response’(Equation 2.2).  
ܻ = ܤ݋ݐݐ݋݉ + ܶ݋݌ െ ܤ݋ݐݐ݋݉
1 + 10(௅௢௚ா஼ఱబି௑) 
Equation 2.2: Concentration-response curve equation – The following equation was used to calculate the EC50 for all of 
the compounds tested using GraphPad Prism 5 (log[agonist] vs. normalised response). Bottom: lower plateau; Top: upper 
plateau; X: concentration of agonist; Y: response. Equation assumes hill slope = 1.0. 
Some of the figures show the raw qRT-PCR data which was shown as ¨Rn against Ct. The Rn 
(normalised reporter) is the ratio of the fluorescence emission intensity of the reporter dye 
verses the fluorescence emission intensity of the internal ROX reference dye. ¨Rn is the 
normalisation of Rn by subtracting the baseline fluorescence. 
2.4.6  Schild regression 
Schild regression is a measure of an antagonist’s potency and is used to calculate the Kd for 
the antagonist-complex (Equation 2.3; Kenakin, 1997).  
ܦ݋ݏ݁ ܴܽݐ݅݋ =  ܤா஼ఱబܣா஼ఱబ  ܦ݋ݏ݁ ܴܽݐ݅݋ = [ܤ]ܭ஻ +  1 ܮ݋݃(ܦ݋ݏ݁ ܴܽݐ݅݋ െ 1) = ܮ݋݃([ܣ݊ݐܽ݃݋݊݅ݏݐ]) െ  ܮ݋݃(ܭ஻) 
Equation 2.3: Schild equation – AEC50 : EC50 of TCDD alone, BEC50 : EC50 of TCDD in the presence of antagonist, [B]: 
Concentration of antagonist, KB: equilibrium dissociation constant of the antagonist. 
The dose-ratio is calculated which is a measure of the increase in agonist concentration 
required to achieve the same response as the antagonist concentration is increased. It can be 
calculated by dividing the EC50 of the agonist in the presence of an antagonist by the EC50 of 
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the agonist in the absence of an antagonist. Increasing the concentration of antagonist will 
move the curve further to the right. Several different concentration-response curves in the 
presence of various concentrations of antagonist are required for Kd (KB) calculation. The 
log(Dose ratio-1) is plotted against log[Antagonist] for each concentration-response curve. 
For competitive antagonism a straight line is expected, with the point at which the line 
intersects the x-axis equalling the Kd for that antagonist. In order to improve accuracy it is 
necessary to perform several different concentrations of antagonist to accurately predict the 
position of the trend line. 
2.5 Retroviral expression of AhR in a mouse cell line 
2.5.1 Overview 
This study and previous work have shown that there are significant species differences in 
AhR activation between rat and human by dioxin-like compounds. It is not currently 
understood what confers these differences; whether it is a difference in the mechanism of 
activation or purely as a result of the ligand binding potential of the AhR. This section of the 
project aimed to discover if the AhR is, at least in part, responsible for these differences by 
directly comparing the activation of rat and human AhR in a common background. This 
involved isolating the AhRs from rat and human then transfecting them into a cell line with 
low levels of AhR. A recombinant Hepa1 mouse cell line with reduced levels of AhR was 
used allowing direct comparison of the two AhRs. Previously the AhR cDNAs were cloned 
into pFastBac1 vectors (Fan et al., 2009). pGEM-T was used to subclone the AhR fragments 
out of pFastBac1 and into pRevTRE retroviral vector. Retroviral expression was used to 
create a stable cell line as previous research had shown direct transfection did not stably re-
introduce the AhR (Ma, personal communication). The new cell lines were then treated with 
TCDD and 5F 203 to see if there was a difference in compound potency and associated 
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CYP1A1 induction compared with wild-type cells. The mRNA levels of CYP1A1 were 
measured using qRT-PCR as described earlier (section 2.4). 
2.5.2 Preparing AhR for subcloning 
2.5.2.1 Rat AhR vector 
The rat AhR cDNA was isolated previously and cloned into pFastBac1 as described by Fan et 
al. (2009). Briefly liver mRNA from a Charles River Wistar rat was extracted and PCR was 
used to clone the AhR. The AhR PCR fragment was then inserted into a pFastBac1 plasmid 
between the SalI and HindIII sites to make the completed AhR vector as shown in Figure 2.2 
(Fan et al., 2009). 
  
Figure 2.2: Vector map of rat AhR in pFastBac1 – The vector map shows the structure of the pFastBac1 plasmid and the 
location of the most important restriction sites. The vector is 7271bp in size including the AhR which is 2556bp (excluding 
restriction sites). The vector was cloned previously by Fan et al. (2009). The diagram shows the location of primer sites for 
PCR of gene of interest. The vector is ampicillin resistant. 
The AhR construct cloned by Fan et al. (2009) contained a polyhistidine-tag (Hexa histidine-
tag; His-tag), containing 6 histamine amino acids, directly at the end of the AhR gene before 
the stop codon and HindIII restriction site. This tag was removed for this experiment to avoid 
Richard Wall 
 
73 
 
the possibility of interference with the expression of the protein and its capacity to bind AhR 
ligands. This was done using PCR and is described in Figure 2.4. 
2.5.2.2 Human AhR vector 
The human AhR cDNA (pSporthAhR2) was a kind gift from Susan Moran (McArdle 
Laboratory for Cancer Research, University of Wisconsin-Madison Medical School) and was 
initially cloned in a pSV-Sport1 vector (Dolwick et al., 1993) from human HepG2 hepatoma 
cells. This was then subcloned into pFastBac1 by Fan et al. (2009) between the SalI and 
HindIII binding sites (Figure 2.3).  
 
Figure 2.3: Vector map of human AhR in pFastBac1 – The vector map shows the structure of the pFastBac1 plasmid and 
the location of the most important restriction sites. The vector is 7281bp in size including the AhR which is 2566bp 
(excluding the restriction sites). The vector was subcloned previously by Fan et al., 2009. The diagram shows the location of 
primer sites for PCR of gene of interest. The vector has ampicillin resistance. 
A His-tag was also added directly after the AhR sequence by Fan et al. (2009) to allow 
purification of the AhR protein however for this experiment it was removed in case it 
interfered with the expression and capability to bind AhR ligands.  
Richard Wall 
 
74 
 
2.5.2.3 Removal of AhR from pFastBac1 
In order to make sure both of the AhR proteins expressed properly in the mouse cell line, it 
was necessary to remove the His-tags. Two primers were designed to PCR the AhR gene out 
of the pFastBac1 plasmid (rat or human). The reverse primer had a secondary role as it 
contained an overhang forcing a stop codon and a HindIII restriction site directly after the 
AhR gene, bypassing the His-Tag completely. This is shown more clearly in Figure 2.4. 
Pro Ser Gly Phe Leu His His His His His His *** 
C C C A G C G G A T T C C T G C A T C A C C A T C A C C A T C A C T A G 
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |       
G G G T C G C C T A A G G A C G T A G T G G T A G T G G T A       
                                    
                                    
G G G T C G C C T A A G G A C A T C T T C G A A    (Reverse Primer) 
 
Pro Ser Gly Phe Leu *** HindIII 
C C C A G C G G A T T C C T G T A G A A G C T T 
| | | | | | | | | | | | | | | | | | | | | | | | 
G G G T C G C C T A A G G A C A T C T T C G A A 
 
Figure 2.4: Primer design with restriction site and stop codon overhang for rat– The figure shows the nucleotide and 
amino acid sequences for rat before and after the use of the reverse primer which forced in a new HindIII restriction site and 
stop codon (***). Reverse primer is shown with the overhang highlighted; Blue: stop codon, Green: HindIII restriction site. 
Amino acid sequence is in bold. The primer is shown from 3’ to 5’ and the AhR sequences are both shown from 5’ to 3’. 
Note: this principle also applies to the human reverse primer as well as rat. 
PCR was conducted using Extensor Hi-Fidelity PCR Master Mix (ABgene, UK) as it has a 
low copy error rate. Each reaction consisted of 12.5 µl of extensor master mix (Buffer 1), 2.5 
µl of 2 µM forward and reverse primers (final concentration of 200 nM), DNA to a final 
concentration of 50 ng and RNA/DNA free water. See Table 2.6 for primer sequences.  
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Gene Sequence 
  
 Human AhR vector  
 
Primer (f)    GTCGACATGAACAGCAGCA 
 
Primer (r)    AAGCTTCTACAGGAATCCACTGGATGTC 
 
  
Rat AhR vector  
 
Primer (f)    GCGGAATTCAAAGGCCTAC 
 
Primer (r)    AAGCTTCTACAGGAATCCGCTGGGTGT 
 
    
 
Table 2.6: PCR primers for rat and human AhR removal from pFastBac1 – Primer sequences for rat and human AhR 
removal and adjustment of restriction site locations. Sequences are from 5’ to 3’. Nucleotides in bold are the overhang; blue: 
stop codon, green: HindIII restriction site. Sequences were designed with assistance from VectorNTI and Primer 3 software. 
The Extensor master mix was used as per manufactures instructions. A PCR thermocycler 
was used with the protocol shown in Table 2.7. 
Step Temperature Time Number of Cycles 
    
Initial denaturation 94oC 2 min 1 cycle 
    
Denaturation 94oC 10 sec  
Annealing 58oC 30 sec 25 cycles 
Extension 68oC 2 min  
    
Final Extention 68oC 7 min 1 cycle 
    
 
Table 2.7: Times and temperatures for Extensor Hi-Fidelity PCR to isolate AhR from pFastBac1- PCR was carried out 
using a thermocycler. Information was taken from the Extensor Hi-Fidelity PCR master mix manual (ABgene, UK). 
PCRs product of 2569 bp and 2578 bp was obtained for rat AhR and human AhR, 
respectively. These products were then purified using a gel to remove any vector debris 
(section 2.3.2.4) then inserted into pGEM-T vectors for further processing (section 2.3.3). 
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2.5.2.4 Purifying the PCR fragment 
The product of the PCR reaction discussed in section 2.5.2.3 was run on a 1x agarose gel 
(section 2.2.1) to remove any pFastbac1 vector debris or unwanted fragments. A small 
background band may also be expected at ~7 kbp bp due to pFastBac1 vector as well as 
various primer dimers. A quick load 1 kbp DNA ladder (Biolabs) was run alongside the 
samples for fragment size measurement. 
The band of interest was excised from the gel manually using a UV transilluminator UVP 
and purified using a QIAquick gel extraction kit (Qiagen) to remove sample from the agarose 
gel (section 2.2.4). The concentration of the PCR product was then measured using a Nano-
drop spectrophotometer and kept at -20oC ready for subcloning into pGEM-T. 
2.5.3 Subcloning into a pGEM-T plasmid 
2.5.3.1 Ligation of PCR product with pGEM-T vector 
The PCR product formed by the Extensor PCR was inserted into pGEM-T by forcing in 3’ 
terminal T-overhangs on to the PCR fragment which greatly improves the efficiency of the 
ligation as described in the pGEM-T manual (pGEM-T Vector Systems - Technical Manual, 
2009). The vector contains specific binding sites and promoters for T7 and SP6 polymerase 
for low error rate transcription, located either side of the multiple cloning site (containing the 
3’ T-overhangs and a wide range of restriction sites). The vector also contains a pUC site 
which allows high-copy replication in E. coli and a phage F1 region to allow rescue of single-
stranded DNA (pGEM-T Vector Systems - Technical Manual, 2009). 
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Figure 2.5: Vector map of pGEM-T without AhR insert – pGEM-T was used to subclone the AhR fragments out of 
pFastBac1 and into pRevTRE retroviral vector. Two new restriction sites were added, SalI and HindIII, when inserting the 
AhR PCR fragments. The AhR, either rat or human, was inserted in the multiple cloning region (3’ T-overhangs). Note: 
Although the vector is shown to be circular in the above diagram, before insertion of the gene with 3’ T overhangs, it is 
always linear. The vector has ampicillin resistance. 
The reactions were set up as described in Table 2.8 using the protocol described in the 
pGEM-T manual (pGEM-T Vector Systems - Technical Manual, 2009). The mixtures were 
incubated overnight at 4oC to obtain the maximum number of transformants. Freeze-thaw 
cycles were avoided to reduce the chance of degradation of the T4 ligase buffer.  
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Reaction Component Standard Reaction 
Positive 
Control 
Background 
Control 
    
2X Rapid Ligation Buffer, T4 DNA 
Ligase 5 µl 5 µl 5 µl 
pGEM-T vector (50ng) 1 µl 1 µl 1 µl 
PCR Product X µl* - - 
Control Insert DNA - 2 µl - 
T4 DNA Ligase (3 Weiss units/µl) 1 µl 1 µl 1 µl 
Nuclease-free water to a final volume of 10 µl 10 µl 10 µl 
 
   
Table 2.8: Ligation reaction volumes for pGEM-T reaction – Shows volumes required for ligation of PCR product to p-
GEM-T vector. Values taken from the p-GEM-T manual (pGEM-T Vector Systems - Technical Manual, Promega, 2009). 
*PCR product mass calculated using Equation 2.2 (Rat/human = 250 ng/µl). 
A simple calculation (Equation 2.3) was used to calculate the amount of PCR product (AhR 
genes; section 2.5.2.4) required for successful ligation. A molar ratio of 5:1 (insert:vector) 
was used. The pGEM-T vector was 3000 bp in size at a mass of 50 ng. 
ng of vector × kbp size of insert
kbp size of vector
 × insert: vector molar ratio = ng of insert 
Equation 2.4: Calculation of the concentration of insert required for ligation - Initial concentration of insert was 
measured using a Nano-drop spectrophotometer. 
The rat and human inserts were 2569 bp and 2578 bp (including a small section of upstream 
region due primer binding), respectively, with a concentration of 250 ng/µl therefore 15 ng of 
insert was added to the standard reaction (Table 2.8). Once the reactions were completed it 
was necessary to use competent bacteria cells to grow successful clones. 
2.5.3.2 Transformation of pGEM-T 
The plasmids produced, when the insert was ligated into the cloning vector, were transformed 
into the chemically competent JM109 cells to allow selection of the successfully ligated 
plasmids. 10 µl of rat or human vector formed from the ligation reaction described in section 
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2.5.3.1 was added to 30 µl chemically competent JM109 cells and left on ice for 20 min. This 
was then incubated at 42oC for 1 min before being incubated on the ice again for a further 2 
min. 200 µl LB medium (warmed to 37oC) was added to the cells and incubated at 37oC for 
20 min. After incubation, the mixture was spread over an LB agar plate, with ampillicin 
antibiotics and incubated overnight at 37oC. Two controls were also run simultaneously with 
the ligation products; a positive control which consisted of an uncut vector (pRevTRE) and a 
negative control of just JM109 cells with no vector, and hence, no ampicillin resistance. After 
this, 4-5 colonies were selected from each plate and grown in an aeration incubator overnight 
at 37oC in 10 ml LB broth.  
The bacteria were processed by one of two methods depending on the intended use of the 
vector after isolation. A simple alkaline lysis protocol (ALP) was used (section 2.2.6) when 
the purity of the DNA was not important and allows quick and efficient isolation of unknown 
colonies ready for testing by double digestion. A Qiagen miniprep DNA isolation kit was 
used (section 2.2.7) when the purity of the sample is important such as sequencing but is 
significantly more expensive to conduct. 
2.5.3.3 Double digestion to confirm successful cloning 
The concentration of DNA obtained from the transformation was measured with a Nanodrop 
spectrophotometer. Gel electrophoresis was then used to confirm the presence of the positive 
clone with ligated AhR gene. The plasmid was double digested with SalI and HindIII 
restriction enzymes using the volumes described in Table 2.9. The reaction was incubated at 
37oC for 2 hours before being returned to ice. 
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Component Volume 
  
DNA 3 µl (~100 ng) 
SalI enzyme 1 µl 
HindIII enzyme 1 µl 
NEBuffer 2 1 µl 
dH2O 14 µl 
  
Table 2.9: Volumes required for double digestion of vector (with AhR insert) – The components were kept on ice until 
required. The mixture was incubated at 37oC for 2 hours. The products formed were then run on a 1x agarose gel for 
conformation. 
The digestion products were run on a 1x agarose gel as described in section 2.2.1. Double 
digestion of a successful clone should give fragments of 2544 bp and 2553 bp for rat AhR 
and human AhR (including removal of upstream region), respectively, as well as 3000 bp for 
the pGEM-T vector. Additional single digestions with SalI and HindIII were conducted on 
the clones for confirmation of successful insertion of the AhR gene. The putative successful 
clones were then sequenced to confirm that the new restriction site and stop codon had been 
successfully forced into the sequence. The sequencing was done at Source Bioscience 
LifeSciences (Oxford, UK) and used the stock primers; T7F: 
TAATACGACTCACTATAGGG and SP6: ATTTAGGTGACACTATAG. Comparison of 
the known AhR sequence and the sequence of the clones was done using AlignX software 
(VectorNTI). A further double digest was then conducted, run on a 1x agarose gel and 
extracted ready for ligation into pRevTRE (section 2.5.4). 
2.5.4 Cloning into pRevTRE 
2.5.4.1 Ligation of insert to pRevTRE 
The gene of interest was removed from the pGEM-T vector by double digestion with SalI 
and HindIII restriction enzymes as described in section 2.5.3.3. This was then run on a 1x 
agarose gel to separate the gene from the vector (section 2.2.1). A quick gel extraction kit 
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was used to remove the digested insert as described in section 2.5.2.4. The concentration of 
the insert was measured using a Nanodrop spectrophotometer.  
 
Figure 2.6: Vector map of pRevTRE without AhR insert – The vector used to produce retrovirus (although specific 
packaging cells are also required). Both rat and human AhRs used SalI and HindIII restriction sites. The vector requires the 
presence of the pRevTet-Off vector (without tetracycline/doxycyline) in order for transcription of the gene in the host cells. 
At the same time the new vector, pRevTRE (Figure 2.6), was also double digested with the 
same enzymes (HindIII and SalI; section 2.5.3.3). The mixture was then run on a 1x agarose 
gel to remove the unwanted part of the vector (section 2.2.1). A gel extraction kit was used to 
excise the double digested vector using the method described in section 2.5.2.4. The 
concentration of the vector was measured using a Nanodrop spectrophotometer. The double 
digested insert and vector DNA obtained from the gel extraction were concentrated using an 
ethanol based assay (section 2.2.5).  
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Component Volume 
  
Plasmid 1 µl 
Insert 7 µl 
Ligation buffer 1 µl 
Ligase enzyme 1 µl 
  
Table 2.10: Volumes of the components required for ligation of the AhR insert with pRevTRE – The enzyme was kept 
on ice at all times. The highest concentration possible of insert was used. The reaction was left overnight at 16oC. 
The double digested gene and vector were then ligated together using T4 ligase overnight at 
16oC. Table 2.10 shows the volumes of ligation components required for the reaction. The 
enzyme was kept on ice however the buffer was warmed to room temperature to allow it to 
be mixed properly before use. The ligation products were then transformed into chemically 
competent JM109 cells. 
2.5.4.2 Transformation of pRevTRE:insert 
The pRevTRE:insert vectors were transformed into JM109 cells as discussed previously in 
section 2.5.3.2. Briefly, the JM109 cells with vector were transformed overnight until 
colonies had formed. From these plates, 4 colonies were selected and grown overnight in 10 
ml LB broth. The samples were then centrifuged to produce a bacterial pellet allowing 
purification using the ALP method as previously discussed in section 2.5.3.2. The 
concentration of the resulting purified vector was measured using a Nanodrop 
spectrophotometer. 
2.5.4.3 Confirmation of successful cloning 
The clones were double digested with SalI and HindIII (described in section 2.5.3.3) and run 
on a 1x agarose gel (section 2.2.1) to confirm that the ligation was successful. Bands would 
be expected at 2544 bp and 2553bp for the rat and human AhR inserts, respectively, and at 
6487 bp for the pRevTRE vector. Successful clones were purified from the bacterial cells 
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again using the Qiagen miniprep kit (section 2.2.7). Sequencing was conducted on the 
successful clones using the following primers; pRevTREfor: 
TCCACGCTGTTTTGACCTCC and pRevTRErev: CCCCCTTTTTCTGGAGAC. It was 
necessary to concentrate the DNA in order to fulfil the requirements of the sequencing 
protocols. This was conducted using ethanol precipitation (section 2.2.5). Sequencing showed 
that the pRevTRE vectors contained the relevant AhR gene.  
2.5.5 Creation of stable virus producing cell lines 
2.5.5.1 Safety of RevTet system 
Although the Moloney murine leukemia virus (MoMuLV) retrovirus is not normally capable 
of infecting human cells, the Revtet system produces a virus which is capable of infecting 
human cells (pRevTet System Handbook). Therefore all of the experiments were conducted 
using Biosafety Level 2 practices and safety equipment. This involves using a designated 
class II laminar flow hood, protective lab attire and decontamination of potentially infectious 
waste in Trigene disinfectant prior to disposal. The AhR genes which were to be infected into 
the BpRc1 cells do not pose a risk to human health. 
2.5.5.2 RevTet system overview 
The retroviral expression was conducted using the RevTet system (Clontech, USA) which 
utilises the MoMuLV retrovirus to infect target cells with the gene of interest. The retrovirus 
system utilises a packaging cell line to synthesise the virus before infecting the host cells. In 
order to start this synthesis, two vectors are required, pRevTet-Off and pRevTRE. The gene 
of interest, AhR, is inserted into the pRevTRE vector with its transcription regulated by the 
pRevTet-Off vector (Figure 2.7). Both vectors are initially treated separately using the 
packaging cells creating two viruses. Both vectors, pRevTet-Off and pRevTRE, contain the 
YLUDOSDFNDJLQJVLJQDOȥDVZHOODVWUDQVcription and processing elements. When the vector 
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is introduced to the packaging cell, a high titer, replication incompetent infectious virus is 
created which can be used to infect the host cells, mouse BpRc1 cells (RevTet System 
Handbook). The pRevTet system (Tet-Off) requires two vectors for gene expression of the 
AhR. pRevTet-Off was added to initiate the transcription of the gene contained in pRevTRE. 
If the pRevTet-Off vector is deactivated by Dox or not present at all, the AhR gene will not 
be transcribed. 
  
Figure 2.7: Vector map of pRevTet-Off vector 
Firstly the host cells, mouse BpRc1 cells, are infected with the pRevTet-Off containing virus. 
The pRevTet-Off vector (inside the virus) contains the Neomycin gene for antibiotic 
selection. Once the virus has been introduced to the host cell, a neomycin antibiotic, G418, is 
added to the medium to select only successfully infected cells. The cells are then infected 
again with the pRevTRE virus (which contains the gene of interest). The pRevTRE contains 
a hygromycin gene for antibiotic selection. Successfully infected cells are selected in the 
same way as before but this time by adding hygromycin B antibiotic to the medium. The cell 
lines which will be created in this section are shown in Table 2.11. 
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Cell line Main attribute Section 
   
PT67 off Packaging cell line PT67 which contains pRevTet-Off 
vector only PT67  
cell lines; 
section 
2.5.5.3 
PT67 hAhR Packaging cell line PT67 which contains pRevTRE human vector only 
PT67 rAhR Packaging cell line PT67 which contains pRevTRE rat 
vector only 
  
 
BpRc1 off AhR deficient mouse cell line containing the pRevTet-Off genetic material only 
BpRc1 
cell lines; 
section 
2.5.6.4 
BpRc1 hAhR 
AhR deficient mouse cell line containing the pRevTet-
Off and the pRevTRE human genetic material (Human 
AhR) 
BpRc1 rAhR AhR deficient mouse cell line containing the pRevTet-Off and the pRevTRE rat genetic material (Rat AhR) 
   
 Table 2.11: Summary of cell lines to be produced in this section 
2.5.5.3 Creation of stable virus-producing PT67 cell line  
The virus was produced by transfecting PT67 packaging cells with either the pRevTet-Off 
vector or the pRevTRE:rAhR/pRevTRE:hAhR vector. Initially the PT67 cells were incubated 
and passaged as discussed in section 2.1.6.1. The cells were then transfected with the vector 
using a chemical transfection reagent called GeneJuice (Novagen). PT67 cells were plated on 
a 35 mm dish overnight with a concentration of 2 x 104 cells/cm2. Before treatment the cells 
were approximately 60% confluent. 3 µl GeneJuice was added to 100 µl of serum-free 
DMEM and mixed thoroughly using a vortex. This mixture was then incubated at room 
temperature for 5 min. 1 µg DNA was then added to the GeneJuice mixture and mixed gently 
using a pipette before being further incubated for 10 min at room temperature. This allows 
formation of the GeneJuice:DNA complex without the presence of fetal bovine serum. This 
mixture was then added to the PT67 cells which were in cDMEM. 
In order to generate a virus-producing cell line, the packaging cells were plated in selective 
medium for 6-7 days. The selection process started approximately 3 days after transfection 
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and utilised either 500 µg/ml G418 (pRevTet-Off) or 300 µg/ml hygromycin (pRevTRE). No 
selection of individual colonies was conducted. The cells were allowed to reach confluence. 
Three different PT67 packaging cell variants were created; PT67 off, PT67 hAhR and PT67 
rAhR. To confirm the presence of the vector in the packaging cell line, end-point PCR was 
carried out using the primers shown Table 2.12.  
Primer name Sequence 
 
 
TREFW GCCTCGATCCTCCCTTTATC 
TRERV TATCCACGCCCTCCTACATC 
 
 
OFFTETFW TGAATGAACTGCAGGACGAG 
OFFTETRV ATACTTTCTCGGCAGGAGCA 
 
 
Table 2.12: Primers used to confirm the presence of either pRevTet-Off and pRevTRE in PT67 and BpRc1 cell lines 
End-point PCR was conducted as discussed in section 2.2.8. The resultant mRNA fragments 
were then run on a 1x agarose gel as described previously in section 2.2.1. Once it was 
confirmed that they possessed the required vector, the cells were stored in liquid nitrogen 
until required or passaged as normal. The viral titre was then calculated to confirm that the 
virus is viable and to help estimate the multiplicity of infection (MOI).  
2.5.6 Creation of BpRc1 cell lines 
2.5.6.1 Determination of the viral titer 
The viral titer was estimated using NIH/3T3 cells (plated 24 hours prior to the experiment) 
and virus-containing medium collected from the three packaging cell lines. Polybrene was 
added to the medium to give a final concentration of 4 µg/ml and filtered through a 0.45 µm 
filter. Six 10-fold dilutions were prepared using fresh medium. Cells were infected with the 
dilutions then, after 48 hours, were subjected to antibiotic selection (pRevTet-Off: 0.5 mg/ml 
G418, pRevTRE: 0.3 mg/ml hygromycin). The virus titer related to the number of colonies 
present at the highest dilution, which actually contains colonies, multiplied by the dilution 
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factor. This gave a viral titer of 6 x 104 recombinant virus particles per ml for PT67 off, 7 x 
104 for PT67 rAhR and 5 x 103 for PT67 hAhR. 
2.5.6.2 Estimation of optimum concentrations of antibiotics 
The optimum concentration of the two selective antibiotics, G418 and hygromycin, were 
calculated by dosing the BpRc1 cells with various concentrations of the antibiotics then 
identifying the lowest concentration required to kill all of the cells within 1 week. A 6-well 
plate was seeded with approximately 1 x 105 cells in 5 ml fresh cDMEM and left overnight to 
settle. The medium was then aspirated and replaced with 5 ml of new cDMEM containing 0, 
50, 100, 200, 400 or 800 µg/ml of either G418 or hygromycin. The selective medium was 
changed every 4 days and the cell density was checked every two days. The optimum 
concentration would be as low as possible but still kill all of the cells within 7 days. The 
experiments showed that the optimum concentrations for G418 and hygromycin were 400 
µg/m and 600 µg/ml, respectively. 
2.5.6.3 Creation of double-stable cell line 
The BpRc1 cells were first infected with virus-containing medium from the PT67 off cell 
line. The wild-type BpRc1 cells were plated in a 100 mm plate overnight at a concentration 
that would give approximately 50% confluence at the time of infection. Virus-containing 
medium was collected from the PT67 off cell line once confluence had occurred and used at 
the highest virus concentration possible (no dilution). Polybrene was added to the medium to 
give a final concentration of 4 µg/ml then it was filtered with a cellulose acetate 0.45 µM 
filter. The cDMEM from BpRc1 cells was then removed and replaced with the PT67 off 
virus-containing medium. The cells were then incubated for 24 hours at 37oC in a 5% CO2 
incubator. After 24 hours the virus-containing medium was replaced by fresh complete 
DMEM medium. Three days after infection, the cells were sub-cultured and subjected to 400 
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µg/ml G418 antibiotic selection for 7 days. Once visible and healthy colonies of cells were 
found, they were isolated using cloning cylinders.  
 
Figure 2.8: Photograph of cloning cylinders used for cell isolation 
To isolate the colonies, the medium was first removed. The cloning cylinders were gently 
placed into Vaseline then positioned around the cell colony (See Figure 2.8). The Vaseline 
was required to produce a watertight seal around the colony. The cloning cylinders, the 
Vaseline and the forceps were autoclaved before use and kept sterile throughout the 
experiment. Once the cylinder was secured, 20 µl 1x trypsin-EDTA was added and incubated 
at 37oC for 2 min. Once the cells were detached from the plate, 60 µl medium was added and 
the cells were transferred to a 25 cm2 flask (containing 10 ml of cDMEM) and grown to 
confluence. Aliquots were then frozen down in liquid nitrogen for future use (section 
2.1.6.2). This produced a stable new cell line called BpRc1: pRevTet-Off (BpRc1 off) and 
will be required to make the two AhR cell line variants. 
In order to produce the BpRc1 cell lines with rat and human AhR, it was necessary to infect 
the BpRc1 off cells with either the virus created from the PT67 rAhR cells or from the PT67 
hAhR cells. The virus from the PT67 rat cells would produce a double-stable cell line called 
Tao BpRc1 rat AhR (BpRc1 rAhR) whereas the virus from the PT67 hAhR cells would 
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produce a double-stable cell line called Tao BpRc1 human AhR (BpRc1 hAhR). Infection 
and selection was done based on the same principle as for the BpRc1 off cell line. The BpRc1 
off cells were plated giving a 50% confluence at the time of infection. Virus-containing 
medium (at maximum viral concentration) was taken either for the PT67 rAhR or the PT67 
hAhR cells and filtered through a 0.45 µM syringe filter. Polybrene was added to the medium 
giving a final concentration of 4 µg/ml and the medium was added to the BpRc1 off cells. 
Cells were infected for 24 hours whereupon the medium was replaced with fresh DMEM. 
The cells were then sub-cultured in antibiotic containing medium after 3 days using 600 
µg/ml hygromycin for 7 days. Healthy colonies were isolated with the cloning cylinders as 
described previously. The chosen cells were then grown in 6-well plates, then in 25 cm2 
flasks to reach confluence before being frozen down in liquid nitrogen for future use. 
Confirmation of the presence of the genes was conducted using qRT-PCR (section 2.5.7). 
2.5.6.4 Creation of transient expression cell line 
The creation of a double stable cell line was unsuccessful after several attempts so the BpRc1 
cells were infected to allow transient expression of the AhR proteins instead of stable 
expression. Infection of the BpRc1 cell lines with the virus from the PT67 off cell line was 
conducted simultaneously with either the virus from the PT67 rat or human cell lines to 
create either BpRc1 rAhR or BpRc1 hAhR. Virus-containing medium (at maximum viral 
concentration) was taken from PT67 off and either the PT67 rAhR or the PT67 hAhR cells 
and filtered through a 0.45 µM syringe filter. Polybrene was added to the medium giving a 
final concentration of 4 µg/ml. The medium was added to BpRc1 cells (at 80% confluence) 
and after 24 hours of infection the cells were transferred to a 96-well plate and left to grow 
for a further 24 hours. Cell treatment with compounds was conducted 48 hours after cell 
infection with the pRevTREs (AhR) and pRevTet-Off vectors (see section 2.4.1). Cells were 
treated with the test compounds (TCDD and 5F 203) prior to confirmation that the infection 
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was successful. Once successful infection was confirmed, the concentration-response curves 
were processed as discussed in section 2.5.8. 
2.5.7 Confirmation of successful infection 
2.5.7.1 Presence of cell infection of pRevTet-Off and pRevTRE 
Once BPRc1 cells were infected by the PT67 viruses, it was necessary to confirm the 
presence of the vectors; pRevTet-Off and either pRevTRE:rAhR or pRevTRE:hAhR in the 
new cell lines. Confirmation of the presence of the vectors was done in the same way as it 
was for the PT67 packaging cells (section 2.5.5.3) by using end-point PCR with primers that 
detect either the pRevTet-Off vector or the pRevTRE vector (Table 2.12; section 2.2.8).  
2.5.7.2 Confirmation of the presence of AhR DNA 
It was important; not only to confirm the presence of the required vectors, but also to confirm 
only one of the AhR vectors was present in each cell line. Therefore a second experiment was 
conducted using primers for the rat and human AhR (Table 2.3). The level of AhR DNA 
located in the cell was required to assess the relative concentrations of the AhRs. BpRc1 
wild-type, BpRc1 rAhR and BpRc1 hAhR cell lines were tested for rat AhR, human AhR and 
mouse AhR (genomic) which were normalised against mouse ȕ-actin (genomic). The primers 
for mouse genomic AhR and ȕ-actin are shown in Table 2.13. A separate experiment showed 
that the RNA had been successfully removed from all of the DNA samples (ȕ-actin primers 
for mRNA gave negative results). 
Primer name Sequence 
 
 
AhRFWgen CGGGCTTCCGCCAGGTGATG 
AhRRVgen AGCTGCTGTGCTGTGTTTGTTCT 
  
ActinFWgen ATGGAGGGGCCGGACTCATCG 
ActinRVgen AGGGGAATCCCAGCACCCAGA 
 
 
Table 2.133ULPHUVWRPHDVXUHPRXVHJHQRPLF$K5DQGȕ-actin. 
Richard Wall 
 
91 
 
2.5.7.3 Absence of PT67 cell contamination 
It was also required to confirm that the infected BpRc1 cell lines were not contaminated with 
PT67 cells. As only a small number of BpRc1 cells were isolated after antibiotic resistance, 
of which the PT67 cells should be resistant too, there would be time for a small number of 
PT67 cells to grow to confluence. Primers were designed to identify PT67 cells by binding to 
the env region (gp70 SU) of the integrated Moloney murine leukemia virus genomic 
structure. The primers should make a 100 bp product and should not be present in the BpRc1 
cells as they do not possess the viral genes. The primer sequences were; PT67FW: 
TTTTCTTCTCCCCCGGGGCCC and PT67RV: TGCACCGAGGGGTGAGGGAG. Due to 
the failure of the stable infected cell lines, this step was no longer required as contamination 
by a limited number of PT67 cells would have no effect on the measurement of induction 
from the BpRc1 cells. 
2.5.8 Species specific investigation measuring CYP1A1 expression 
2.5.8.1 Expression of AhR mRNA 
The ability of AhR mRNA to be transcribed from the pRevTRE vectors was measured using 
qRT-PCR. The three BpRc1 cell lines (wild-type, rAhR and hAhR) were measured for rat 
AhR, human AhR, mouse AhR and mouse ȕ-actin mRNA after 4 hours treatment with the 
vehicle (0.1% DMSO). The rat AhR primers were run at 63oC to increase their specificity as 
they were binding non-specifically to the mouse AhR as well. The mRNA levels for the three 
AhR genes were normalised against ȕ-actin by normalising the Ct threshold value for all 
three AhR genes. The same conditions were used for each of the three genes (excluding the 
anneal/extension temperature) and assumed that all three genes worked at 100% efficiency. 
The protocol for mRNA preparation and qRT-PCR was discussed previously (section 2.4). 
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2.5.8.2 Treatment with TCDD and 5F 203 
The method of qRT-PCR previously discussed in section 2.4 was utilised to measure the 
induction of CYP1A1 mRNA in the genetically engineered BpRc1 cells upon treatment with 
various AhR agonists. After confirmation of successful infection the cells, which were treated 
either with TCDD or 5F 203 were processed as previously discussed in section 2.4. Briefly, 
the cells (plated in a 96-well plate) were treated with various concentrations of either TCDD 
or 5F 203 for 4 hours. Treatment used conditioned medium as discussed in section 2.4.1. The 
RNA was purified from the cells and stabilised into cDNA. qRT-PCR was then used to 
measure the levels of mouse CYP1A1 DQG PRXVH ȕ-actin. The sequences of the mouse 
primers and probes are shown in section 2.4.4.2. A 10 nM TCDD only control and a vehicle 
only control were also conducted. Concentration-response curves of TCDD and 5F 203 were 
also conducted in BpRc1 wild-type cells as a comparison.  
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3. Results 
3.1 PCR measurement of CYP1A1 mRNA induction as a measure of AhR 
agonism and antagonism 
3.1.1 Overview 
In order to measure activation of the AhR, measurement of the induction of CYP1A1 was 
conducted using mRNA isolated from rat liver cells (H4IIE), human breast carcinoma cells 
(MCF-7), mouse fibroblast cells (NIH/3T3) and mouse AhR-deficient cells (BpRc1) using 
qRT-PCR. The levels of CYP1A1 mRNA were normalised against two reference genes, 
AhR and ȕ-actin, which were unaffected by the treatments (Head and Kennedy, 2007; 
Laupeze et al., 2002; Walker et al., 1999; Wu et al., 2002). 
3.1.2 Method optimisation 
3.1.2.1 The use of conditioned medium 
Bazzi (2008) showed that the fetal bovine serum (added to the cMEM/cDMEM medium) 
used to treat the cells also contained AhR ligands such as indirubin (Adachi et al., 2001).  
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Figure 3.1: Effect of conditioned vs. fresh medium – Rat H4IIE cells were treated with either 10 nM TCDD in 0.1% 
DMSO, fresh cMEM, conditioned (24 hrs) cMEM or 1 µM CH223191 in 0.1% DMSO for 4 hours. Cell treatment, RNA 
isolation and qRT-PCR analysis was as described in method. The normalised response (% of maximal CYP1A1 mRNA 
induction by 10 nM TCDD) is shown on a log scale, and each bar represents the mean of 3 biological replicates ± S.D. 
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The effect of the cMEM medium on the induction of CYP1A1 was confirmed in rat H4IIE 
cells (Figure 3.1). A positive control of 10 nM TCDD and a known antagonist of the AhR 
(negative control), CH223191, were used to compare against values derived from the 
medium samples. The fresh medium induced CYP1A1 mRNA by 15% of the maximum 
induction by 10 nM TCDD (100% or maximal induction). Conditioned medium and 
CH223191 (in 0.1% DMSO) gave mRNA levels of 0.4% and 0.1%, respectively, of the 
maximal response by 10 nM TCDD. There is a 30-fold difference between fresh and 
conditioned medium. Furthermore fresh medium gives a maximum signal to noise ratio of 
only 7-fold whereas conditioned medium gives a ratio of 250-fold. Based on this evidence, 
conditioned medium was always used when treating cells for concentration-response curves.  
3.1.2.2 Isolated RNA quality  
In order to confirm the quality of RNA purified from the rat H4IIE, human MCF7 and 
mouse NIH/3T3 cells, RNA samples were run on a 1x agarose gel. Initially the RNA was 
isolated and purified from cells using ‘Absolutely RNA® Miniprep Kit’ (Stratagene, 
Netherlands). The RNA samples were then run on a 1x agarose gel for 60 min at 100 V. 
Figure 3.2 shows the gel with the three species; rat (H4IIE), human (MCF-7) and mouse 
(BpRc1). 
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Figure 3.2: Agarose gel of RNA quality – RNA samples of rat H4IIE-C3, human MCF-7 and mouse BpRc1 cells were run 
on a 1x agarose gel. The 1x gel was made as described in section 2.2.1 and run for 60 min at 100 V. The gel was stained 
with ethidium bromide for 20 min before being photographed with a BioRad chemdoc UV camera. (A) 1 kbp Plus DNA 
ladder (Invitrogen), (B) rat H4IIE-C3, (C) human MCF-7, (D) mouse BpRc1 cells and (E) Negative control. The bands 18S 
and 26S are labelled. 
Figure 3.2 shows that the purified RNA is of good quality with two distinct bands seen at 
28S and 18S. This also indicates that the RNA has negligible genomic contamination or 
RNA degradation. 
3.1.2.3 Standard curves 
In order to validate the primer set and probe, the PCR efficiency was measured. A known 
amount of cDNA was diluted in master mix with the relevant probe and primers for the 
particular gene of interest. The efficiency curves were produced by diluting a known 
concentration of cDNA followed by measurement using qRT-PCR. 
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28S 
18S 
Richard Wall 
 
96 
 
0.01 0.03 0.1
15
20
25
30
35
40
cDNA concentration Pg/Pl
C t
 
0.01 0.03 0.1
20
25
30
35
cDNA concentration Pg/Pl
C t
 
0.01 0.03 0.1
15
20
25
30
cDNA concentration Pg/Pl
C t
 
 
 
   
 
CYP1A1 ȕ-Actin AhR  
    
H4IIE 84.5% 89.4% 94.6% 
MCF-7 93.5% 92.4% 94.0% 
BpRc1 91.3% 95.3% 79.9% 
    
    
    
Figure 3.33&5HIILFLHQF\IRU&<3$ȕ-actin and AhR measured in (A) rat H4IIE cells, (B) human MCF-7 cells 
and (C) mouse BpRc1 cells - A 5 point dilution series of cDNA was used to produce a concentration gradient. cDNA 
quantity is plotted against the Ct ZKHUHWKHIOXRUHVFHQFHWKUHVKROGLVFURVVHG5HG&<3$JUHHQ$K5EOXHȕ-actin. The 
initial quantity of input cDNA is shown on the x-axis as a relative amount, and the Ct for each dilution is shown on the Y-
axis, graph shows all 3 replicates separately. The fit of the data to the line was determined by r2 analysis, and the efficiency 
of PCR was determined from the slope of the line. (D) The table shows the calculated efficiencies as percentage. Final 
probe and primer concentrations were 50-300 nM.  
Figure 3.3 shows the PCR efficiencies of all three genes in (A) rat, (B) human and (C) 
PRXVH FHOOV 7KH ȕ-actin, CYP1A1 and AhR PCR efficiencies are shown in Figure 3.3D. 
There was no interference between the three dyes used (FAM, HEX and CY-5) validating 
the use of CY-5 for the probe dye. This also confirms both the ability of the assay to detect 
all three genes and that they all have the desired efficiency. The r2 YDOXHV IRU ȕ-actin, 
CYP1A1 and AhR in all species were >0.99 demonstrating the precision of the dilutions 
A B 
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used. The PCR reactions were run in the same well in a multiplex for all of the genes hence 
these efficiencies demonstrate the PCR efficiency in multiplex. 
3.1.2.4 Normalisation genes are unaffected by the treatment 
An important aspect of the qRT-PCR strategy of normalising CYP1A1 against two reference 
JHQHVȕ-actin and AhR, is that the two genes are unaffected by the treatment. In order to test 
this, rat or human cells were treated with TCDD for 4 hours as a model agonist, and qRT-
PCR performed for the two reference JHQHVȕ-actin and AhR. This data was normalised as 
fold difference of vehicle control (Figure 3.4). 
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Figure 3.4(IIHFWRI7&''RQWKHQRUPDOLVDWLRQJHQHVȕ-actin and AhR measured in (A) rat H4IIE cells and (B) 
human MCF-7 cells – Cells were treated with various concentration of TCDD. qRT-PCR was conducted to measure AhR 
DQG ȕ-actin mRNA levels. The graph shows the normalised fold-difference mRNA levels against vehicle control. The 
graphs show that ȕ-actin and AhR are not affected by the treatment compounds. Each point is the mean of three biological 
replicates ± S.D. 
Both graphs show that the normalisation genes are not affected by the TCDD treatment and 
DUH WKHUHIRUH VXLWDEOH WR QRUPDOLVH &<3$ P51$ 0RXVH $K5 DQG ȕ-actin were also 
unaffected by the treatment (data not shown). 
3.1.3 Validating the method of mRNA measurement 
3.1.3.1 Agonism - TCDD 
The method of measuring agonism was developed previously (Bazzi, 2008; Bell et al., 2009; 
Wall, 2008). Additional improvements were made during this project so the method was 
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validated again. Furthermore, in order to confirm the repeatability of the assay between 
experiments and to confirm that each experiment will give the same EC50, several TCDD 
concentration-response curves, which were conducted over the period of the study, were 
compared (Figure 3.5). Rat H4IIE and human MCF-7 cells were treated with various 
concentrations of TCDD which were then plotted against normalised CYP1A1 mRNA and 
compared against a vehicle control (VC). 
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Figure 3.5: Comparison of three TCDD concentration-response curves in A) rat H4IIE cells and B) human MCF-7 
cells - H4IIE cells or MCF-7 cells were treated with the indicated concentrations of TCDD for 4 hours. The graph shows 
four curves taken from various experiments and calibrations over a period of the study. Concentration-response curves were 
created by plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-
PCR ZDV XVHG WR PHDVXUH WKH OHYHO RI LQGXFWLRQ RI &<3$ DQG FRPSDUHG DJDLQVW FRQWURO JHQHV ȕ-actin and AhR. 
QbasePlus was used to normalise the data, which was plotted using 10 nM TCDD only control as 100% of the maximal 
response. Each point is the mean of three biological replicates ± S.D.VC: Vehicle control. 
The graph shows that a concentration of more than 1 nM, in rat, and 10 nM, in human, is 
required to reach the maximal response. Furthermore the vehicle control provides less than 
0.5% of the maximal response in both cell lines. The EC50 of the three rat cell curves were 
33.7 pM, 33.9 pM and 32.0 pM (Mean = 33 pM, S.D. = 1 pM) and the three human cell 
curves were 675 pM, 633 pM and 740 pM (Mean = 683 pM, S.D. = 50 pM). This shows that 
the method provides reproducible results and can therefore be used for accurate comparison 
between other experiments.  
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3.1.3.2 Antagonism - CH223191 
CH223191 has been shown to have antagonistic activity for the AhR in mouse and human 
cells, but the antagonistic activity has not been quantified (Kim et al., 2006). Initially, an 
experiment was conducted to confirm that CH223191 has no agonistic activity in rat cells. 
&HOOVZHUHWUHDWHGZLWKYDULRXVFRQFHQWUDWLRQVRI&+XSWRDFRQFHQWUDWLRQRIȝ0 
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Figure 3.6: CH223191 has no agonistic properties and is an antagonist of TCDD induction of CYP1A1 – (A) 
CH223191 has no agonistic properties (compared with a TCDD only curve). (B) Concentration-response curve for 
CH223191 antagonism of CYP1A1 induction by 1 nM TCDD. For both experiments rat H4IIE cells were treated with test 
compounds for 4 hours. Concentration-response curves were created by plotting the % of maximal CYP1A1 mRNA 
induction by 10 nM TCDD against concentration of agonist. qRT-PCR was used to measure the level of induction of 
CYP1A1 and coPSDUHG DJDLQVW FRQWURO JHQHV ȕ-actin and AhR. QbasePlus was used to normalise the data which was 
plotted using 10 nM (A) or 0.1 nM (B) TCDD only control as 100% of the maximal response. Results were compared with 
a vehicle control (VC) and a 10 nM TCDD only (TC). Each point is the mean of three biological replicates ± S.D. 
Figure 3.6A shows CH223191 compared with a TCDD only concentration-response curve. 
The graph demonstrates that compared with TCDD, CH223191 has no agonistic properties 
in this experiment. A concentration-inhibition curve was constructed using a set 
concentration of 1 nM TCDD which gave approximately 90-100% of the maximal induction 
of CYP1A1 in the presence of various concentrations of CH233191 (Figure 3.6B). The 
inhibition of 1 nM TCDD induction of CYP1A1 in the presence of increasing concentrations 
of CH223191 was compared against a vehicle control (VC) and a 10 nM TCDD only control 
(TC). The IC50 was 411 nM (95% CI = 300 nM – 562 nM). In order to perform a Schild 
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analysis, several concentration-response curves are required to get a reliable estimate for the 
Kd. Using the concentration-inhibition curve in Figure 3.6B, it was possible to find the 
window of measurable response where the CH223191 affected the induction of CYP1A1 by 
TCDD. Another limiting factor was the maximum concentration of TCDD that could be 
used which is 10 nM. Previous work had shown that a higher concentration would not stay in 
solution and could therefore provide inaccurate information. Therefore, TCDD concentration 
response curves in the range of 1 pM to 10 nM were performed in the presence of four 
concentrations of CH223191; 30 nM, 100 nM, 300 nM and 1 µM (Figure 3.7A).  
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Figure 3.7: Schild analysis of CH223191 – (A) TCDD concentration-response curves in the absence and presence of 30 
nM, 100 nM, 300 nM and 1 µM CH223191, (B) Schild plot of CH223191. Cells were treated with various concentrations of 
TCDD in the presence or absence of either: 30 nM, 100 nM, 300 nM or 1 µM CH223191 for 4 hours in rat H4IIE cells. 
Concentration-response curves were created by plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD 
against concentration of agonist. qRT-PCR was used to measure the level of induction of CYP1A1 and compared with 
FRQWURO JHQHV ȕ-actin and AhR. QbasePlus was used to normalise the data which was plotted using 10 nM TCDD only 
control as 100% of the maximal response. Results were compared with an antagonist only control (AC), a vehicle control 
(VC) and a 10 nM TCDD only control (TC). Schild plot was plotted as the Log[Dose Ratio –1] against Log[Antagonist]. 
Schild shift was calculated by GraphPad Prism 5. Each point (A) is the mean of three biological replicates ± S.D. 
Cells were treated for the particular combination of compounds for 4 hours. An antagonist 
only control (AC), vehicle control (VC) and a 10 nM TCDD only control (TC) were 
included. The TCDD only control (TC) was included for comparison as well as accurate 
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measure of the 100% maximal induction. A TCDD only curve was included as comparison 
which included a vehicle control (VC). The graph shows that as the concentration of 
antagonist is increased, the further to the right the curve is in comparison to the TCDD only 
curve. The EC50 for TCDD alone was 115 pM (95% CI = 89 pM – 147 pM), +30 nM: EC50 
was 313 pM (95% CI = 266 pM -368 pM), +100 nM: EC50 was 1.08 nM (95% CI = 933 pM 
- 1.24 nM), +300 nM: EC50 was 4.11 nM (95% CI = 3.34 nM - 5.04 nM) and +1 µM: EC50 
was 16.2 nM (95% CI = 12.4 nM - 21.0 nM). This shift to the right can be used to calculate 
the Kd of CH223191 by measuring the EC50’s of each curve and compare them with the 
TCDD only curve. This analysis was done automatically by GraphPad Prism 5 software. The 
Log[Dose ratio -1] was plotted against Log[Antagonist Dose] as shown in Figure 3.7B. The 
Kd was calculated to be 18.2 nM (95% CI = 14.1 nM to 23.6 nM). The slope of the line was 
1.26 ± 0.03 with an r2 value of 0.99 showing that the line fits well to the data.  
3.1.4 Mixed halogenated dibenzo-p-dioxins 
3.1.4.1 Summary of substituted-dibenzo-p-dioxins in rat H4IIE cells 
Concentration data in food, combined with previous potency research, has shown that these 
compounds may have a significant impact on TEQ based risk assessment (Table 1.2). 
Therefore calculating the potency of these compounds will allow a better estimation for risk 
assessment. Rat H4IIE cells were treated with various chlorinated, brominated or mixed 
halogenated dibenzo-p-dioxins for 4 hours to calculate their potency based on the induction 
of CYP1A1 mRNA. The structures, EC50s and REP values calculated in this work are 
summarised in Table 3.1 to allow comparison.  
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Structure EC50 (95% CI) REP 
   
2-B-7,8-DiCDD 
R1=H; R2=Br; R3=H; R4=Cl; R5=Cl 904 pM (710 pM – 1.15 nM) 0.05 
2,3,7-TriBDD 
R1=H; R2=Cl; R3=Cl; R4=Br; R5=H 1160 pM (813 pM – 1640 pM) 0.04 
TCDD 
R1=H; R2=Cl; R3=Cl; R4=Cl; R5=Cl 47.6 pM (36.4 pM – 62.2 pM) 1
a
 
2-B-3,7,8-TriCDD 
R1=H; R2=Br; R3=Cl; R4=Cl; R5=Cl 23.7 pM (15.4 pM – 36.6 pM) 2.01 
2,3-DiB-7,8-DiCDD 
R1=H; R2=Br; R3=Br; R4=Cl; R5=Cl 168 pM (138 pM – 206 pM) 0.28 
1-B-2,3,7,8-TetraCDD 
R1=Br; R2=Cl; R3=Cl; R4=Cl; R5=Cl 398 pM (264 pM - 599 pM) 0.12 
2-B-1,3,7,8-TetraCDD 
R1=Cl; R2=Br; R3=Cl; R4=Cl; R5=Cl 86.4 pM (65.3 pM – 114 pM) 0.55 
   
Table 3.1: A summary of the potency of substituted-dibenzo-p-dioxins as AhR agonists in rat H4IIE cells - EC50 
values are shown with their 95% confidence intervals. 1a: The REP is a comparison with the EC50 of TCDD within this 
experimental group. 
The results show that all of the compounds are within 25-fold less potent than TCDD with 
the exception of 2-B-3,7,8-TriCDD which is shown to be 2-fold more potent than TCDD. 
The full concentration response curves are also shown below (Figure 3.8 to Figure 3.11). 
Some of the compounds were also tested in human MCF-7 cells (Figure 3.9).  
3.1.4.2 Tri-substituted-dibenzo-p-dioxins 
The potency of two tri-substituted dibenzo-p-dioxins, 2-B-7,8-DiCDD and 2,3,7-TriBDD, 
was measured in rat H4IIE cells. The compounds are structurally similar to 2,3,7-TriCDD 
which is a known low potency AhR ligand (REP = 0.0015; Behnisch et al., 2003) but was 
not considered in the WHO TEF 2005 risk assessment (Van den Berg et al., 2006). The 
increase in the levels of CYP1A1 mRNA was used as a measure for AhR activation. Figure 
3.8 shows the potency of the two compounds compared against TCDD in rat H4IIE cells. 
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Figure 3.8: Potency of 2-B-7,8-DiCDD and 2,3,7-TriBDD as AhR agonists – Rat H4IIE cells were treated with various 
concentrations of either: 2-B-7,8-DiCDD, 2,3,7-TriBDD or TCDD. Concentration-response curves were created by plotting 
the % of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-PCR was used to 
PHDVXUHWKHOHYHORILQGXFWLRQRI&<3$DQGFRPSDUHGDJDLQVWFRQWUROJHQHVȕ-actin and AhR. QbasePlus was used to 
normalise the data which was plotted using 10 nM TCDD only control as 100% of the maximal response. Results were 
compared with a vehicle control (VC) and a 10 nM TCDD only control (TC). Each point is the mean of three biological 
replicates ± S.D. 
The potencies of 2-B-7,8-DiCDD (Figure 3.8A) and 2,3,7-TriBDD (Figure 3.8B) were 
estimated to be 1.16 nM (95% CI is shown in Table 3.1) and 904 pM, respectively. This 
produced REPs of 0.04 and 0.05 for 2-B-7,8-DiCDD and 2,3,7-TriBDD, respectively. The 
EC50 of TCDD was calculated to be 47.6 pM (36.4 pM – 62.2 pM) and was used throughout 
sections 3.1.4 and 3.1.5. 
3.1.4.3 Tetra-substituted-dibenzo-p-dioxins 
TCDD is one of the most potent chlorinated congeners and is the most characterised of the 
AhR ligands. Two mixed halogenated dibenzo-p-dioxins with the same backbone structure 
as TCDD, 2-B-3,7,8-TriCDD and 2,3-DiB-7,8-DiCDD, were tested to investigate the effect 
of substituting chlorine for bromine. All of the compounds were tested in rat H4IIE cells. 
Additionally TCDD and 2-B-3,7,8-TriCDD were tested in human MCF-7 cells to allow 
species comparison. Figure 3.9 shows the comparison of these two compounds in rat and 
human.  
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Figure 3.9: Comparison of 2-B-3,7,8-TriCDD and TCDD agonism of AhR in different species – (A) Rat H4IIE and (B) 
human MCF-7 cells treated with 2-B-3,7,8-TriCDD or TCDD for 4 hours. Concentration-response curves were created by 
plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-PCR was 
used to measure the level of induction of CYP1A1 and compared with FRQWUROJHQHVȕ-actin and AhR. QbasePlus was used 
to normalise the data which was plotted using 10 nM TCDD only control as 100% of the maximal response. Results were 
compared with a vehicle control (VC) and a 10 nM TCDD only control (TC). Each point is the mean of three biological 
replicates ± S.D. 
The EC50s of TCDD and 2-B-3,7,8-TriCDD in rat (Figure 3.9A) were 47.6 pM and 23.7 pM, 
respectively. The data shows that 2-B-3,7,8-TriCDD is 2-fold more potent than TCDD at 
inducing CYP1A1 mRNA (p<0.0001). The two compounds were then tested in human 
MCF-7 cells under the same experimental conditions (Figure 3.9B). The EC50s in human 
were 465 pM (95% CI = 341 pM – 633 pM) for TCDD and 187 pM (95% CI = 111 pM – 
319 pM) for 2-B-3,7,8-TriCDD. Analysis showed that 2-B-3,7,8-TriCDD was ~2.5-fold 
more potent at inducing CYP1A1 mRNA than TCDD (p<0.005). 2-B-3,7,8-TriCDD gave a 
REP of 2.01 and 2.49 in rat H4IIE and human MCF-7 cells, respectively. 
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Figure 3.10: Potency of 2,3-DiB-7,8-DiCDD as an AhR agonist- Rat H4IIE cells were treated with 2,3-DiB-7,8-DiCDD 
or TCDD for 4 hours. Concentration-response curves were created by plotting the % of maximal CYP1A1 mRNA induction 
by 10 nM TCDD against concentration of agonist. qRT-PCR was used to measure the level of induction of CYP1A1 and 
FRPSDUHGDJDLQVWFRQWUROJHQHVȕ-actin and AhR. QbasePlus was used to normalise the data which was plotted using 10 
nM TCDD only control as 100% of the maximal response. Results were compared with a vehicle control (VC) and a 10 nM 
TCDD only control (TC). Each point is the mean of three biological replicates ± S.D. 
Investigation of the potency of 2,3-DiB-7,8-DiCDD found an EC50 of 168 pM (Figure 3.10) 
which produced a REP of 0.28. This shows that the compound is still a potent agonist which 
is ~3-fold less potent than TCDD. 
3.1.4.4 Penta-substituted-dibenzo-p-dioxins 
A selection of penta-substituted halogenated dibenzo-p-dioxins, 1-B-2,3,7,8-TetraCDD and 
2-B-1,3,7,8-TetraCDD, were tested in rat H4IIE cells and compared against TCDD. 
1,2,3,7,8-PentaCDD is a potent AhR ligand in the same magnitude as TCDD with a TEF of 
1 (Van den Berg et al., 2006). 
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Figure 3.11: Potency of 1-B-2,3,7,8-TetraCDD and 2-B-1,3,7,8-TetraCDD as AhR agonists – Rat H4IIE cells were 
treated with 1-B-2,3,7,8-TetraCDD and 2-B-1,3,7,8-TetraCDD for 4 hours. TCDD was also plotted for comparison. 
Concentration-response curves were created by plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD 
against concentration of agonist. qRT-PCR was used to measure the level of induction of CYP1A1 and compared against 
FRQWURO JHQHV ȕ-actin and AhR. QbasePlus was used to normalise the data which was plotted using 10 nM TCDD only 
control as 100% of the maximal response. Results were compared with a vehicle control (VC) and a 10 nM TCDD only 
control (TC). Each point is the mean of three biological replicates ± S.D. 
According to the results in Figure 3.11A, the EC50 for 1-B-2,3,7,8-TetraCDD was 398 pM 
(whereas the EC50 for TCDD was 47.6 pM). This means that the compound is 10-fold less 
potent than TCDD with a REP of 0.12. Figure 3.11B shows rat H4IIE cells treated with 2-B-
1,3,7,8-TetraCDD which gives an EC50 of 86.4 pM (95% CI = 65.3 pM – 114 pM). This 
means that the compound is only approximately 2-fold less potent than TCDD producing a 
REP of 0.55. 
3.1.5 Mixed halogenated dibenzofurans 
3.1.5.1 Summary of substituted-dibenzofurans in rat H4IIE cells 
Concentration data in food, combined with previous potency research, has shown that these 
compounds may have a significant impact on TEQ based risk assessment (Table 1.3). Rat 
H4IIE cells were treated with various chlorinated, brominated or mixed halogenated 
dibenzofurans for 4 hours to calculate their potency based on the induction of CYP1A1 
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mRNA. The structures, EC50s and REP values calculated in this work are summarised in 
Table 3.1 to allow comparison.  
7
8
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R5
 
   
Structure EC50 (95% CI) REP 
   
2,7,8-TriBDF 
R1=H; R2=Br; R3=H; R4=H; R5=H; R6=Br; R7=Br 2020 pM (1100 pM – 3710 pM) 0.02 
2-B-7,8-DiCDF 
R1=H; R2=Br; R3=H; R4=H; R5=H; R6=Cl; R7=Cl 129 nM (90.1 nM – 184 nM) 0.0004 
TCDF 
R1=H; R2=Cl; R3=Cl; R4=H; R5=H; R6=Cl; R7=Cl 413 pM (196 pM - 869 pM) 0.12 
3-B-2,7,8-TriCDF 
R1=H; R2=Cl; R3=Br; R4=H; R5=H; R6=Cl; R7=Cl 151 pM (106 pM - 214 pM) 0.32 
2,3-DiB-7,8-DiCDF 
R1=H; R2=Br; R3=Br; R4=H; R5=H; R6=Cl; R7=Cl 80.3 pM (65.0 pM – 99.1 pM) 0.59 
2-B-6,7,8-TriCDF 
R1=H; R2=Br; R3=H; R4=H; R5=Cl; R6=Cl; R7=Cl 305 pM (214 pM – 434 pM) 0.16 
PeCDF 
R1=H; R2=Cl; R3=Cl; R4=Cl; R5=H; R6=Cl; R7=Cl 278 pM (179 pM - 433 pM) 0.17 
4-B-2,3,7,8-TetraCDF 
R1=H; R2=Cl; R3=Cl; R4=Br; R5=H; R6=Cl; R7=Cl 150 pM (86.9 pM - 260 pM) 0.32 
1-B-2,3,7,8-TetraCDF 
R1=Br; R2=Cl; R3=Cl; R4=H; R5=H; R6=Cl; R7=Cl 351 pM (275 pM – 449 pM) 0.14 
1,3-DiB-2,7,8-TriCDF 
R1=Br; R2=Cl; R3=Br; R4=H; R5=H; R6=Cl; R7=Cl 214 pM (119 pM – 386 pM) 0.22 
   
Table 3.2: A summary of the potency of substituted-dibenzofurans as AhR agonists in rat H4IIE cells - EC50 values 
are shown with their 95% confidence intervals. The REP is comparison with the EC50 of TCDD within this experimental 
group (See Table 3.1). 
The results show that all of the compounds are within 43-fold less potent than TCDD with 
the exception of 2-B-7,8-DiCDF which is shown to be ~2700-fold less potent than TCDD. 
The full concentration response curves are also shown below (Figure 3.12 to Figure 3.14). 
3.1.5.2 Tri-substituted-dibenzofurans 
The potency of 2-B-7,8-DiCDF was tested in rat H4IIE cells and compared against TCDD. 
The compound has the same backbone structure as 2,7,8-TriCDF although one of the 
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chlorine atoms is substituted with bromine. 2,7,8-TriCDF has been previously tested with a 
REP of 0.0015 (Behnisch et al., 2003), however the compound is not included in the WHO 
TEF estimations. 
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Figure 3.12: Potency of 2-B-7,8-DiCDF and 2,7,8-TriBDF as AhR agonists – Rat H4IIE cells were treated with 2-B-7,8-
DiCDF or 2,7,8-TriBDF for 4 hours. TCDD was also plotted for comparison. Concentration-response curves were created 
by plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-PCR was 
XVHGWRPHDVXUHWKHOHYHORILQGXFWLRQRI&<3$DQGFRPSDUHGDJDLQVWFRQWUROJHQHVȕ-actin and AhR. QbasePlus was 
used to normalise the data which was plotted using 10 nM TCDD only control as 100% of the maximal response. Results 
were compared with a vehicle control (VC) and a 10 nM TCDD only control (TC). Each point is the mean of three 
biological replicates ± S.D. 
Figure 3.12A shows the potency of 2-B-7,8-DiCDF which was calculated as 129 nM (95% 
CI is shown in Table 3.2). This was 10,000-fold less potent than TCDD and gave a REP of 
0.00037. This was compared with 2,7,8-TriBDF, which provided an EC50 of 2.02 nM 
(Figure 3.12B) and was calculated to be approximately 50-fold less potent than TCDD with 
a REP of 0.024. 
3.1.5.3 Tetra-substituted-dibenzofurans 
TCDF is one of the most potent members of the dibenzofuran family (TEF = 0.1; Van den 
Berg et al., 2006). Two mixed halogenated versions of the compound, 3-B-2,7,8-TriCDF 
and 2,3-DiB-7,8-DiCDF, were tested and compared alongside TCDD. The compounds were 
tested in rat H4IIE cells for 4 hours to measure the induction of CYP1A1 mRNA. 
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Figure 3.13: Potency of TCDF, 3-B-2,7,8-TriCDF, 2,3-DiB-7,8-DiCDF and 2-B-6,7,8-TriCDF as AhR agonists - Rat 
H4IIE cells were treated with (A) TCDF, (B) 3-B-2,7,8-TriCDF, (C) 2,3-DiB-7,8-DiCDF, (D) 2-B-6,7,8-TriCDF or TCDD 
for 4 hours Concentration-response curves were created by plotting the % of maximal CYP1A1 mRNA induction by 10 nM 
TCDD against concentration of agonist. qRT-PCR was used to measure the level of induction of CYP1A1 and compared 
DJDLQVWFRQWUROJHQHVȕ-actin and AhR. QbasePlus was used to normalise the data which was plotted using 10 nM TCDD 
only control as 100% of the maximal response. Results were compared with a vehicle control (VC) and a 10 nM TCDD 
only control (TC). Each point is the mean of three biological replicates ± S.D. 
Previous work by this author (which was newly calibrated based on GC/MS data) calculated 
the EC50 of TCDF (A) as 413 pM (95% CI = 196 pM – 869 pM; Wall, 2008). Figure 3.13 
shows the potency of (B) 3-B-2,7,8-TriCDF, (C) 2,3-DiB-7,8-DiCDF and (D) 2-B-6,7,8-
TriCDF compared with TCDD. The EC50 for 3-B-2,7,8-TriCDF was 151 pM, the EC50 for 
2,3-DiB-7,8-DiCDF was 80.3 pM and the EC50 for 2-B-6,7,8-TriCDF was 305 pM. The 
results show that the three mixed halogenated dibenzofurans are between 2 and 10-fold less 
A 
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potent than TCDD (p<0.0001 for all three compounds) and the three mixed halogenated 
dibenzofurans are also statistically different from one another using a T-test (p<0.005). The 
REP for 3-B-2,7,8-TriCDF, 2,3-DiB-7,8-DiCDF and 2-B-6,7,8-TriCDF was calculated to be 
0.32, 0.59 and 0.16, respectively. 
3.1.5.4 Penta-substituted-dibenzofurans 
Based on the WHO TEQ summary, PeCDF is a high potency ligand approximately 3-fold 
less potent than TCDD (REP = 0.3; Van den Berg et al., 2005).  
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Figure 3.14: Potency of PeCDF, 4-B-2,3,7,8-TetraCDF, 1-B-2,3,7,8-TetraCDF and 1,3-DiB-2,7,8-TriCDF as AhR 
agonists - Rat H4IIE cells were treated with (A) PeCDF, (B) 4-B-2,3,7,8-TetraCDF, (C) 1-B-2,3,7,8-TetraCDF and (D) 
1,3-DiB-2,7,8-TriCDF for 4 hours. Concentration-response curves were created by plotting the % of maximal CYP1A1 
mRNA induction by 10 nM TCDD against concentration of agonist. qRT-PCR was used to measure the level of induction 
RI&<3$DQGFRPSDUHGDJDLQVWFRQWUROJHQHVȕ-actin and AhR. QbasePlus was used to normalise the data which was 
plotted using 10 nM TCDD only control as 100% of the maximal response. Results were compared with a vehicle control 
(VC) and a 10 nM TCDD only control (TC). Each point is the mean of three biological replicates ± S.D. 
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Four penta-substituted dibenzofurans were tested including PeCDF (2,3,4,7,8-PeCDF) and 
4-B-2,3,7,8-TetraCDF which have the same structure. 1-B-2,3,7,8-TetraCDF and 1,3-DiB-
2,7,8-TriCDF are based on the structure 1,2,3,7,8-PeCDF (TEF = 0.03, Van den Berg et al., 
2006) which is 50-fold less potent than TCDD. The four compounds were tested in rat H4IIE 
cells for 4 hours and compared against a concentration-response curve of TCDD.  
The EC50 for PeCDF shown in Figure 3.14A was calculated previously by this author (newly 
calibrated) as 278 pM (95% CI = 179 pM – 433 pM; Wall, 2008), which was shown to be 5-
fold less potent than TCDD. Figure 3.14B shows the potency of 4-B-2,3,7,8-TetraCDF 
compared against TCDD in rat H4IIE cells which was 150 pM which gave a REP of 0.32. 
The EC50 for 1-B-2,3,7,8-TetraCDF was calculated to be 351 pM producing a REP of 0.14. 
Finally the EC50 for 1,3-DiB-2,7,8-TriCDF was calculated to be 214 pM giving a REP of 
0.22. 
3.1.6 Mixed halogenated biphenyls  
3.1.6.1 Summary of substituted-biphenyls in rat H4IIE cells 
Concentration data in food, combined with previous potency research, has shown that these 
compounds may have a significant impact on TEQ based risk assessment (section 1.3.3). Rat 
H4IIE cells were treated with various chlorinated, brominated or mixed halogenated 
biphenyls for 4 hours to calculate their potency based on the induction of CYP1A1 mRNA. 
The structures, EC50s and REP values calculated in this work are summarised in Table 3.3 to 
allow comparison.  
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Structure EC50 (95% CI) REP 
   
TCDD 
R1=H; R2=Cl; R3=Cl; R4=Cl; R5=Cl 28.9 pM (19.9 pM – 41.9 pM) 1
b
 
3,3’,4,4’,5-PentaCB (PCB 126) 
R1=H; R2=Cl; R3=Cl; R4=Cl; R5=Cl; R6=Cl 281 pM (225 pM – 352 pM) 0.10 
4’-B-3,3’,4,5-TetraCB (PXB 126B) 
R1=H; R2=Cl; R3=Cl; R4=Cl; R5=Br; R6=Cl 130 pM (92.2 pM – 183 pM) 0.22 
3’,4’-DiB-3,4,5-TriCB (PXB 126H) 
R1=H; R2=Cl; R3=Cl; R4=Cl; R5=Br; R6=Br 200 pM (78.2 pM – 513 pM) 0.14 
3’,4’,5-TriB-3,4-DiCB (PXB 126V) 
R1=H; R2=Br; R3=Cl; R4=Br; R5=Br; R6=Br 72.2 pM (48.4 pM – 108 pM) 0.40 
3,3’,4,4’,5-PentaBB (PBB 126) 
R1=H; R2=Br; R3=Br; R4=Br; R5=Br; R6=Br 622 pM (487 pM – 796 pM) 0.05 
2,3,3’,4,4’-PentaCB (PCB 105) 
R1=Cl; R2=H; R3=Cl; R4=Cl; R5=Cl; R6=Cl 1.60 µM (1.56 µM – 1.63 µM) 0.000002 
4’-B-2,3,3’,4-TetraCB (PXB 105) 
R1=Cl; R2=H; R3=Cl; R4=Cl; R5=Br; R6=Cl 2.46 µM (2.10 µM – 2.90 µM) 0.00001 
2,3’,4,4’,5-PentaCB (PCB 118) 
R1=Cl; R2=Cl; R3=Cl; R4=H; R5=Cl; R6=Cl 11.8 µM (10.5 µM – 13.2 µM) 0.000003 
4’-B-2,3’,4,5-TetraCB (PXB 118) 
R1=Cl; R2=Cl; R3=Cl; R4=H; R5=Br; R6=Cl 775 nM (655 nM – 917 nM) 0.0001 
2,3,3’,4,4’,5-HexaCB (PCB 156) 
R1=Cl; R2=Cl; R3=Cl; R4=Cl; R5=Cl; R6=Cl 122 nM (104 nM – 144 nM) 0.0002 
4’-B-2,3,3’,4,5-PentaCB (PXB 156) 
R1=Cl; R2=Cl; R3=Cl; R4=Cl; R5=Br; R6=Cl 139 nM (95.5 nM – 203 nM) 0.0002 
 
  
Table 3.3: A summary of the potency of substituted-biphenyls as AhR agonists in rat H4IIE cells - EC50 values are 
shown with their 95% confidence intervals. 1b: The REP is comparison with the EC50 of TCDD within this experimental 
group. 
The results show that all of the non-ortho-substituted biphenyls are within 10-fold less 
potent than TCDD. The mono-ortho-substituted biphenyls were shown to be at least 5000-
fold less potent than TCDD (PCB 156 and PXB 156) and up to 500,000-fold less potent than 
TCDD (PCB 105). The full concentration-response curves are also shown below (Figure 
3.15 to Figure 3.22). Three compounds, PCB 105, 118 and 156, were selected for further 
analysis based on their high environmental abundance. These congeners may have a less-
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than-additive effect on the total TCDD-like toxicity of a mixture and could therefore be 
useful when studying the theory of additivity. The use of qRT-PCR will be applied to 
measure CYP1A1 mRNA induction of the compounds in the presence of TCDD to 
determine if the compounds have any antagonistic properties. 
3.1.6.2 3,3,4,4,5-substituted biphenyls (PXB 126) 
PCB 126 is the most characterised and one of the most potent of the polychlorinated 
biphenyls. Several congeners with the same backbone structure but with different 
substitutions were tested to see if they had equally potent properties. Several PCB 126 
congeners, PXB 126B, PXB 126H, PXB 126V and 3,3’,4,4’,5-PentaBB (PBB 126), were 
tested to see if the addition of bromine had a positive impact on the ability of the compound 
to elicit a AhR-mediated response. These compounds were all tested in rat H4IIE cells. The 
induction of CYP1A1 mRNA by PCB 126 and PXB 126B were also tested in human MCF-7 
cells to gauge the species-specific response of the compounds.  
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Figure 3.15: Potency and species comparison of PXB 126B and PCB 126 as AhR agonists – (A) Rat H4IIE and (B) 
human MCF7 cells were treated with various concentrations of PXB 126B or PCB 126. Concentration-response curves 
were created by plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. 
qRT-PCR was used to measure the level of induction of CYP1A1 mRNA DQGFRPSDUHGDJDLQVWFRQWUROJHQHVȕ-actin and 
AhR. QbasePlus was used to normalise the data which was plotted using 10 nM TCDD only control as 100% of the 
maximal response. Results were compared with a vehicle control (VC) and a 10 nM TCDD only control (TC). Each point is 
the mean of three biological replicates ± S.D. 
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The agonistic properties of TCDD, PCB 126 and PXB 126B were tested in rat H4IIE (Figure 
3.15A) and human MCF-7 cells (Figure 3.15B). In rat, the EC50 for TCDD was 28.9 pM 
(95% CIs are shown in Table 3.3), PCB 126 was 281 pM and PXB 126B was 130 pM. PCB 
126 was 10-fold less potent than TCDD with a REP of 0.10. This corresponds well with the 
WHO TEF value of 0.1 (Van den Berg et al., 2006). PXB 126B was 5-fold less potent than 
TCDD and, in turn, 2-fold more potent than PCB 126. A REP of 0.22 was calculated for this 
compound. The EC50s for PCB 126 and PXB 126B were significantly different (p = 0.0006). 
In human MCF-7 cells, the EC50 for TCDD was 464 pM (95% CI = 341 pM – 633 pM), PCB 
126 was 3.81 nM (95% CI = 2.89 nM – 5.02 nM) and PXB 126B was 947 pM (95% CI = 
807 pM – 1.11 nM). The REP calculated for PCB 126 was 0.12 which is supported by the 
REP calculated in rat H4IIE cells and WHO TEF (0.1; Van den Berg et al., 2006). PXB 
126B is 2-fold less potent than TCDD giving a REP of 0.49 and is 5-fold more potent than 
PCB 126 in human MCF-7 cells. TCDD and PCB 126 were shown to be 15-fold more potent 
in rat than in human cells. PXB 126B was shown to be 7-fold more potent in rat than human 
cells. Two other PXB 126 substituted compounds and PBB 126 were tested in rat H4IIE to 
measure their potencies. 
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Figure 3.16: Potency of PXB 126H, PXB 126V and PBB 126 as AhR agonists – Rat H4IIE were treated with various 
concentrations of (A) 3’,4’-DiB-3,4,5-TriCB (PXB 126H), (B) 3’,4’,5-TriB-3,4-DiCB (PXB 126V) or (C) 3,3’,4,4’,5-
PentaBB (PBB 126). TCDD was also plotted for comparison. (D) Comparison of REPs and EC50s for non-ortho-substituted 
biphenyls (PXB 126). Concentration-response curves were created by plotting the % of maximal CYP1A1 mRNA 
induction by 10 nM TCDD against concentration of agonist. qRT-PCR was used to measure the level of induction of 
CYP1A1 and compared against FRQWURO JHQHV ȕ-actin and AhR. QbasePlus was used to normalise the data which was 
plotted using 10 nM TCDD only control as 100% of the maximal response. Results were compared with a vehicle control 
(VC) and a 10 nM TCDD only control (TC). Each point is the mean of three biological replicates ± S.D. 
The potency of PXB 126H, PXB 126V and PBB 126 are shown in Figure 3.16. The EC50s 
were 200 pM for PXB 126H, 72.2 pM for PXB 126V and 622 pM for PBB 126. The EC50 of 
TCDD was shown in Figure 3.15A. This gave REPs of 0.15, 0.40 and 0.05 for PXB 126H, 
PXB 126V and PBB 126, respectively. All three compounds were within 2- to 20-fold less 
potent than TCDD in rat H4IIE cells. 
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3.1.6.3 2,3,3,4,4-substituted biphenyls (PXB 105) 
PCB 105 was identified as an environmentally abundant AhR ligand. Furthermore previous 
research has suggested in may also have antagonist properties. Therefore to investigate what 
impact these properties could have on risk assessment, the agonistic and antagonistic 
properties of the compound were investigated. The activation of the AhR was measured by 
the subsequent induction of CYP1A1. Figure 3.17 shows the potency of PCB 105 and 
TCDD in rat H4IIE and human MCF-7 cells. 
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Figure 3.17: PCB 105 is a partial agonist of rat AhR but an antagonist of human AhR – (A) Rat H4IIE or (B) human 
MCF7 cells were treated with various concentrations of PCB 105. (C) Rat H4IIE or (D) human MCF-7 cells were treated 
with various concentrations of TCDD in the absence or presence of 3 µM and 10 µM PCB 105, respectively. 
Concentration-response curves were created by plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD 
against concentration of agonist. qRT-PCR was used to measure the level of induction of CYP1A1 and compared against 
FRQWURO JHQHV ȕ-actin and AhR. QbasePlus was used to normalise the data which was plotted using 10 nM TCDD only 
control as 100% of the maximal response. Results were compared with a vehicle control (VC), putative antagonist only 
(AC) and a 10 nM TCDD only control (TC). Each point is the mean of three biological replicates ± S.D. 
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Figure 3.17 shows that PCB 105 was shown to be a relatively weak agonist with EC50s of 
16.0 µM (95% CI = 15.6 µM – 16.3 µM) in rat H4IIE cells (Figure 3.17A) and no 
measurable response up to 10 µM PCB 105 in human MCF-7 cells (Figure 3.17B). TCDD 
gave an EC50 of 28.9 pM (95% CI = 19.9 pM – 41.9 pM) in rat H4IIE cells and 241 pM 
(95% CI = 161 pM – 362 pM) in human MCF-7 cells. The data shows that PCB 105 is 
55,000-fold less potent at inducing CYP1A1 mRNA than TCDD in rat cells. A REP value of 
0.0000018 was calculated from the data in rat H4IIE cells which is 15-fold less than the TEF 
value of 0.00003 derived by the 2005 WHO consortium (Van den Berg et al., 2006). The 
antagonistic property of the compound was assessed by treating cells with various 
concentrations of TCDD but in the presence of a set concentration of PCB 105. Figure 3.17 
also shows TCDD concentration-response curves in rat H4IIE cells (C) or human MCF-7 
cells (D) in the presence or absence of PCB 105. The concentration of PCB 105 added was 
the concentration required to produce 20% of the maximal response which was 3 µM in rat 
cells based on the data in Figure 3.17A. As no response was detected in human cells, the 
highest possible concentration (10 µM) was used instead. The antagonist effects were 
assessed by the ability of PCB 105 to compete with TCDD. The EC50 for TCDD in the 
presence of PCB 105 was increased to 806 pM (95% CI = 191 pM – 3.39 nM) from 28.9 pM 
in its absence. These results clearly indicate that PCB 105 has a statically significant 
(p<0.0001) effect on the ability of TCDD induce CYP1A1 mRNA (activate the AhR). These 
results, in combination with Figure 3.17A, show that PCB 105 is a partial agonist (agonist 
and antagonist properties) in rat cells. Figure 3.17D shows human MCF-7 cells treated in the 
same way. The data show that there is a significant antagonistic effect on the potency of 
TCDD when in the presence of 10 µM PCB 105: the EC50 for TCDD was significantly 
(p<0.0001) increased to 16.6 nM (95% CI = 13.9 nM – 19.7 nM) from 28.9 pM. This 
compound is therefore a partial agonist in rat and an antagonist in human.  
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The effect of substituting a chlorine atom with a bromine atom was investigated by treating 
rat H4IIE cells with PXB 105 for 4 hours. 
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Figure 3.18: PXB 105 is a partial agonist of rat AhR – (A) Agonist properties, rat H4IIE cells were treated with various 
concentrations of PXB 105 for 4 hours. (B) Antagonistic properties, rat H4IIE cells were treated with various 
concentrations of TCDD in the presence or absence of 1 µM PXB 105. Concentration-response curves were created by 
plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-PCR was 
XVHG WRPHDVXUH WKH OHYHO RI LQGXFWLRQRI&<3$DQG FRPSDUHG DJDLQVW FRQWURO JHQHV ȕ-actin and AhR. Results were 
compared with an antagonist only control (AC), a vehicle control (VC) and a 10 nM TCDD only control (TC) which is 
normalised as 100% of the maximal response. Each point is the mean of three biological replicates ± S.D.  
Figure 3.18A shows the potency of PXB 105 in comparison with TCDD. The EC50 was 
estimated to be 2.46 µM (95% CI = 2.10 µM – 2.90 µM) based on the assumption that the 
curve would reach 100% response. The data shows that PXB 105 is about 100,000-fold less 
potent at inducing CYP1A1 mRNA than TCDD with a REP of 0.00001. The compound is 
also shown to be 5-fold more potent than the chlorinated substituent, PCB 105. The 
antagonistic properties were measured by treating rat H4IIE cells with various 
concentrations of TCDD in the presence of 1 µM PXB 105, which was shown to produce 
~25% of the maximal response (Figure 3.18B). The EC50 for TCDD in the presence of PXB 
105 was 5.56 nM (95% CI = 1.60 nM – 19.3 nM) which is statistically different from TCDD 
alone, EC50 = 28.9 pM (p <0.0001). This was a decrease of 200-fold in the ability of TCDD 
to induce CYP1A1 mRNA and clearly shows that PXB 105 is a partial agonist. 
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3.1.6.4 2,3,4,4,5-substituted biphenyls (PXB 118) 
The next compound to be analysed was PCB 118. This was shown to be the most 
environmentally prevalent PCB based on previous literature. Figure 3.19 shows rat and 
human cells treated with PCB 118 or TCDD for 4 hours. CYP1A1 mRNA was measured 
using qRT-PCR and normalised against 10 nM TCDD only (defined as 100% response). 
-16
0
20
40
60
80
100
120
-13 -12 -11 -10 -9 -8 -7 -6 -5
-1VC TC
TCDD
PCB 118
Log[agonist]
%
 
o
f M
ax
im
al
 
R
es
po
n
se
 
-16
0
20
40
60
80
100
120
-13 -12 -11 -10 -9 -8 -7 -6 -5
-1VC TC
PCB 118
TCDD
Log[agonist]
%
 
o
f M
ax
im
al
 
Re
sp
on
se
 
-16 -15
0
20
40
60
80
100
120
-13 -12 -11 -10 -9 -8
-1
TCDD only
VC AC TC
TCDD + 1 PM PCB 118
Log[agonist]
%
 
o
f M
ax
im
al
 
R
es
po
n
se
-16 -15
0
20
40
60
80
100
120
-13 -12 -11 -10 -9 -8
-1VC AC TC
TCDD only
TCDD + 10 PM PCB 118
Log[agonist]
%
 
o
f M
ax
im
al
 
R
es
po
n
se
 
Figure 3.19: PCB 118 is a partial agonist of AhR of rat and human AhR – (A) Rat H4IIE or (B) human MCF7 cells 
were treated with various concentrations of PCB 118. (C) Rat H4IIE cells and (D) human MCF-7 cells were treated with 
various concentrations of TCDD in the presence or absence of 1 µM or 10 µM PCB 118, respectively. All of the graphs 
show a TCDD concentration-response curve for comparison. Concentration-response curves were created by plotting the % 
of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-PCR was used to measure 
the level oILQGXFWLRQRI&<3$DQGFRPSDUHGDJDLQVWFRQWUROJHQHVȕ-actin and AhR. QbasePlus was used to normalise 
the data which was plotted using 10 nM TCDD only control as 100% of the maximal response. Results were compared with 
an antagonist only control (AC), a vehicle control (VC) and a 10 nM TCDD only control (TC). Each point is the mean of 
three biological replicates ± S.D. 
The agonistic potency of PCB 118 was measured in rat H4IIE (Figure 3.19A) and human 
MCF-7 cells (Figure 3.19B). The EC50 for PCB 118 in rat cells was 11.8 µM (95% CI = 10.5 
A 
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µM – 13.2 µM) but no accurate EC50 could be derived from the human data. This was 
compared to rat and human cells treated with TCDD. The data shows that PCB 118 is 
~400,000-fold less potent than TCDD in rat. No REP could be calculated from the data 
derived from the human cells but for rat the REP is 0.000003 which is 10-fold lower than the 
TEF calculated by the 2005 WHO consortium (0.00003; Van den Berg et al., 2006). In order 
to calculate the antagonistic properties of the compounds, the concentration that produced 
20% of the maximal response was extrapolated from the data in Figure 3.19. The value for 
PCB 118 in rat was 3 µM but as there was no significant response detected in human, the 
highest concentration available was used which was 10 µM. The concentration of PCB 118 
was treated simultaneously with various concentrations of TCDD to detect if the compound 
has any effect on the potency of TCDD. Figure 3.19C shows TCDD in the presence and 
absence of 3 µM PCB 118 in rat H4IIE cells. The EC50 for TCDD in the presence of PCB 
118 was increased from 28.9 pM (p<0.001) to 306 pM (95% CI = 75.2 pM – 1.25 nM). The 
graph also shows TCDD without the addition of PCB 118. The two EC50s are statistically 
different based on the 95% confidence intervals, with the graph showing a distinctive shift of 
the TCDD curve to the right suggesting it has a reduced ability to induce CYP1A1. The 
compound was next tested in human MCF-7 cells, shown in Figure 3.19D. The EC50 for 
TCDD in the presence of 10 µM PCB 118 gives an EC50 of 10.9 nM (95% CI = 8.6 nM – 
13.8 nM) compared to 28.9 pM (TCDD alone) which is a statistically significant shift of the 
TCDD curve to the right (p <0.0001). The two EC50s are also significantly different from 
one another based on their 95% confidence intervals. A concentration of 10 µM had very 
little agonistic effect but produced a measurable antagonist effect. From this combined data 
it is possible to conclude that PCB 118 is a partial agonist in rat H4IIE and human MCF-7 
cells. A mixed halogenated PXB 118 was tested, which has a chlorine atom (position 4’; 
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Table 3.3) substituted with a bromine atom. The compound was tested in rat H4IIE cells to 
measure any putative agonist and antagonist properties. 
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Figure 3.20: PXB 118 is a partial agonist of AhR in rat – (A) Agonist properties, rat H4IIE cells were treated with 
various concentrations of PXB 118 for 4 hours. (B) Antagonistic properties, rat H4IIE cells were treated with various 
concentrations of TCDD in the presence or absence of 300 nM PXB 118. Concentration-response curves were created by 
plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-PCR was 
XVHG WRPHDVXUH WKH OHYHO RI LQGXFWLRQRI&<3$DQG FRPSDUHG DJDLQVW FRQWURO JHQHV ȕ-actin and AhR. Results were 
compared with an antagonist only control (AC), a vehicle control (VC) and a 10 nM TCDD only control (TC) which is 
normalised as 100% of the maximal response. Each point is the mean of three biological replicates ± S.D.  
Figure 3.20A shows the EC50 of PXB 118 in rat H4IIE cells to be 775 nM (95% CI = 655 
nM – 917 nM) which is 25,000-fold less potent than TCDD and is 10-fold more potent than 
PCB 118 at inducing CYP1A1 mRNA under the same conditions. The antagonist properties 
were measured by treating cells with various concentrations of TCDD in the presence of 300 
nM PXB 118 (Figure 3.20B) which gave an EC50 of 96.2 pM (95% CI = 45.5 pM – 203 pM) 
compared with TCDD alone (EC50 = 28.9 pM). The two EC50s were shown to be 
significantly different (p <0.005) with PXB 118 reducing the potency of TCDD by 3-fold. 
This data shows that PXB 118 is a partial agonist, nearly 10-fold more potent than the 
structurally similar but fully chlorinated congener, PCB 118. A REP of 0.00003 was 
calculated for PXB 118. 
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3.1.6.5 2,3,3,4,4,5-substituted biphenyls (PXB 156) 
The final compound to be tested with qRT-PCR was PCB 156. Previous research has 
suggested this is the most potent of the mono-ortho-substituted PCBs at inducing CYP1A1 
mRNA (Van den Berg et al., 1998) although also the less environmentally prevalent of the 
three compounds tested. Figure 3.21 shows the potency of PCB 156 in comparison to TCDD 
in rat H4IIE and human MCF-7 cells. 
-16
0
20
40
60
80
100
120
-13 -12 -11 -10 -9 -8 -7 -6 -5
-1VC TC
TCDD
PCB 156
Log[agonist]
%
 
o
f M
ax
im
al
 
Re
sp
on
se
 
-16
0
20
40
60
80
100
120
-13 -12 -11 -10 -9 -8 -7 -6 -5
-1VC TC
PCB 156
TCDD
Log[agonist]
%
 
o
f M
ax
im
al
 
Re
sp
on
se
 
-16 -15
0
20
40
60
80
100
120
-13 -12 -11 -10 -9 -8
-1
TCDD only
VC AC TC
TCDD + 30 nM PCB 156
Log[agonist]
%
 
o
f M
ax
im
al
 
R
es
po
n
se
-16 -15
0
20
40
60
80
100
120
-13 -12 -11 -10 -9 -8
-1VC AC TC
TCDD only
TCDD + 300 nM PCB 156
Log[agonist]
%
 
o
f M
ax
im
al
 
Re
sp
on
se
 
Figure 3.21: PCB 156 is a pure agonist of rat and human AhR – (A) Rat H4IIE or (B) human MCF7 cells were treated 
with various concentrations of PCB 156. The graphs also show a TCDD concentration-response curves for comparison. (C) 
Rat H4IIE cells or (D) human MCF-7 cells were treated with various concentrations of TCDD in the presence or absence of 
30 nM or 300 nM PCB 156, respectively. Concentration-response curves were created by plotting the % of maximal 
CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-PCR was used to measure the level of 
LQGXFWLRQRI&<3$DQG FRPSDUHG DJDLQVW FRQWURO JHQHV ȕ-actin and AhR. Results were compared with an antagonist 
only control (AC), a vehicle control (VC) and a 10 nM TCDD only control (TC) which is normalised as 100% of the 
maximal response. Each point is the mean of three biological replicates ± S.D.  
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According to the data, PCB 156 is the most potent AhR agonist of the three fully chlorinated 
mono-ortho-substituted PCBs with an EC50 of 122 nM (95% CI = 104 nM – 144 nM) in rat 
(Figure 3.21A) and EC50 of 3.59 µM (95% CI = 2.81 µM – 4.59 µM) in human (Figure 
3.21B). This clearly indicates that PCB 156 is an agonist in rat and human cell lines. The 
2005 WHO TEF for PCB 156 is 0.00003 (Van den Berg et al., 2006) however this data gives 
a REP value of ~0.0003 in rat and human. This is a 10-fold increase in the REP/TEF 
estimation but is supported by the original 1998 WHO TEF value (0.0005; Van den Berg et 
al., 1998). The data clearly shows that there is a 30-fold difference in the potency of PCB 
156 between rat and human AhR compared with a 10-fold difference with TCDD. The 
antagonistic effects were measured by treating cells with TCDD in the presence of 1 µM and 
10 µM, respectively. In rat H4IIE cells (Figure 3.21C), the EC50 for TCDD with PCB 156 
was 46.3 pM (95% CI = 24.8 pM – 86.2 pM). The 95% confidence overlap between the two 
EC50s shows that they are not statistically different leading to the conclusion that PCB 156 is 
not an antagonist of rat AhR (p = 0.175). Figure 3.21D shows the same experiment in human 
MCF-7 cells. The EC50 for TCDD in the presence of 300 nM PCB 156 in human cells was 
1.55 nM (95% CI = 411 pM – 5.88 nM). This shows that there is a statistically significant 
difference between the EC50 of TCDD alone and that of TCDD with PCB 156 (p <0.005) 
which signifies that this compound is a partial agonist of AhR in human MCF-7 cells in 
these conditions.  
Another structurally similar compound, PXB 156, was tested on rat H4IIE cells to see if it 
shared similar AhR activation characteristics with PCB 156. 
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Figure 3.22: PXB 156 is a partial agonist of AhR in rat – (A) Agonist properties, rat H4IIE cells were treated with 
various concentrations of PXB 156 for 4 hours. (B) Antagonistic properties, rat H4IIE cells were treated with various 
concentrations of TCDD in the presence or absence of 100 nM PXB 156. Concentration-response curves were created by 
plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-PCR was 
XVHG WRPHDVXUH WKH OHYHO RI LQGXFWLRQRI&<3$DQG FRPSDUHG DJDLQVW FRQWURO JHQHV ȕ-actin and AhR. Results were 
compared with an antagonist only control (AC), a vehicle control (VC) and a 10 nM TCDD only control (TC) which is 
normalised as 100% of the maximal response. Each point is the mean of three biological replicates ± S.D.  
Figure 3.22A shows that PXB 156 is an agonist of the AhR with an EC50 of 139 nM (95% CI 
= 95.5 nM – 203 nM). This was 5,000-fold less potent than TCDD and of equal potency to 
PCB 156 based on 95% confidence intervals but statistically different based on a t-test 
analysis (p-value <0.05). A REP of 0.0002 was calculated for PXB 156 which demonstrates 
that the compound has equal potency to PCB 156 (p=0.48). The antagonistic effects were 
measured using cell treated with TCDD in the presence of 100 nM PXB 156 (Figure 3.22B). 
The TCDD EC50 was estimated to be 2.68 nM (95% CI = 166 pM – 43.0 nM) compared with 
28.9 pM for TCDD alone and was shown to be significantly different (p=0.0021). This data 
shows that PXB 156 is partial agonist in rat H4IIE cells. 
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3.1.7 2-Amino-isoflavones 
3.1.7.1 Chr-13 is a partial agonist in rat and an antagonist in human 
The initial screening of a library of 2-amino-
isoflavones with respect to their ability to agonise or 
antagonise mouse or human AhR was conducted by 
Dr. Michael Denison and Dr. Guochun He 
(University of California, USA). Based on the results from this screening, two compounds, 
which showed unusual species differences, were selected for further analysis with qRT-PCR 
in rat H4IIE and human MCF-7 cells (Wall et al., 2012b). Due to the high similarities in the 
ligand binding domains of the mouse and rat AhRs (Hahn et al., 1997), it was expected that 
the compounds would elicit a similar response. Measurement of CYP1A1 mRNA by qRT-
PCR was utilised as it is a more accurate method of detecting AhR activation than luciferase-
based reporter assays. Therefore, 2-amino-3-(4-chlorophenyl)-7-methoxychromen-4-one 
(Chr-13) and 6-chloro-3-(4-methoxyphenyl)chromen-2-one (Chr-19) were chosen for further 
analysis. Figure 3.23 shows rat H4IIE cells and human MCF-7 cells treated with either Chr-
13 or TCDD. EC50s of 113 pM (95% CI = 83.0 pM – 152 pM) and 661 pM (95% CI = 515 
pM – 847 pM) for rat and human AhR, respectively, were estimated for cells treated with 
TCDD, showing that the potency of TCDD was 6-fold lower in the human MCF-7 cell line 
compared with rat H4IIE cells (p<0.0001). Furthermore, it is clear that Chr-13 was 
significantly less potent than TCDD at activating the AhR. Assuming that Chr-13 can 
achieve a maximal response, the EC50 for rat H4IIE cells treated with Chr-13 was 41.5 µM 
(95% CI = 35.2 µM – 49.0 µM), which is comparable to the data obtained in mouse 
H1L6.1c2 cells where a 10 µM concentration of Chr-13 gave a 50% response (See section 
4.4.2.1). In human MCF-7 cells, no agonism was detected even at the highest concentration 
of 100 µM. These results indicate that the compound is an agonist in rat but not in human (at 
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the concentrations used), and is similar to the initial screening results which showed Chr-13 
to be agonist in mouse but not human cells (See section 4.4.2.1). This result is not surprising 
given the high sequence identity of the mouse and rat AhR ligand binding domain (Pandini 
et al., 2009). 
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Figure 3.23: Chr-13 is a pure agonist of rat AhR and a pure antagonist of human AhR – (A) Rat H4IIE or (B) human 
MCF-7 cells were treated with various concentrations of Chr-13 for 4 hours to measure its agonist properties. (C) rat H4IIE 
or (D) human MCF-7 cells were treated with various concentrations of TCDD in the presence of 10 µM (rat) or 100 µM 
(human) Chr-13 for 4 hours. Concentration-response curves were created by plotting the % of maximal CYP1A1 mRNA 
induction by 10 nM TCDD against concentration of agonist. qRT-PCR was used to measure the level of induction of 
&<3$ DQG FRPSDUHG DJDLQVW FRQWURO JHQHV ȕ-actin and AhR. QbasePlus was used to normalise the data which was 
plotted using 10 nM TCDD only control as 100% of the maximal response. Vehicle control (VC), an antagonist only 
control (AC) and a 10 nM TCDD only control (TC). Each point is the mean of three biological replicates ± S.D. 
Investigation of the antagonistic effects of Chr-13 was performed by treating rat or human 
cells with various concentrations of TCDD but in the presence of a set concentration of Chr-
13 which induces ~20% of the maximal agonistic response of 10 nM TCDD. This was 
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estimated to be 10 µM for the rat cells, but as no response was detected in human cells, at 
concentrations up to 100 µM Chr-13. The antagonistic effect of Chr-13 in rat H4IIE cells is 
shown in Figure 3.23C. Although the screening data showed that Chr-13 was not 
antagonistic in the mouse H1L6.1c2 cell line (section 4.4.2.1) it was still important to 
confirm its effect in the rat H4IIE cell line. The addition of 10 µM Chr-13 to the TCDD 
concentration-response curve resulted in a background induction of ~25% of the maximal 
induction which corresponds well with the data shown in Figure 3.23A. The EC50 for TCDD 
in the presence of 10 µM Chr-13 was 237 pM (95% CI = 24.9 pM – 2.25 nM) in rat H4IIE 
cells which was not significantly different (p>0.05) from the EC50 for TCDD alone. The 
results confirm that Chr-13 has no antagonistic effects. Figure 3.23D shows human MCF-7 
cells treated with TCDD in the presence and absence of 100 µM Chr-13. A concentration of 
100 µM was shown in Figure 3.23B to have no AhR agonistic activity consequently there is 
no background of induction when treated simultaneously with TCDD. However, the data did 
show a shift of the TCDD concentration-response curve to the right, reducing the potency of 
TCDD by 5-fold compared to TCDD in the absence of Chr-13. The EC50 for TCDD in the 
presence of 100 µM Chr-13 was 3.02 nM (95% CI = 2.55 nM – 3.55 nM) which was 
significantly higher (p<0.0001) than the EC50 of TCDD alone. Consequently, these data 
show that Chr-13 is a weak antagonist in human MCF-7 and an agonist in rat H4IIE cells. 
3.1.7.2  Chr-19 is an agonist in rat and a partial agonist in human 
Figure 3.24 shows the concentration-response curves 
of Chr-19 and TCDD agonism of AhR in rat H4IIE 
and human MCF-7 cells, as measured by qRT-PCR 
of CYP1A1 induction. Rat H4IIE (Figure 3.24A) and 
human MCF-7 cells (Figure 3.24B) were treated with either Chr-19 or TCDD. Chr-19 was 
agonistic in both rat H4IIE and human MCF-7 cells, with the compound being 
O O
Cl
O
 
Richard Wall 
 
128 
 
approximately 20-fold more potent in rat cells (p<0.0001). Assuming that the compound will 
attain maximal response, the EC50 for Chr-19 in rat H4IIE cells was 7.70 µM (95% CI = 5.22 
µM – 11.3 µM), and in human MCF-7 cells, the EC50 was estimated to be 140 µM (95% CI 
= 65.4 µM – 317 µM). The data shows that Chr-19 is significantly less potent at activating 
the AhR and inducing CYP1A1 than TCDD.  
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Figure 3.24: Chr-19 is a pure agonist of rat AhR and a partial agonist of human AhR – (A) Rat H4IIE and (B) human 
MCF-7 cells were treated with various concentrations of Chr-19 for 4 hours. (C) Rat H4IIE and (D) human MCF-7 cells 
were treated with various concentrations of TCDD in the presence of 3 µM (rat) or 30 µM (human) Chr-19 for 4 hours. 
Concentration-response curves were created by plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD 
against concentration of agonist. qRT-PCR was used to measure the level of induction of CYP1A1 and compared against 
FRQWURO JHQHV ȕ-actin and AhR. QbasePlus was used to normalise the data which was plotted using 10 nM TCDD only 
control as 100% of the maximal response separately for rat and human. Results were compared with a vehicle control (VC) 
and a 10 nM TCDD only control (TC). Each point is the mean of three biological replicates ± S.D. 
The antagonistic effects of Chr-19 were examined by treating cells with TCDD in the 
presence or absence of a set concentration of Chr-19 (i.e. that produces ~20% of maximal 
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induction response). This value was found to be 1 µM and 10 µM for rat and human, 
respectively. Figure 3.24 shows the analysis of antagonistic activity of Chr-19 in C) rat 
H4IIE cells and D) human MCF-7 cells. It can be seen in Figure 3.24C that there was no 
shift of the TCDD curve to the right. The EC50 for TCDD in the presence of 1 µM Chr-19 
was 182 pM (95% CI = 31.0 pM – 1.07 nM) which was not significantly different (p>0.05) 
from the EC50 obtained from cells treated with TCDD only. Figure 3.24D shows human 
MCF-7 cells treated with TCDD in the presence and absence of Chr-19. An EC50 of 1.76 nM 
(95% CI = 897 pM – 3.47 nM) for TCDD with 10 µM Chr-19 was calculated which was 
statistically significantly higher than that obtained with TCDD alone (p<0.05). This indicates 
that Chr-19, at 10 µM, reduces the potency of TCDD activation of AhR by 3-fold and is 
hence a weak antagonist of the AhR. Combined with the data from Figure 3.24B, which 
showed Chr-19 was an agonist of human AhR, it can be concluded that this compound is a 
partial agonist in human MCF-7.  
3.1.8 AZFMHCs 
3.1.8.1 Overview 
Several compounds received from AstraZeneca were thought 
to have a higher potency than TCDD when activating the AhR 
based on medicinal research conducted on the compounds so 
were deemed suitable to test with the validated method of 
measuring AhR activation. A full characterisation of the 
family was conducted, measuring the potency of the 
compounds to activate the AhR based on the induction of 
CYP1A1, CYP1B1 and CYP1A2 and measuring the affinity 
using a competitive ligand binding assay.   
N+
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NN
R1
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AZ1: R1=CF3, R2=H, R3=C 
AZ2: R1=CF3, R2=CH3, R3=N 
AZ3: R1=CH3, R2=CH3, R3=C 
AZ4: R1=CF3, R2=NH2, R3=N 
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3.1.8.2 Measurement of AhR activation by mRNA induction 
The fused mesoionic heterocycle compounds (AZFMHCs) were tested to measure their 
agonistic and antagonistic properties in rat H4IIE cells (Figure 3.25).  
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Figure 3.25: Agonistic and antagonistic properties of the AZFMHCs in comparison to TCDD – (A) Agonistic 
properties were measured by treating rat H4IIE cells with various concentrations of the compounds for 4 hours. 
Concentration-response curves were created by plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD 
against concentration of agonist. Results were compared with a vehicle control (VC) and a 10 nM TCDD only control (TC). 
(B) The antagonistic properties were measured by treating H4IIE cells with a concentration that gives approximately 20% 
of the maximal induction by 10 nM TCDD for that compound in the presence of 1 nM TCDD. qRT-PCR was used to 
measure the level of induction of CYP1A1 in both experiments and was compared against FRQWUROJHQHVȕ-actin and AhR. 
QbasePlus was used to normalise the data which was plotted using the TCDD only control as 100% of the maximal 
response. In both cases, each point is the mean of three biological replicates ± S.D. 
Figure 3.25A shows the agonistic potencies of the four AZFMHCs. The EC50 and 95% 
confidence intervals (95% CI) for TCDD and the four AZFMHCs were as follows; TCDD 
was 25.5 pM (95% CI = 18.2 pM – 36.0 pM), AZ1 was 5.05 pM (95% CI = 2.81 pM – 9.09 
pM), AZ2 was 1.17 nM (95% CI = 888 pM – 1.55 nM), AZ3 was 9.08 nM (95% CI 6.01 nM 
– 13.7 nM) and AZ4 was 3.46 nM (95% CI = 3.07 nM – 3.90 nM). The EC50s for AZ2, 3 
and 4 are estimates based on the predicted maximal induction equal to 10 nM TCDD. AZ1 
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was shown to be the only compound which was significantly more potent that TCDD 
(p<0.0001) by 5-fold and was investigated further.  
Figure 3.25B shows each of the four compounds in the presence of 1 nM TCDD. The data 
showed that none of the compounds elicit an antagonist effect on TCDD induction of 
CYP1A1 under these test conditions. To confirm that AZ1 induces other genes associated 
with AhR activation, the induction of CYP1B1 and CYP1A2 mRNA was also measured 
(Figure 3.26) in rat H4IIE. 
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Figure 3.26: Induction of AhR-mediated genes – (A) CYP1B1, (B) CYP1A2. Rat H4IIE were treated with various 
concentrations of TCDD for 4 hours. CYP1B1 and CYP1A2 were measured separately from the normalisation genes using 
SYBR green qRT-PCR master mix. Concentration-response curves were created by plotting the % of maximal CYP1B1 or 
CYP1A2 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-PCR was used to measure the level of 
LQGXFWLRQRI&<3$DQG FRPSDUHG DJDLQVW FRQWURO JHQHV ȕ-actin and AhR. QbasePlus was used to normalise the data 
which was plotted using 10 nM TCDD only control as 100% of the maximal response. Results were compared with a 
vehicle control (VC) and a 10 nM TCDD only (TC). Each point is the mean of three biological replicates ± S.D. 
Figure 3.26A shows the levels of CYP1B1 mRNA induction in rat cells treated with either 
TCDD or AZ1. The EC50 for TCDD was 34.0pM (95% CI = 13.9pM – 82.9pM) and AZ1 
was 6.3pM (95% CI = 4.0pM – 10.0pM). The data shows that AZ1 is 5-fold more potent at 
inducing CYP1B1 than TCDD in rat H4IIE cells (p<0.0001) with no overlap in the 95% 
confidence intervals. The mRNA levels of CYP1A2 are shown in Figure 3.26B. The EC50 of 
TCDD was 35.7pM (95% CI = 17.3pM – 73.6pM) and AZ1 was 3.4pM (95% CI = 1.7pM – 
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6.8pM). This shows that AZ1 is 10-fold more potent than TCDD (p<0.0001) with no overlap 
of 95% confidence intervals. TCDD and AZ1 were then tested in human MCF-7 cells to 
determine if the compound has the same high potency across species. 
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Figure 3.27: Concentration-response curve for AZ1 induction of CYP1A1 in human MCF7 cells – Human MCF7 cells 
were treated with various concentrations of TCDD for 4 hours. Concentration-response curves were created by plotting the 
% of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-PCR was used to 
PHDVXUHWKHOHYHORILQGXFWLRQE\&<3$DQGZDVFRPSDUHGDJDLQVWFRQWUROJHQHVȕ-actin and AhR. QbasePlus was used 
to normalise the data which was plotted using 10 nM TCDD only control as 100% of the maximal response. Results were 
compared with a vehicle control (VC). Each point is the mean of three biological replicates ± S.D. 
It can be seen from Figure 3.27 that AZ1 is 4-fold more potent than TCDD in human MCF-7 
cells as well as rat H4IIE-C3 cells. The EC50 for AZ1 was 65.4pM (95% CI = 45.6pM – 
93.7pM) and the EC50 for TCDD was 241 pM (95% CI = 161 pM – 362 pM) which are 
significantly different (p<0.0001). This shows that AZ1 is a significantly more potent 
agonist than TCDD in both rat H4IIE and human MCF-7 cells. 
3.1.8.3 Saturation binding ([3H]-TCDD) and competitive binding (TCDD and AZ1) 
As part of an investigation into the potency of AZ1, the ligand binding was measured to 
confirm that the compound underwent the same mechanism of action as TCDD to induce 
CYP1A1. Unlabelled TCDD was also measured and used for comparison. The method of 
ligand-binding was adapted from Bradfield and Poland (1988) and Bazzi et al. (2009). A rat 
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liver from a female Charles River Wistar rat was homogenised and repeatedly centrifuged to 
separate the cytosolic protein from the rest of the tissue. A Bradford assay using different 
concentrations of BSA was used to calculate the protein concentration of the rat cytosol. 
This was diluted to 5 mg/ml for subsequent experiments. The Kd and Bmax were calculated 
using 5 mg/ml rat cytosol treated with various concentrations of [3H]-TCDD in the presence 
and absence of TCAOB (section 1.5.1). Figure 3.28 shows total and non-specific binding 
which were measured experimentally and the specific binding which was calculated. 
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Figure 3.28: (A) Total and non-specific binding of [3H]-TCDD, (B) Specific binding of [3H]-TCDD – (A) 200 µl of 5 
mg/ml rat liver cytosol was treated with various concentration of [3H]-TCDD (0 nM – 2.5 nM) in the absence (total 
binding) and presence (non-specific binding) of 200 nM TCAOB. Samples were incubated for 16 h at 4oC. Incubation was 
terminated with the addition of 10 mg/ml dextran-coated charcoal. The counts per minute (cpm) were measured using a 
scintillation counter then converted into bound [3H]-TCDD in pmol/mg. Data points are mean ± S.D (n = 4). (B) The 
specific binding was calculated from total binding minus non-specific binding and plotted as mean ± S.D. The Kd and Bmax 
were calculated from this data using a quadratic curve equation (GraphPad Prism 5). 
Figure 3.28 shows the binding of [3H]-TCDD to the rat liver cytosol. The Kd was estimated, 
using the GraphPad Prism 5 software, to be 1.24 nM (95% CI = 0.58 nM – 1.90 nM). The 
Bmax was estimated to be 26.9 fmol/mg (95% CI = 20.0 fmol/mg – 33.7 fmol/mg) or 0.13 nM 
(95% CI = 0.10 nM – 0.16 nM) when incorporating the 0.2 ml volume of the reaction. 
The Ki of unlabelled (non-radiolabelled) TCDD was calculated by competitive binding 
analysis. A 200 µl aliquot of 5 mg/ml rat liver cytosol was incubated with 1 nM [3H]-TCDD, 
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various concentrations of unlabelled TCDD and 200 nM TCAOB (non-specific binding 
only). The mixture was then incubated for 16 h at 4oC. The incubation was terminated with 
10 mg/ml dextran-coated charcoal. The counts per minute (cpm) were measured using a 
scintillation counter and converted into bound [3H]-TCDD (nM). The % of maximally bound 
[3H]-TCDD (nM) was plotted against the concentration of unlabelled TCDD (Figure 3.29A). 
The IC50 (concentration that inhibits/displaces 50% of [3H]-TCDD) was extrapolated from 
the graph, then the Ki was calculated using data obtained from Figure 3.28 (1 nM [3H]-
TCDD with a Kd of 1.24 nM). 
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Figure 3.29: Competitive binding of (A) unlabelled TCDD and (B) AZ1 – Rat liver cytosol was treated with various 
concentrations of TCDD in the presence of 1 nM [3H]-TCDD ± 200 nM TCAOB. Total (without TCAOB) and non-specific 
(with TCAOB) binding was measured to allow the calculation of specific binding of (A) TCDD or (B) AZ1 to the AhR. Rat 
liver cytosol was incubated with TCDD or AZ1 and 1 nM [3H]-TCDD (with and without TCAOB) for 16 h at 4oC. The 
specific binding was plotted against concentration of TCDD. This allowed measurement of the IC50 and Ki. Data points are 
mean ± S.D. (n = 3; total binding only). 
The IC50 for unlabelled TCDD was calculated to be 2.11 nM (95% CI = 1.32 nM – 3.40 
nM). The Ki was calculated to be 1.17 nM (95% CI = 729 pM – 1.88 nM). The binding 
properties of AZ1 were investigated as part of its comparison with TCDD (Wall et al., 
2012a). The IC50 was estimated as for unlabelled TCDD and the Kd was calculated using 
parameters calculated from section 3.1.8.3. Figure 3.29B shows the specific binding of [3H]-
TCDD plotted against the concentration of the competitor, AZ1. The IC50 of AZ1 was 
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calculated to be 269 pM (95% CI= 182 pM – 396 pM) and the Ki was calculated to be 149 
pM (95% CI = 101 pM – 219 pM). Thus AZ1 has a statistically significantly higher affinity 
(~8-fold) than TCDD (p < 0.0001).  
3.2 Investigation of AhR species differences 
3.2.1 Overview 
The AhR cDNA from rat and human were isolated and cloned into pFastbac1 vectors as 
discussed previously in section 2.5.2 (Fan et al., 2009). The AhR cDNA were cloned into the 
pRevTRE vector which was then subsequently used to infect AhR deficient mouse BpRc1 
cells. All the transfection and infection procedures were conducted in exactly the same way 
for rat and human AhR genes. Briefly, high fidelity PCR was used to copy the cDNA out of 
the pFastbac1 vector. At the same time the His-tag was removed and a new HindIII 
restriction site was added directly after the stop codon of the AhR gene. This PCR product 
was ligated and subcloned into pGEM-T before being double digested out with SalI and 
HindIII and re-ligated into pRevTRE. The pRevTRE vectors (rat and human) were 
transfected into PT67 packaging cells to produce a virus along with pRevTet-Off. The 
replication-defective viruses were then used to infect the mouse BpRc1 cells to produce 
BpRc1 rAhR and BpRc1 hAhR. 
3.2.2 Preparing the pGEM-T:insert vectors  
The AhR cDNA were copied from the pFastBac1 vector using high-fidelity PCR. The 
concentrations were measured using a Nanodrop spectrophotometer and diluted to 250 ng/µl. 
The PCR products were run on a 1x agarose gel to confirm the size of the products and to 
allow extraction of the AhRs from background debris. The size of the fragments for human 
and rat AhR were calculated to be 2569 bp (rat) and 2578 bp (human) in size using 
Richard Wall 
 
136 
 
VectorNTI Advance 11™ (Invitrogen). Figure 3.30 shows that there was no contamination 
or other PCR products.  
 
 
Figure 3.30: Gel of AhR PCR products – The products of the PCR reaction which copied the AhR gene from the 
pFastbac1 vector were run on a 1x gel. (A) 1 kbp DNA ladder (Biolabs), (B) rat AhR (C) human AhR. (D) Negative 
control, which consisted of the loading dye and distilled water, was also clear of contamination. The gel was made as 
described in section 2.2.1 and run for 70 min at 100 V. The gel was stained with ethidium bromide for 20 min (and washed 
for 30 min) before being photographed with a BioRad chemdoc UV camera. 
After extraction and purification, the PCR fragments were ligated into pGEM-T. Successful 
colonies were picked and grown overnight. After further purification, potential clones were 
selected and double digested with SalI and HindIII. Once a successful clone was identified, a 
more detailed investigation was conducted which included single digestions as well as a 
double digestion.  
 
 
2569/2578 bp 
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Figure 3.31: Gel of digestion products of pGEM-T with ligated the A) rat AhR insert or B) human AhR insert – All 
the digests were compared against a 1 kbp DNA ladder (Biolabs; A and G). (B) Double digest was conducted on the 
pGEM-T with insert using SalI and HindIII. Single digests with (C) SalI only and (D) HindIII only were also conducted. A 
negative control (E) was run to confirm the loading dye and distilled water used was free of contamination. The pGEM-T 
with insert was also run on the gel uncut (F). The gel was made as described in the legend of Figure 3.30 (70 min; 90 V). 
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Figure 3.31 shows pGEM-T with insert digested with either SalI, HindIII, both or neither. 
The total size of the linear vector was 5.5 kbp (rat was 5569 bp and human was 5578 bp). 
This consisted of the 3 kbp pGEM-T vector and the 2.5 kbp AhR insert (2544 bp for rat and 
2553 bp for human). The pGEM-T vector does have a SalI digestion site already so SalI 
should cut twice. The two gels show that the gene was ligated in the 5’ direction, based on 
the bands from SalI digestion sites, which shows that only one visible digestion has occurred 
(Figure 3.31). A single digestion with HindIII cut the vector as expected but also appeared to 
have experienced star activity and randomly cut in a different location to produce a low 
concentration 3 kbp product. This is a common problem with HindIII but in this instance has 
no effect on the confirmation of successful ligation. Sequencing was conducted at Source 
Bioscience (Life Science, Nottingham) on both pGEM-T vectors to confirm the presence of 
the AhR and successful removal of the His-tag. The sequencing data was analysed using 
Align X software (VectorNTI Advance 11™, Invitrogen) by comparing against the predicted 
sequence of the pGEM-T and vector insert (data not shown). 
3.2.3 Subcloning to pRevTRE vectors 
The AhR cDNA were then cloned out of pGEM-T and into the viral vector, pRevTRE. The 
gene was double digested out of pGEM-T using SalI and HindIII. The same confirmation 
checks were also carried out on the pRevTRE: insert vectors. The digested vectors were run 
on a 1x agarose gel so that the pRevTRE: insert fragments could be cut out and purified. The 
gene was then ligated into the new vector. Figure 3.32 shows the ligation product digested 
with either SalI, HindIII, both or neither. The gels also show the pRevTRE vector (digested 
once with SalI; lane F), the AhR gene only (E) and a negative digestion sample (G). 
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Figure 3.32: Gel of digestion products of pRevTRE ligated with (A) rat AhR insert or (B) human AhR insert – All 
the digests were compared against a 1 kbp DNA ladder (Biolabs; A and H). A double digest (B) was conducted on the 
pRevTRE with insert using SalI and HindIII. A single digest with SalI only (C) and HindIII only (D) was also conducted. 
Controls of AhR only and pRevTRE were run to compare against (E and F). A negative control (G) was run to confirm the 
loading dye and distilled water used was free of contamination. The 1x gel was made as described in the legend of Figure 
3.30 (70 min; 90 V). 
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The two gels in Figure 3.32 show that the AhR was successfully subcloned from pGEM-T 
into pRevTRE. Single digestion (C and D) produced bands of ~9 kbp whereas double 
digestion produced bands of ~6.5 kbp (pRevTRE vector) and 2.5 kbp (AhR gene). There was 
no detectable contamination in the experiment (G). Sequencing was then conducted on the 
purified pRevTRE: insert vectors to confirm the cDNA was present in the vector. The data 
(not shown) was analysed using Align X software (VectorNTI Advance 11™, Invitrogen). 
Alignment showed only the 3’ end of the AhR gene (HindIII; stop codon) and clearly shows 
that the His-tags were successfully removed during the high-fidelity PCR (whilst still 
retaining the stop codon and HindIII digestion site). 
3.2.4 Producing stable virus producing PT67 cell lines 
PT67 packaging cell lines were individually transfected with one of the three vectors to 
produce three stable-virus producing cell lines. The cell lines were called PT67 off, PT67 
hAhR and PT67 rAhR, which are explained further in section 2.5.5.3. To confirm that the 
vectors were stably integrated into the genomic DNA, endpoint PCR was used to confirm 
either the presence or absence of the vectors. Briefly, genomic DNA was isolated from the 
cells and RNAse treated. PCR was then conducted to identify the pRevTet-Off or pRevTRE 
vectors. Figure 3.33 shows two 2x agarose gels of the PCR products formed by the pRevTet-
Off or pRevTRE primers from the three virus producing cell lines. A band should form at 
171 bp to indicate the presence of the pRevTet-Off vector and a band at 232 bp should 
indicate the pRevTRE vector. 
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Figure 3.33: Agarose gel confirming the presence of A) pRevTet-Off vector and B) pRevTRE vector – Genomic DNA 
was isolated as described in the method. End-point PCR was conducted. A: The primers were designed to detect only the 
pRevTet-Off vector and not the pRevTRE vector. The resultant mRNA fragments were run on a 2x agarose gel (60 min; 90 
V). B: The primers were designed to detect only the pRevTRE vector (human or rat) and not the pRevTet-Off vector. The 
resultant mRNA fragments were run on a 2x agarose gel (70 min; 90 V). (A) ladder, (B) PT67 wild-type, (C) PT67 off, (D) 
PT67 hAhR, (E) PT67 rAhR and (F) negative control. 
Figure 3.33A shows that only the PT67 off cell line contains the pRevTet-Off vector. Figure 
3.33B shows the PCR products formed by the pRevTRE primers, confirming that only PT67 
rAhR and PT67 hAhR contain the pRevTRE vector with a band at 232 bp.  
3.2.5 Stable expression of AhR in BpRc1  
The antibiotic concentrations for selection were experimentally calculated for the BpRc1 
cells. BpRc1 cells were treated with six different concentrations of antibiotic for 7 days. The 
lowest concentration that killed all of the cells was then recorded. The concentrations were 
found to be 400 µg/ml for G418 and 600 µg/ml for hygromycin. BpRc1 cells were then 
infected with the PT67 viruses as discussed in the method. The related antibiotic was then 
171bp 
232bp 
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added to kill any cells that did not contain the resistance to the antibiotic (located within the 
vector). The cells were left to grow to confluence over a period of approximately 1 month at 
which time the cells were harvested. After selection and growth, the BpRc1 cells were tested 
to confirm the presence of the required vectors. Each cell line should have pRevTet-Off with 
either pRevTRE:rAhR or pRevTRE:hAhR. End-point PCR was conducted using genomic 
DNA isolated from the cells. The PCR was designed to locate either the vector or the AhR 
insert however the experiments produced negative results and did not produce a double 
stable cell line with rat and human AhR expressed. Therefore a cell line that transiently 
expresses AhR was produced by simultaneously infecting the BpRc1 cells with the two 
vectors then immediately (~48 hours) testing for AhR activation. If stable cells had been 
created, a control would have been conducted to show that the BpRc1 cell lines were not 
contaminated with any PT67 cells which already have the vectors transfected in. Primers 
designed to detect the env gene in the PT67 cells would be used to identify the cell line.  
3.2.6 Transient expression of AhR in BpRc1 
Transiently infected BpRc1 cell lines were created to allow comparison between rat and 
human AhR without double stable cell lines. They were infected for 72 hours with the 
viruses then treated with either TCDD or 5F 203 for 4 hours. As briefly discussed in section 
3.2.5, three important conformational assays were performed to: (1) confirm the presence of 
the two vectors, (2) confirm the presence of the relevant AhR DNA and (3) confirm absence 
of any PT67 cells or viral genes. Firstly, vector specific primers were used to confirm the 
presence of the two vectors in both of the cell lines. The system requires both vectors to be 
present in order to successfully transcribe the gene of interest (AhR). Primers have already 
been shown to be specific to the vector only (Figure 3.33). 
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Figure 3.34: Confirmation of the presence of (A) pRevTet-Off and (B) pRevTRE vectors in BpRc1 – Cells were 
grown as previously described. Genomic DNA was isolated and end-point PCR was conducted as described is sections 
2.2.2 and 2.2.8. The resultant PCR products were run on a 1x agarose gel (70 min; 100 V). Two primer pairs were used 
which were designed to locate pRevTet-Off and pRevTRE. (A) 100bp Ladder, (B) BpRc1 rAhR, (C) BpRc1 hAhR and (D) 
BpRc1 wild-type. 
The two gels in Figure 3.34 show the two vectors, pRevTet-Off and pRevTRE, in the BpRc1 
rAhR and BpRc1 hAhR cell lines. Figure 3.34A shows that there are distinctive bands at 171 
bp for the rat and human clones showing the presence of pRevTet-Off vectors. Figure 3.34B 
confirms the presence of the pRevTRE vectors with bands at 232 bp in the rat and human 
clones. Confirmation of the correct AhR was conducted on genomic DNA using qRT-PCR 
as the primers are more specific with the probe included. The human AhR primers were run 
DVDPXOWLSOH[ZLWKPRXVHȕ-actin mRNA primers (negative control) at 59oC. The rat AhR 
primers were run separately at 63oC to make binding more specific to the rat AhR only. 
0RXVHȕ-actin was also run separately with the rat samples as a negative control. 
232bp 
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Figure 3.35: Confirmation of the presence of either rat or human AhR DNA in BpRc1– (A) Rat AhR and (B) human 
AhR. Genomic DNA was obtained from BpRc1 wild-type, BpRc1 rAhR and BpRc1 hAhR cell lines. Rat and human AhR 
primers were used in a multiplex with mouse ȕ-actin primers (negative control). (C) Mouse ȕ-actin and (D) mouse AhR. 
Genomic DNA was obtained by BpRc1 cell line variants using either ȕ-actin or AhR with SYBR green dye. Cells were 
grown as previously described. Genomic DNA was isolated as described in the method. The experiment was repeated to 
confirm the results. ¨5n is the normalisation of Rn (normalised reporter) by subtracting the baseline fluorescence. Ct (cycle 
threshold) is the point at which the signal passes the fluorescence threshold. 
Figure 3.35 shows the genomic DNA levels of rat, human and mouse AhR (with mouse 
JHQRPLF ȕ-actin as a reference gene). Figure 3.35A clearly shows that rat AhR primers 
amplify the target only in BpRc1 rAhR cells and Figure 3.35B shows that the human AhR 
primers only detected a target in BpRc1 hAhR cells. No cross contamination of AhR genes 
ZDVLGHQWLILHG)XUWKHUPRUHPRXVHȕ-actin mRNA primers/probe was run with the genomic 
DNA as a negative control to show that there was no mRNA contamination in the DNA 
samples (not shown). Figure 3.35&DQG'VKRZPRXVHȕ-actin and AhR, respectively, were 
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induced equally in all three cell lines. Along with the evidence from Figure 3.34, this shows 
that the AhR genes have been successfully introduced into the AhR deficient BpRc1 mouse 
cell line and are at a concentration that can be measured using qRT-PCR. The next step was 
to confirm if the genes are being transcribed by the pRevTet-Off vector. Similar to the DNA 
experiment, the mRNA was isolated from the cells and qRT-PCR was used to detect the 
levels of rat, human and/or mouse mRNA levels which were compared against ȕ-actin 
mRNA levels. Confirmation of PT67 cells was not conducted as an effect from accidental 
contamination would have no noticeable effects on the activation of the infected AhRs in the 
time frame between infection and CYP1A1 mRNA measurement. 
3.2.7 Confirmation of rat/human AhR mRNA transcription  
Although both the pRevTet-Off and pRevTRE vectors were successfully identified, 
confirmation of the presence of AhR mRNA transcription still needed to be confirmed. In 
the process of confirming the AhR, it was also possible to quantitate the mRNA produced 
from transcription. Figure 3.36 show the qRT-PCR analysis of mRNA isolated from BpRc1 
wild-type, BpRc1 rAhR and BpRc1 hAhR. qRT-PCR was used to improve the selectivity of 
the primers by utilising a probe. Primers were used to identify AhR mRNA (rat, human and 
mouse), and a PRXVHȕ-actin mRNA primer/probe set which was used to normalise the data. 
$K5DQGȕ-actin were run as a duplex with the Ct threshold normalised so that all three AhR 
genes could be directly compared for quantitation purposes. Figure 3.36 shows the AhR 
levels in the three cell lines. Mouse AhR mRNA was further measured in NIH/3T3 cells 
(positive control) and H4IIE/MCF-7 cells (negative control). qRT-PCR was conducted as it 
provided more accuracy than end-point PCR due to the addition of a species specific probe. 
The rat AhR primers were run at 63oC to stop the primers from binding to the mouse AhR 
which shares high homology to the rat AhR.  
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Figure 3.36: Confirmation of the presence of either rat or human AhR mRNA in the BpRc1 cell lines – Cells were 
created as previously described and genomic DNA was isolated (section 2.5)3ULPHUVWKDWDPSOLI\PRXVHȕ-actin mRNA 
and either, (A) rat AhR or (B) human AhR, where used to detect the appropriate AhR vector (as a multiplex reaction). (C) 
0RXVH$K5DQGȕ-actin were measured in the three BpRc1 cell lines (as a multiplex reaction), a positive control (NIH/3T3 
cells) and two negative controls (H4IIE and MCF-FHOOV'DQG($K5P51$OHYHOVZHUHQRUPDOLVHGDJDLQVWPRXVHȕ-
actin mRNA and compared. ¨5n is the normalisation of Rn (normalised reporter) by subtracting the baseline fluorescence. 
Ct (cycle threshold) is the point at which the signal passes the fluorescence threshold. 
Figure 3.36 confirms that the two AhR genes are being transcribed by the pRevTet-Off 
vector to produce AhR mRNA. Figure 3.36A shows that only BpRc1 rAhR contains rat AhR 
mRNA which shows the pRevTRE: rAhR vector is been successfully transcribed. Figure 
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3.36B shows that only BpRc1 hAhR has transcribed human AhR mRNA demonstrating that 
this cell line has undergone successful transcription of the pRevTRE: hAhR vector. The 
levels of mouse AhR mRNA was measured in the three BpRc1 cell lines as well as in the 
three controls (Figure 3.36C). The BpRc1 cell lines have equal quantities of AhR mRNA as 
expected. The BpRc1 cell line only has deficient levels of AhR so the PCR should still detect 
significant levels. Another mouse cell line, NIH/3T3, was used as a positive control 
producing similar quantities of mouse AhR mRNA as BpRc1 cell lines. Rat H4IIE and 
human MCF-7 were used as negative controls and the figure shows that the mouse AhR 
primers did not amplify any part of the rat or human mRNA. All of the mRNA levels were 
QRUPDOLVHG DJDLQVWȕ-actin and tabulated to compare between cell lines (Figure 3.36D and 
E). The levels of mouse AhR mRNA were approximately similar for all three of the BpRc1 
cell lines and NIH/3T3 which does not confirm that the BpRc1 cell line has a reduced AhR 
concentration. However, as the BpRc1 and NIH/3T3 come from different tissue direct 
comparisons of thHOHYHOVRI$K5XVLQJȕ-actin as a normalisation gene was limited.  
3.2.8 Species/tissue specific differences 
Evidence from previous authors (Bazzi, 2008; Budinsky et al., 2010; Silkworth et al., 2006; 
Xu et al., 2000) and this research has shown that many persistent organic pollutants are 
significantly more potent at inducing rat AhR than human AhR. BpRc1 cells were derived 
from the Hepa1c1c7 cell line which according to the literature has an EC50 of 88.5 pM when 
treated with TCDD (Hepa1c1c7; Dere et al., 2006). To demonstrate this, both rat and human 
cells were treated with various concentrations of TCDD for 4 hours. 
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Figure 3.37: TCDD concentration-response curve in rat H4IIE, human MCF-7, mouse NIH/3T3 and mouse BpRc1 – 
(A) Rat (H4IIE), human (MCF-7), mouse (NIH/3T3) and mouse (BpRc1) cells were treated with various concentrations of 
TCDD for 4 hours, after which, RNA was purified and cDNA was synthesised. Concentration-response curves were created 
by plotting the % of maximal CYP1A1 mRNA induction against concentration of agonist. qRT-PCR was used to measure 
the induction of the gene of interest, CYP1A1 and the two normalisation genes, AhR and ȕ-actin. VC: Vehicle control, TC: 
10 nM TCDD only control (in H4IIE cells). Each point is the mean of three biological replicates ± S.D. (B) Raw qRT-PCR 
data showing CYP1A1 mRNA levels in mouse NIH/3T3 and BpRc1 cells. ¨5n is the normalisation of Rn (normalised 
reporter) by subtracting the baseline fluorescence. Ct (cycle threshold) is the point at which the signal passes the 
fluorescence threshold. 
Figure 3.37A shows the induction of CYP1A1 mRNA in rat (H4IIE), human (MCF-7) and 
mouse (BpRc1 and NIH 3T3) cells treated with TCDD for 4 hours. The EC50 for TCDD 
induction of CYP1A1 in BpRc1 cells was1.65 nM (95% CI = 1.12 nM – 2.44 nM) compared 
with 74 pM (95% CI = 4.9 pM - 110 pM) in H4IIE cells and 675 pM (95% CI = 524 pM – 
869 pM) in MCF-7 cells. This reiterates the previous finding that the potency of TCDD is 
approximately 10-fold higher in rat cells than in human. The same maximal response was 
reached in the BpRc1 rAhR, BpRc1 hAhR and BpRc1 wild-type cell lines but not for the 
mouse (NIH/3T3) cells. CYP1A1 mRNA was not detected in NIH/3T3 cells although the 
ability of the primers to amplify mouse CYP1A1 mRNA was confirmed in BpRc1 cells. 
Primers will detect either variant of the mouse CYP1A1 mRNA. This is confirmed in Figure 
3.37B which shows that NIH/3T3 does not express CYP1A1 mRNA compared with BpRc1 
which did express CYP1A1 mRNA. 
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3.2.9 Comparison of wild-type vs. Infected BpRc1 cells 
Previous research has shown that 5F 203 is more potent at inducing CYP1A1 mRNA in 
human cells than in rat cells (Bazzi, 2008) making it a useful compound for comparison 
between the two species. Based on this rat and human cells were treated with various 
concentrations of 5F 203 and compared with cells treated with TCDD. 5F 203 concentration-
response curves were conducted in the presence of a 10 nM TCDD only control to allow 
normalisation of the relative mRNA levels against the TCDD only curve. All of the curves 
also contained a vehicle control to show the background levels of CYP1A1 mRNA. Figure 
3.38 shows wild-type BpRc1 cells treated with TCDD or 5F 203 for 4 hours.  
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Figure 3.38: Comparison of 5F 203 and TCDD as AhR agonists in mouse BpRc1 wild-type cells – Mouse BpRc1 wild-
type cells were treated with various concentrations of 5F 203. Concentration-response curves were created by plotting the 
% of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-PCR was used to 
measure the level of induction of mouse CYP1A1 and compared against control gene, mouse ȕ-actin. QbasePlus was used 
to normalise the data which was plotted using 10 nM TCDD only control as 100% of the maximal response. Results were 
compared with a vehicle control (VC) and a 10 nM TCDD only control (TC). Each point is the mean of three biological 
replicates ± S.D. 
Figure 3.38 shows that the EC50 for wild-type BpRc1 cells treated with TCDD was 1.65 nM 
(95% CI = 1.12 nM – 2.44 nM) however 5F 203 did not give a recordable EC50 value. Figure 
3.39 and Figure 3.40 shows rat (H4IIE and BpRc1 rAhR) and human (MCF-7 and hAhR) 
cells, respectively, treated with 5F 203 or TCDD for 4 hours. 
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Figure 3.39: Comparison of 5F 203 with TCDD as AhR agonists in rat H4IIE cells and BpRc1 rAhR cells – (A) Rat 
H4IIE or (B) BpRc1 rAhR cells were treated with various concentrations of 5F 203. Concentration-response curves were 
created by plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. qRT-
PCR was used to measure the level of induction of mouse CYP1A1 and compared against control gene, PRXVHȕ-actin. 
QbasePlus was used to normalise the data which was plotted using 10 nM TCDD only control as 100% of the maximal 
response. Results were compared with a vehicle control (VC) and a 10 nM TCDD only control (TC). Each point is the mean 
of three biological replicates ± S.D. 
Figure 3.39A shows concentration-response curves of CYP1A1 mRNA induction by 5F 203 
and TCDD in rat H4IIE cells. The EC50 of 5F 203 was 675 nM (95% CI = 524 nM – 869 
nM) and TCDD was 74 pM (95% CI = 49 pM – 111 pM). From this analysis it is possible to 
conclude that 5F 203 is a weak AhR agonist in rat cells. The same experiment was 
conducted in the BpRc1 rAhR cell line using the same concentrations of TCDD and 5F 203 
(Figure 3.39B). The EC50 for TCDD was 1.46 nM (95% CI = 1.02 nM – 2.10 nM) and for 5F 
203 was 11.0 µM (95% CI = 8.98 µM – 13.5 µM). TCDD was shown to be approximately 
1000-fold more potent than 5F 203 at inducing CYP1A1 mRNA in the BpRc1 rAhR cells. 
However both TCDD and 5F 203 were 20-fold more potent in the wild-type H4IIE cell line 
than the BpRc1 rAhR cell line. Further to this, the results from BpRc1 rAhR were compared 
against those obtained from BpRc1 wild-type when treated with TCDD. Comparison shows 
that the two EC50s (BpRc1 wild-type vs. BpRc1 rAhR) are not significantly different (p = 
0.6133). The same experiment was then carried out in human MCF-7 and BpRc1 hAhR 
cells. 
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Figure 3.40: Comparison of 5F 203 with TCDD as AhR agonists in human MCF-7 cells and BpRc1 hAhR cells – (A) 
Human MCF7 or (B) BpRc1 hAhR cells were treated with various concentrations of 5F 203. Concentration-response curves 
were created by plotting the % of maximal CYP1A1 mRNA induction by 10 nM TCDD against concentration of agonist. 
qRT-PCR was used to measure the level of induction of mouse CYP1A1 and compared against control gene, mouse ȕ-actin. 
QbasePlus was used to normalise the data which was plotted using 10 nM TCDD only control as 100% of the maximal 
response. Results were compared with a vehicle control (VC) and a 10 nM TCDD only control (TC). Each point is the mean 
of three biological replicates ± S.D. 
Figure 3.40A shows that the EC50 for 5F 203 induction of CYP1A1 was 1.18 nM (95% CI = 
818 pM – 1.72 nM) and for TCDD the EC50 was 689 pM (95% CI = 550 pM – 861 pM). 
This data shows that 5F 203 is a potent agonist of human AhR and is only approximately 5-
fold less potent than TCDD at inducing CYP1A1 mRNA in human cells. The two 
compounds were tested in BpRc1 hAhR cells (Figure 3.40B). TCDD gave an EC50 of 1.97 
nM (95% CI = 1.21 nM – 3.20 nM) however 5F 203 did not produce a measurable response. 
The response of TCDD in BpRc1 hAhR was shown not to be statistically significantly 
different to BpRc1 wild-type (p=0.54). Furthermore TCDD was found to be 3-fold more 
potent at inducing CYP1A1 mRNA in human MCF-7 cell line than in the BpRc1 hAhR cell 
line (p=0.0004). The induction of CYP1A1 mRNA of TCDD in BpRc1 hAhR was compared 
against the response in BpRc1 rAhR cells and the two EC50s were also found not to be 
statistically significantly (p=0.27). 
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4. Discussion 
4.1 Alternative methods 
4.1.1 mRNA measurement  
Recent research by Hu et al. (2007) showed that CYP1A1 induction is a non-specific 
biomarker of AhR activation and supports the hypothesis that CYP1A1 may not necessarily 
be related to dioxin-like toxicity. However their work was conducted in vivo which is a much 
more complex model to investigate compared with in vitro, using potentially complex 
atypical compounds which may not bind in the same binding site as the more conventional 
dioxin-like AhR agonists. There is also a significant volume of research that shows CYP1A1 
is a specific biomarker for AhR activation by dioxin-like compounds (Behnisch et al., 2001; 
Nebert et al., 2000, 2004; Schmidt et al., 1996; Vanden Heuvel et al., 1994). Another method 
of mRNA quantitation is northern blotting which has high specificity but low sensitivity. The 
chemicals used are toxic and there is a risk of RNAse contamination. Microarray analysis 
measures the expression of large numbers of genes but has low resolving power. The method 
is also too expensive and this project is only interested in the expression of CYP1A1 (as a 
measure of AhR activation). In both northern blot and microarray assays, large sample sizes 
are required which is why qRT-PCR was chosen. Finally, the use of luciferase based assays 
containing AhR (DRE) binding sites, has become a common method of measurement of AhR 
activation as it is both quick to use and cheap to operate allowing large numbers of samples 
to be analysed on a budget (Burke and Mayer, 1974; Sanderson et al., 1996). Covered briefly 
in section 1.3.5.2, the luciferase cells were created by transfecting the firefly (Photinus 
pyralis) luciferase gene into the cell genome along with DRE binding sites and promoter 
regions upstream. The activated AhR binds to these DRE sites allowing transcription, and 
ultimately translation, of the exogenous luciferase protein which can then be measured using 
a luminometer. However measurement of CYP1A1 mRNA by qRT-PCR was utilised for 
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these studies over luciferase based assays because it not only allows detection and a more 
exacting quantitation of AhR-dependent expression of an endogenous gene (CYP1A1), but it 
would confirm that the responses examined were not due to selective effects on expression 
from the integrated luciferase reporter plasmid that might not be seen on other AhR-
responsive genes. qRT-PCR has a large advantage over other methods of CYP1A1 mRNA 
measurement in that it allows the analysis of several genes in a single experiment which can 
be used as reference genes. 
4.1.2 Protein measurement 
Quantitative analysis of the activation of AhR, through measurements of CYP1A1 mRNA, is 
critically dependent on the methodology for mRNA measurement. CYP1A1 (EROD and 
AHH) are induced by TCDD-like compounds (Kennedy, 1993). EROD activity has 
historically been used as a measure of AhR activation (Clemons et al., 1997, 1998; 
Hilscherova et al., 2001; Peters et al., 2004; Sanderson et al., 1996; Schmitz et al., 1995; 
Silkworth et al., 2005). EROD activity measures the rate of CYP1A1-mediated deethylation 
of 7-ethoxyresorufin (7-ER) leading to the production of highly-fluorescent resorufin, 
measured using a plate reader. The method replaced AHH activity in the mid 1980’s due to 
the increased safety and economy of EROD, compared with AHH measurement. The system 
also has a greater efficiency and is much more cost effective (Whyte et al., 2004). The 
advantage of EROD, which measures the rate of deethylation of 7-ethoxyresorufin, is that it 
measures the whole mechanism of AhR activation and CYP1A1 translation unlike PCR. PCR 
technology has allowed the measurement of CYP1A1 mRNA which provides a more 
sensitive measurement of AhR activation compared with EROD (Vanden Heuvel et al., 
1994). Research has shown that certain compounds (e.g. PCBs) inhibit the EROD enzyme-
substrate reaction at high concentrations making mixture experiments impossible to measure 
accurately, and illustrating the generic pitfall that enzyme activity measurement can be a 
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flawed measure of AhR activation (Garrison et al., 1996; Kennedy et al., 1993; Petrulis et al., 
1999; Sawyer et al., 1984). CYP1A1 mRNA induction is one of the most potent effects of 
AhR activation so would be expected to give both the most accurate and most sensitive 
results. Measurement of resorufin requires that the cells are treated for longer periods of time 
to allow translation of the enzymes. Longer periods of treatment can lead to the metabolism 
of some compounds, including 3-MC (Riddick et al., 1994) and TCDF (Clemons et al., 
1997). In this thesis, a method of measuring the induction of CYP1A1 was calibrated using 
qRT-PCR. Several variables that affect accurate measurement of CYP1A1 mRNA were 
identified and optimised, yielding a methodology with considerable statistical power for the 
determination of the potency of an agonist for inducing CYP1A1 mRNA. Statistical power is 
a prerequisite for detecting small differences in potency. Such quantitative measurement of 
induction potency enables the application of a variety of pharmacological tools to investigate 
the nature of agonism. 
4.2 qRT-PCR method optimisation  
4.2.1 Calibration of PCR method 
This study required a robust method of measuring the agonistic and antagonistic properties of 
a variety of AhR-related compounds. The measurement of CYP1A1 mRNA induction was 
decided to be the most accurate way to measure ligand induced AhR activation and was 
therefore chosen as the marker for AhR activation. Measurement of CYP1A1 mRNA was 
conducted using qRT-PCR which required optimisation before RNA quantitation. The PCR 
efficiency was measured using a dilution curve of known cDNA which found the efficiency 
RI&<3$ȕ-actin and AhR to be approximately 100% for all of the species tested (Figure 
3.3). The use of conditioned medium significantly reduced the effect of AhR ligands 
contained within the cell culture medium increasing the background to noise ratio (Figure 
3.1). This demonstrates that the concentrations of the probes and primers are satisfactory and 
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that the assay is robust. An overlay of several separate TCDD concentration-response curves 
in rat and human cells, show that the results are reproducible and therefore comparison 
between curves is possible (Figure 3.5). qRT-PCR has been shown to be a reliable tool for 
measuring the differences in CYP1A1 mRNA between samples providing a high 
discriminatory power for statistically significant differences between concentration-response 
curves. TCDD concentration-response curves from rat H4IIE and human MCF-7 cells were 
compared to demonstrate the reproducibility of the qRT-PCR method of CYP1A1 mRNA 
measurement (Figure 3.5). 
4.2.2 CH223191 is a potent antagonist 
The ability of the qRT-PCR method to detect antagonism was demonstrated using a known 
antagonist, CH223191. The initial experiment confirmed that CH223191 was a pure 
antagonist and showed no significant increase in CYP1A1 induction compared with TCDD 
which was confirmed by previous research (Kim et al., 2006). Further experimentation 
effectively demonstrated the antagonistic properties of CH223191 with the chosen assay. The 
IC50 for antagonism of 1 nM TCDD induced CYP1A1 mRNA (411 nM) compared 
favourably to that obtained by Kim et al. (2006) despite the different cell line and protocols 
used. Based on the IC50, four concentrations of the antagonist were selected to perform Schild 
analysis on the TCDD concentration-response curve (Figure 3.7). Cells were treated with 
TCDD in the presence of each of the four concentrations of CH223191 to extrapolate the Kd 
of the antagonist which was calculated to be 18.2 nM. Choi et al. (2012) investigated a range 
of compounds based on the structure of CH223191. They found that CH223191 was a potent 
antagonist and gave an IC50 of 10 nM -100 nM. The other compounds tested were shown to 
be a range of high to low potency antagonists showing that substitutions on the pyrazole 
group were important for antagonistic potency. Figure 3.7 successfully demonstrated the shift 
of the concentration-response curve to the right as the concentration of antagonist was 
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increased. It was also noted during experimentation that the antagonist reduced the induction 
potency of various AhR agonists present in the unconditioned cell culture medium used 
hence the use of conditioned medium with significantly reduced AhR agonist levels. 
Furthermore, the experiment has characterised the potency of the antagonist using five 
significantly different EC50s derived from the TCDD concentration-response curves shown in 
Figure 3.7A. More importantly this experiment has successfully shown that this method of 
antagonist detection can actually detect antagonistic properties of a compound and 
furthermore these properties can be quantitated. 
4.3 Reliability of the results obtained 
4.3.1 TCDD 
TCDD is a well characterised standard when calculating the potency of dioxin-like HAHs 
and REPs of AhR agonists. The EC50s calculated in this work were compared with the 
literature (derived from various techniques) to determine the reliability of the data obtained in 
this project (Table 4.1) 
Method TCDD EC50 Study 
   
qRT-PCRa 33 pM (± 1 pM) Current study 
   ERODc 9.0 pM (± 2.1 pM) Clemons et al., 1998 
CALUXb 10 pM Murk et al., 1996 
ERODd 10 pM Peters et al., 2004 
ERODb 11.8 pM (± 3.9 pM) Clemons et al., 1997 
ERODc 14 pM (± 4 pM) Chen et al., 2001 
ERODd 19.6 pM (± 5.6 pM) Sanderson et al., 1996 
ERODd 34.5 pM (± 1.96 pM) Hilscherova et al., 2001 
qRT-PCRa 40 pM (± 13 pM) Bazzi, 2008 
ERODc 41 pM (23 pM – 74 pM) Silkworth et al., 2005 
ERODc 50 pM (± 13 pM) Schmitz et al., 1995 
ERODc 50 pM (37 pM – 65 pM) Zeiger et al., 2001 
   
Table 4.1: Comparison of TCDD EC50 values taken from the literature - All data was derived from H4IIE cells. Values 
in parentheses are 95% confidence intervals or ± Standard Deviation/Standard Error. Cells were treated for: a4 hours, b24 
hours, c48 hours, d72 hours. qRT-PCR: Quantitative Real-time Polymerise Chain Reaction, EROD: Ethoxyresorufin-O-
deethylation. CALUX: Chemical Activated LUciferase gene eXpression. 
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The EC50 calculated in this work corresponds well with the values found in the literature. The 
majority of the values calculated previously use EROD analysis to calculate the EC50; 
however, it was deemed suitable to compare directly with the values calculated in this work 
(Chaty et al., 2008). 
4.3.2 TCDF, PeCDF and PCB 126 
REPs are based on a mixture of data derived from biochemical, receptor binding, toxicity and 
carcinogenicity studies (Haws et al., 2006; Van den Berg et al., 2006).  
Compound Method REP Study 
    TCDF qRT-PCRa 0.115 Current study 
    
 ERODb 0.03 Bols et al., 1997 
 ERODc 0.092 Bandiera et al., 1984 
 AHHd 0.12 Wiebel et al., 1996 
 ERODc 0.15 Li et al., 1999 
    
PeCDF qRT-PCRa 0.171 Current study 
    
 AHHc 0.28 Bandiera et al., 1984 
 ERODc 0.28 Sanderson et al., 1996 
 ERODb 0.4 Bols et al., 1997 
 ERODd 0.41 Behnisch et al., 2002 
 Luciferased 0.69 Sanderson et al., 1996 
 DR-CALUXd 0.84 Behnisch et al., 2002 
    
PCB 126 qRT-PCRa 0.103 Current study 
    
 Luciferased 0.017 Sanderson et al., 1996 
 ERODc 0.02 Tillitt et al., 1991 
 ERODc 0.047 Sanderson et al., 1996 
 ERODc 0.05 Koistinen et al., 1996 
 ERODb 0.1 Bols et al., 1997 
 ERODd 0.1 Hanberg et al., 1990 
 ERODb 0.18 Schmitz et al., 1995 
 ERODc 0.323 Sawyer and Safe, 1982 
    
Table 4.2: Comparison of REP values taken from the literature – Potency data shown as REPs (their potency in 
comparison to TCDD; see section 1.4.2.1). All REPs were calculated from assays on H4IIE cells. Cells were treated for: a4 
hours, b48 hours, c72 hours, d24 hours. qRT-PCR: Quantitative Real-time Polymerise Chain Reaction, EROD: 
Ethoxyresorufin-O-deethylation. Luciferase: Luciferase cells. AHH: Aryl hydrocarbon hydroxylase. 
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TCDF, PeCDF and PCB 126 were tested in rat (H4IIE or primary cultures) in previous work 
by this author but the concentrations were re-adjusted after they were confirmed using 
GC/MS. The new EC50s calculated from this adjustment were compared with the literature 
(Table 4.2). The WHO gave TCDF a TEF of 0.1 based on previous REPs calculated in vivo 
(DeVito and Birnbaum, 1995; Takagi et al., 2003; Weber et al., 1984) and in vitro models in 
rat H4IIE cells (Table 4.2; Haws et al., 2006). In this study, the REP for TCDF was 
calculated to be 0.115 which compares well with the TEF of 0.1. The REP also compares 
well with values from the literature (REPs: 0.03 – 0.15). A TEF of 0.3 was estimated for 
PeCDF from in vivo (Fattore et al., 2000; Johnson et al., 2000; NTP TR-525, 2006; Pluess et 
al., 1998; Wærn et al., 1995; Walker et al., 2005) and in vitro data (Table 4.2; Haws et al., 
2006 supplementary data). PeCDF gave a REP of 0.171 in this work which is slightly lower 
than the TEF of 0.3. It is also slightly lower than the values calculated in the literature (REPs: 
0.28 - 0.84). The reason for this difference may be due to the preparation of the compound 
prior to treatment of the cells or the contamination of the stock. The original 1998 TEF for 
this compound was 0.5 (Van den Berg et al., 1998) which appears to match the literature data 
more closely. Finally a TEF of 0.1 was calculated for PCB 126 from in vivo (Hemming et al., 
1995; NTP TR-520, 2006; Van Birgelen et al., 1994) and in vitro data (Table 4.2; Haws et 
al., 2006 supplementary data). A REP of 0.103 was calculated for PCB 126 in this work 
which corresponds well with the TEF of 0.1. The literature also supports the use of a TEF of 
0.1 (REPs: 0.017 - 0.323). This comparison shows that the REPs calculated in this project 
match with the predicted values from the WHO consortium (Van den Berg et al., 2006) and 
REPs calculated in previous literature. The antagonistic properties of the three compounds 
have been investigated previously and found that none of the three compounds are partial 
agonists in rat H4IIE cells (Wall, 2008). 
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4.3.3 Mixed halogenated dioxin-like HAHs 
One of the main aims of this project was to characterise the agonist properties of several 
mixed halogenated dioxin-like AhR ligands based on their ability to induce CYP1A1 mRNA. 
REPs were calculated, based on the EC50 of TCDD, for all of the compounds tested (PXDDs: 
Table 3.1; PXDFs: Table 3.2; PXBs: Table 3.3). Several of the compounds tested were well 
known AhR agonists which already have allocated TEFs calculated through meta-analysis of 
REP data which corresponds well with the REPs in this project (section 4.3.2).  
Compound WHO 2005 TEF 
Estimated 
REP from this 
study* 
Difference 
 
   
2,3,7,8-TetraCDD 1 1 = 
2-B-3,7,8-TriCDD 
 
3 + 3-fold 
2,3-DiB-7,8-DiCDD 
 
0.3 - 3-fold 
1,2,3,7,8-PentaCDD 1   
1-B-2,3,7,8-TetraCDD 
 
0.1 - 10-fold 
2-B-1,3,7,8-TetraCDD 
 
0.3 - 3-fold 
 
 
  
2,3,7,8-TetraCDF 0.1 0.1 = 
3-B-2,7,8-TriCDF 
 
0.1 = 
2,3-DiB-7,8-DiCDF 
 
0.3 + 3-fold 
2,3,4,7,8-PentaCDF 0.3 0.3 = 
4-B-2,3,7,8-TetraCDF 
 
0.3 = 
1,2,3,7,8-PentaCDF 0.03   
1-B-2,3,7,8-TetraCDF 
 
0.1 + 3-fold 
1,3-DiB-2,7,8-TriCDF 
 
0.3 + 10-fold 
 
 
  
3,3’,4,4’,5-PentaCB 0.1 0.1 = 
4’-B-3,3’,4,5-TetraCB 
 
0.3 + 3-fold 
3’,4’-DiB-3,4,5-TriCB 
 
0.1 = 
3’,4’,5-TriB-3,4-DiCB 
 
0.3 + 3-fold 
3,3’,4,4’,5-PentaBB 
 
0.03 - 3-fold 
2,3,3’,4,4’-PentaCB 0.00003 0.000003 - 10-fold 
4’-B-2,3,3’,4-TetraCB 
 
0.00001 - 3-fold 
2,3’,4,4’,5-PentaCB 0.00003 0.000003 - 10-fold 
4’-B-2,3’,4,5-TetraCB 
 
0.00003 = 
2,3,3’,4,4’,5-HexCB 0.00003 0.0003 + 10-fold 
4’-B-2,3,3’,4,5-PentaCB 
 
0.0003 + 10-fold 
 
   
 
Table 4.3: Estimated REPs compared with TEFs – TEFs were taken from Van den Berg et al., 2006. *REP values from 
this study were rounded to the nearest half log to allow more simplistic comparison with the TEFs. 
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These compounds were used as controls to show reproducibility of the data and allow 
comparison with REPs found in the literature (Table 1.2, Table 1.3; Behnisch et al., 2003; 
Olsman et al., 2007; Samara et al., 2009). There was general agreement between this work 
and literature for all of the compounds with a few exceptions. 2-B-7,8-DiCDF was found to 
be 10-fold more potent in this project than in the literature (0.000037; Olsman et al., 2007), 
2,7,8-TriBDF was found to be 50-fold more potent in this study compared with the literature 
(0.00049; Olsman et al., 2007) and finally 2-B-6,7,8-TriCDF was ~250-fold more potent in 
this study then compared with the literature (0.00066; Olsman et al., 2007). Previous 
literature has used the TEFs of only chlorinated compounds (Table 1.5) for the equivalent 
brominated and mixed halogenated congeners in order to calculate their TEQs (Ohta et al., 
2004; Food Standards Agency, 2006a, 2006b, 2006c; Colles et al., 2008; Fernandes et al., 
2008). Table 4.3 compares the REPs calculated in this paper with the TEF of the equivalent 
chlorinated congener. A few compounds of notable potency were identified including 2-B-
3,7,8-TriCDD which was found to be 3-fold more potent than TCDD in both rat and human 
cell lines and which has been confirmed in the literature (Olsman et al., 2007). Only a few 
other compounds have been found to be more potent than TCDD so this is a remarkable 
finding. Also identified as very potent AhR agonists were 2-B-1,3,7,8-TetraCDD and 2,3-
DiB-7,8-DiCDF, which gave REPs of 0.3 corresponding well with values found in the 
literature (Behnisch et al., 2003; Olsman et al., 2007). 2,3-DiB-7,8-DiCDD was found to be 
slightly less potent in this paper compared with other authors (Behnisch et al., 2003; Olsman 
et al., 2007; Samara et al., 2009).  
4.3.4 PCBs 
The REPs calculated in this work for PCB 105 and 118 (~0.000003) were 10-fold less than 
the TEF values calculated by the WHO (0.00003, Van den Berg et al., 2006). On the other 
hand, the REP for PCB 156 obtained in this work (0.0003) was 10-fold more than the value 
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calculated by the WHO (0.00003, Van den Berg et al., 2006). The agonistic and antagonist 
study of PCB 105 and PCB 118 showed that both compounds were partial agonists of rat 
AhR and PCB 105 was shown to be a pure antagonist of human AhR whereas PCB 118 was 
shown to be a partial agonist. Clemons et al. (1998) treated rat H4IIE cells with TCDD in the 
presence of PCB 105 and PCB 118, and demonstrated a shift of the concentration response 
curves to the right in comparison to TCDD alone. Clemons et al., (1998) also showed that 
PCB 77 was partially antagonised by both PCB 105 and PCB 118 in H4IIE cells. Hestermann 
et al. (2000) indicated that PCB 118 may be a partial agonist as opposed to a complete 
antagonist. The authors also showed that PCB 105 and PCB 128 were competitive 
antagonists of the AhR. The REPs for PCB 105 in rat H4IIE cells (used to calculate the TEF) 
ranged from 0.0000075 (Tillitt et al., 1991) to 0.000668 (Sawyer and Safe, 1982). The purity 
of the compound was >99% in the Tillitt study but was undetermined in the majority of the 
other studies. As the compound is a very weak agonist, even <1% contamination of a more 
potent agonist could produce a response. In this study no known potent agonists were found 
in the PCB 105 stock (Table 2.1). The REPs used to calculate PCB 118 (in rat H4IIE cells) 
ranged from 0.000002 (Hanberg et al., 1990) to 0.00001 (Bols et al., 1997) in order to create 
a TEF of 0.00003 (Van den Berg et al., 2006). None of the purities of the PCB 118 stocks 
used in these studies could be confirmed so the effect of more potent agonists was impossible 
to calculate. There were no significant impurities found in the PCB 118 stock used in this 
project. PCB 156 was found to be a pure agonist in rat H4IIE cells and a weak partial agonist 
in human MCF-7. Clemons et al. (1998) also showed that PCB 156 had partial agonistic 
properties in RTL-W1 rainbow trout liver cells although Hesterman et al. (2000) found that 
PCB 156 had no effect on CYP1A induction in PLHC-1 fish cells. A REP range of 0.000026 
(Aarts et al., 1998) to 0.1 (Chen et al., 2004) in rat H4IIE cells was used to calculate the TEF 
of PCB 156 (Table 4.4; Haws et al., 2006). These REPs from the literature are almost all 
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higher than the TEF applied to this compound (0.00003; Van den Berg et al., 2006) but fit 
well with the REP calculated in this project (0.0002; Figure 3.21). The purity of the PCB 156 
stocks used to calculate these TEFs were not confirmed which could mean they are also 
contaminated with more potent dioxin-like HAHs (during synthesis). One interesting point is 
that the range of REPs calculated for PCB 156, as well as other mono-ortho-substituted PCBs 
(not shown), differ widely between authors compared with the other compounds where TEFs 
where calculated, showing the difficulty in measuring the potency of these weak agonists. 
 Method REP Study 
  
Evidence of low REP (~0.00003)  
 CALUXa 0.000026 Aarts et al., 1998 
 ERODb 0.000052 Bols et al., 1997 
 ERODc 0.000054 Tillitt et al., 1991 
 ERODa 0.00007 Schmitz et al., 1995 
 ERODc 0.0000895 Sawyer and Safe, 1982 
    
Evidence of high REP (~0.0003)  
 ERODb 0.0001 Hanberg et al., 1990 
 CALUXd 0.00014 Brown et al., 2001 
 ERODa 0.0003 Schmitz et al., 1995 
 ERODb 0.1 Chen et al., 2004 
    
Table 4.4: Comparison of the REPs calculated for PCB 156 - All REPs calculated in rat H4IIE cells. Cells were treated 
for: a48 hours, b24 hours, c72 hours, d20 hours. EROD: Ethoxyresorufin-O-deethylation. Luciferase: Luciferase cells. 
CALUX: Chemical Activated LUciferase gene eXpression. 
Assuming the TEF is the best representation of PCB 156, the most likely explanation for the 
high REP (0.0003) calculated in this study is that it was contaminated with low 
concentrations of PCB 126 (section 2.1.4) which could have increased the agonistic 
properties of PCB 156 through additivity. However based on the data from Table 4.4, it is 
possible to see that the majority of the literature supports a higher REP in the region of 
~0.0001.  
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4.3.5 AZFMHCs are AhR agonists 
4.3.5.1 AZ1 is a very potent AhR agonist 
The AZFMHCs were previously identified of AhR agonists during a routine drug screening 
investigation by AstraZeneca. Measurement of the ability of the AZFMHCs to induce 
CYP1A1 mRNA in rat H4IIE cells showed that all of the compounds were at least medium 
potency AhR agonists. One of the compounds, AZ1, was shown to be an exceptionally potent 
inducer, being 5-fold more potent at inducing CYP1A1 RNA compared to TCDD. AZ2, 3 
and 4 were shown to be less potent inducers, at least 45-fold less potent than TCDD. None of 
the AZ compounds demonstrated any antagonistic properties. The ability of AZ1 to induce 
two other AhR-related metabolism genes, CYP1A2 and CYP1B1, provides strong evidence 
that the compound does activate the AhR The ability of AZ1 to activate the AhR was not 
confined to rat cells although both AZ1 and TCDD were ~10-fold less potent at inducing 
CYP1A1 in human MCF-7 than in rat H4IIE cells. This finding is reminiscent of many other 
studies which show that the human AhR is less responsive to ligands than is the rat AhR 
(Budinsky et al., 2006; Xu et al., 2000). However, the results confirm that both substances 
are potent activators of the AhR in human, and that AZ1 is more potent than TCDD. This is 
an interesting finding as TCDD is one of the most potent along with 1,2,3,7,8-
pentachlorodibenzo-p-dioxin and some of the mixed halogenated dibenzo-p-dioxins and 
dibenzofurans investigated in this study. For further analysis of the compound, it would be 
useful to measure the CYP1A1 protein levels using EROD in order to visualise the whole 
mechanism of AhR activation by this compound. 
4.3.5.2 AZ2, 3 and 4 are medium potency agonists 
AZ1 was shown to be a highly potent AhR agonist however the other family members were 
shown only to be medium potency agonists approximately 100-1000-fold less potent than 
AZ1. Structurally the most important characteristic for high potency, based on the four 
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compounds tested, is that there is no group on the R2 position (section 3.1.3.1). Also, the fact 
that AZ3 was the least potent compound suggests that the CF3 group at R1 is beneficial for 
high potency. All of the compounds have a very similar structure to alpha-QDSKWKRIODYRQHĮ-
1)DQGȕ-1)ZKLFKDUHDOVRSRWHQWOLJDQGVRIWKH$K5Į-NF is a potent antagonist but has a 
strong affinity for the AhR (Gasiewicz and Rucci, 1991; Santostefano et al., DQGȕ-NF 
has been shown to be a potent agonist of the AhR (Chirulli et al., 2007). The three 
AZFMHCs were significantly less potent than TCDD (AZ2 = 45-fold less potent, AZ3 = 
350-fold less potent and AZ4 = 135-fold less potent than TCDD) and thus only AZ1 was 
chosen for further investigation. 
4.3.5.3 Ligand binding shows AZ1 and TCDD are high affinity ligands 
In order to confirm the hypothesis that AZ1 is acting through AhR activation, the ability for 
AZ1 to compete with TCDD for binding to the AhR was investigated. The Kd and Bmax for 
[3H]-TCDD was 1.24 nM and 26.9 fmol/mg, respectively. This data fits well with 
measurements made by previous authors (using the same [3H]-TCDD) who found the Kd and 
Bmax to be 0.27 nM – 1.45 nM and 40 fmol/mg, respectively (Bazzi, 2008; Jiang, 2004). The 
affinity of AZ1 and TCDD were measured using a ligand binding assay which showed that 
AZ1 (IC50 = 269 pM) had a 14-fold higher affinity for the AhR than TCDD (IC50 = 2.11 nM). 
This compares well with previous findings from other authors using the same [3H]-TCDD 
and unlabelled TCDD who found the IC50 to be 1.65 nM (TCDD; Bazzi, 2008). This shows 
that the two compounds share the same binding site on the AhR, and proves that AZ1 is 
agonising the AhR.  
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4.4 Structure-activity relationships 
4.4.1 Affinity vs. Potency 
4.4.1.1 Comparison of potency and affinity of HAHs 
In this project, only potency data for the HAHs was estimated however investigation of the 
full mechanism also requires measurement of affinity. The potency data estimated in this 
study was compared against binding affinity data derived from Bandiera et al. (1982, 1984).  
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Figure 4.1: CYP1A1 mRNA induction vs. AhR binding in rat – The potency data (mRNA induction) was conducted in 
this study using rat H4IIE cells and the affinity data was taken from Bandiera et al. (1982, 1984). A test group containing the 
five pure HAH AhR agonists (TCDD, TCDF, PeCDF, PCB 126 and PCB 156) was used to plot the linear trend line. Slope = 
1.169, r2 = 0.901. 
Figure 4.1 shows that there is a relationship between binding affinity and potency, 
demonstrating that as affinity increases, so does the potency. The five potent pure agonists (in 
rat): TCDD, TCDF, PeCDF, PCB 126 and PCB 156 all have potency related to affinity 
whereas PCB 105 and PCB 118 do not fit the trend, as they have a low potency despite a 
reasonably high affinity. This, as discussed early, is most likely due to their 
antagonist properties (binding to receptor without activating it), leading to a high affinity 
compared with the potency. The difficulty with this analysis is the lack of data points for 
Richard Wall 
 
166 
 
these compounds. PCB 156 fits well with the data despite the fact that it is contaminated with 
a potentially significant concentration of PCB 126. The purity of the compounds used in the 
affinity study was not confirmed so they may also be equally contaminated. Only a few 
researchers have conducted binding affinity experiments on HAHs (Bandiera et al., 1982, 
1984; Brown et al., 1994; Poland and Glover, 1977), so one possible piece of further work 
would be to do binding studies on all of the mixed halogenated compounds in this study to 
allow a more detailed structure-activity relationship study. Even less work has been 
conducted on the binding affinity of compounds interacting with the human AhR due to the 
large quantities of tissue required to conduct the assay. Previous work has shown that human 
AhR has up to 10-fold lower binding affinity for TCDD than mouse, perhaps partly 
explaining the difference in the potency of TCDD between the two species (Ema et al., 1994; 
Harper et al., 1988; Ramadoss and Perdew, 2004). Assuming other rodents have a similar 
binding affinity for dioxin-like HAHs, this could explain differences (seen here between rat 
and human) in the potency of these ligands but would require more data on human AhR 
binding affinity to confirm this statement. Direct comparison of ligand binding to the rat or 
human AhR may explain the differences seen of ligand potency between rat and human. 
4.4.2 Chr compounds 
4.4.2.1 Luciferase induction by Chr compounds 
The two recombinant AhR-responsive luciferase cell culture models, mouse H1L6.1c2 and 
human HG2L6.1c3 cells, were used to obtain screening data (Conducted by Prof. Michael 
Denison; Wall et al., 2012b) on the AhR agonist activity of all of the Chr compounds at a 
single concentration (10 µM). The results from mouse and human are displayed as direct 
comparisons with the data normalised to the maximal induction response obtained with 
TCDD (1 nM for H1L6.1c2 cells and 10 nM for HG2L6.1c3 cells; Figure 4.2A). The results 
show that none of the compounds were particularly potent agonists especially in the human 
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cell line. However, Chr-4, 6, 7, 8, 10, 11, 13, 14, 15, 16, 17, 18 and 19 were agonists for the 
mouse AhR signalling pathway and Chr-3, 15, 16 and 19 were agonists for the human AhR; 
the remaining compounds were inactive as AhR agonists in either cell system. 
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Figure 4.2: AhR agonist and antagonistic activity of 2-amino-isoflavone derivatives in recombinant mouse and 
human hepatoma cell lines – (A) Mouse H1L6.1c2 and human HG2L6.1c3 cells were incubated with 10 µM Chr 
compound, TCDD (1 nM for mouse and 10 nM for human) or 0.1% DMSO control for 24 hours. (B) Mouse H1L6.1c2 and 
human HG2L6.1c3 cells were incubated with 10 µM Chr compound in the presence of TCDD (1 nM for mouse and 10 nM 
for human cells), TCDD alone or 0.1% DMSO control for 24 hours. Luciferase activity was measured and normalised 
against TCDD (maximal response). White bars = mouse, black bars = human. Error bars are S.D., n = 3. *Luciferase activity 
was significantly higher (p-value WKDQWKDWRI'062FRQWURO The figure was taken from Wall et al. (2012b). 
To determine the ability of the isoflavones to antagonise mouse and human AhR action, cells 
were co-incubated with TCDD (1 nM for mouse H1L6.1c2 and 10 nM for human 
HG2L6.1c3) in the absence or presence of 10 µM of the indicated compound and luciferase 
activity determined after 24 hours of incubation. The data (Figure 4.2B) shows that while 
none of the Chr compounds exerted an antagonistic effect on TCDD dependent activation of 
AhR signalling in mouse H1L6.1c2 cells, a large number of the compounds (Chr-2, 3, 4, 5, 6, 
8, 9, 13, 17, 18 and 19) antagonised TCDD-dependent induction of luciferase in the human 
HG2L6.1c3 cells. These results demonstrate clear species differences in the relative potency 
and agonist and/or antagonist activity of these compounds. This reduction of AhR-dependent 
transcription of luciferase, when the isoflavones were incubated in the presence of TCDD, 
A B 
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shows that the compounds must have a relatively good affinity for the AhR and that they 
have very low agonistic efficacy. Comparison of the results in both Figure 4.2A and B 
suggests that Chr-1 does not interact with the AhR as it neither activates nor inhibits it.  
From the luciferase assays, two compounds were selected for further analysis by qRT-PCR to 
provide a quantitative measure of agonism and antagonism. Chr-13 was shown to be a strong 
agonist (compared to the other Chr compounds) in mouse H1L6.1c2 cells but a strong 
antagonist in human HG2L6.1c3 cells, indicating a significant species difference. The second 
compound selected was Chr-19 which was shown to be a weak agonist in both mouse and 
human cell lines, but more interestingly was also shown to be an antagonist in the human cell 
line, thus demonstrating that this compound is a partial agonist in human. 
4.4.2.2 Structure activity relationship of Chr compounds 
The ability of the compounds to competitively affect the activity of TCDD allowed 
measurement of the shift in potency of TCDD and hence measurement of their antagonistic 
effect. The luciferase screening data for Chr-13 matched well with the results obtained 
through qRT-PCR, however for Chr-19, although qualitatively the same result was obtained 
there were some discrepancies. The results obtained in the screening data (Figure 4.2) 
showed that a 10 µM concentration of Chr-19 reduced the response to 10 nM TCDD in 
human cells by 80% of the maximal response (a 5-fold reduction) whereas when qRT-PCR 
was used, 10 µM Chr-19 only reduced the response to 10 nM TCDD by 10% (Figure 3.24D). 
One possibility that could explain these divergent results is that there exist inter-tissue 
differences in the cell lines that modulate the overall AhR-mediated response for this 
particular compound, although this remains to be determined. Zhang et al. (2003) previously 
examined AhR activation by a variety of agonists in both HepG2 and MCF-7 cells and while 
most compounds showed a similar pattern of induction, they also identified several 
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compounds which exhibited differences in potency between the two cell lines and this must 
relate to cell specific differences as the AhR was identical. 
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Compound Chr- R R1 R2 
    1 H H O 
2 6-Cl H O 
3 7-Cl H O 
4 H 4’-Cl O 
5 6-Cl 4’-Cl O 
6 7-Cl 4’-Cl O 
7 H 4’-OMe O 
8 6-Cl 4’-OMe O 
9 7-Cl 4’-OMe O 
10 H 3’,4’-(OMe)2 O 
11 6-Cl 3’,4’-(OMe)2 O 
13 7-OMe 4’-Cl O 
14 7-OMe 3’,4’-(OMe)2 O 
15 7-Cl H NH 
16 6-Cl H NH 
17 7-OMe H O 
18 7-OMe 4’-OMe O 
    
O O
O
Cl
CH3
 
 
Chr-19 
O
O
Cl
Cl Cl
Cl
 
 
TCDD 
Table 4.5: Structures of the 2-amino-isoflavones (2-amino-3-phenylchromen-4-one; Chr) compounds - The structures 
were drawn using ChemSketch. Table was taken from Wall et al. (2012b). 
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A basic analysis of the structure-activity relationships, based mainly on the screening data, 
was conducted. Firstly, Chr-2 and 3 were shown to be human AhR antagonists however, if 
the ether oxygen (position 1; Table 4.5) was substituted with a secondary amine, such as in 
Chr-15 and 16, the compounds become agonists in human cells instead. Furthermore, the 
position of the chlorine atom on these molecules (position 6 or 7) had no effect on the 
agonistic or antagonist activity of the compounds. This is shown by compounds Chr-5, 8 and 
16 which have a chlorine atom on position 7, and Chr-6, 9 and 15 which have a chlorine atom 
on position 6, yet there is no difference in the ability of these compounds to activate or inhibit 
the AhR (results were the same for all six compounds). 
The data also suggests that a chlorine atom is required somewhere on the molecule (Chr-1 
has no effects), although based on the number of compounds tested, the precise location 
(position 3, 4 or 4’) does not seem to affect the compound’s properties. The slightly reduced 
ability of Chr-4 as an antagonist may suggest that there needs to be a chlorine atom on 
position 6 or 7 in order for it to antagonise completely the AhR at a concentration of 10 µM. 
The chlorine atoms would provide a high electron density which has been shown to be 
important for high affinity in similar compounds (Henry et al., 1999). 
Chr-13 and 19 are relatively unique in this group of compounds making it difficult to assess 
what contributes to their species-specific differences in effect. A methoxy group on position 
7 is the most likely explanation for why Chr-13 and 17 are agonists in mouse but antagonists 
in human. Furthermore as discussed earlier the chlorine on position 4’ appears to have no 
effect on AhR binding or activation. The unusual partial agonistic properties of Chr-19 are 
likely related to the substitution of the amino group on position 2 with a carbonyl group and 
the removal of the carbonyl group from position 4. If there is a methoxy group on position 3’ 
it appears that the compound will simply not interact significantly with the AhR, as seen in 
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Chr-10, 11 and 14. Using alpha-naphthoflavone as the backbone structure, Gasiewicz et al. 
(1996) and Henry et al. (1999) investigated the effect of chemical substituents on AhR 
activity. They showed that a methoxy group in the 3’ position not only increased affinity for 
receptor binding (Gasiewicz et al., 1996; Henry et al., 1999), but was very important for 
antagonist activity (Henry et al., 1999; Lu et al., 1996). The reason for the lack of effect of 
Chr-1 is unclear as Chr-4 and 7 have antagonistic properties and also have no atom or group 
on the first benzene ring. Based on the potency of Chr-18 and 19, it would be interesting to 
test other classes of compounds with similar (AhR binding) structures for instance, 
chromones and coumarins (such as warfarin). 
In terms of AhR agonism, the most potent of the compounds (Chr-13 and 15) were still 
10,000-fold less potent than TCDD at activating the AhR and inducing CYP1A1 mRNA. 
Their agonistic and antagonistic ability suggests they have similar potency to the mono-
ortho-chlorinated polychlorinated biphenyls (PCBs) such as PCB 105 and PCB 118 (Table 
3.3). Isoflavones have been shown to have EC50 values in the 10 µM range (Amakura et al., 
2003), although more potent isoflavones have been identified. Biochanin A, for example, has 
a similar structure to Chr-7, but with hydroxyl groups on positions 5 and 7, and it was shown 
to be only 100-fold less potent than TCDD (Medjakovic and Jungbauer, 2008). Daidzein, an 
isoflavone which is similar in structure to Chr-18 but with hydroxyl groups on positions 7 
and 4’ instead of methoxy groups, was shown to be a weak agonist in mouse Hepa1 cells at 
similar concentrations as Chr-18 (Zhang et al., 2003). Furthermore Zhang et al. (2003) also 
showed that daidzein had no AhR agonistic activity in human MCF-7 or HepG2 cells, similar 
to Chr-18. Several compounds with flavone and isoflavone structures were tested in human 
MCF-7 and mouse Hepa1 cells with most of the compounds having no or very limited AhR 
activity. Similarly, Zhang et al. (2003) reported species-specific differences by several 
flavonoid compounds relative to AhR agonist and antagonist activity.  
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Quercetin and kaempferol (both flavonols) are the most abundant flavonoids found in the diet 
and based on EROD analysis, Ciolino et al. (1999) reported that quercetin was an AhR 
agonist and that kaempferol was an antagonist in MCF-7 cells. Several other flavonoid 
derivatives have also been identified as AhR ligands including galangin, which was shown to 
act as an AhR antagonist (Ciolino and Yeh, 1999b) and chrysin, shown to be one of the 
strongest flavonoid agonists. While chrysin is a partial agonist in human cells it produces no 
antagonistic effects in rat H4IIE cells demonstrating that many compounds based on the 
flavonoid structure have species-specific differences (Van der Heiden et al., 2007). 
4.4.3 Brominated and mixed halogenated dioxin-like HAHs 
The addition of bromine had different effects on each of the three groups of compounds 
(PXDDs, PXDFs and PXBs). A bromine substitution on the dibenzo-p-dioxin backbone 
reduced the potency of the compounds, compared to the compound with Cl at the same 
position(s), with the exception of 2-B-3,7,8-TriCDD, which may be due to the increase in the 
size of the molecule. As previously discussed in section 1.2.2, the dibenzo-p-dioxin backbone 
appears to already be the perfect size for high potency compared with dibenzofurans and 
biphenyls, where an increase in size (substituents i.e. addition of Cl) is required to get 
~equivalent potency. Figure 4.3A and B compare the structures of TCDD and 2-B-3,7,8-
TriCDD. The bromine atom makes the compound slightly larger and was shown to improve 
its ability to activate the AhR presumably by having a higher affinity. The substitution of 
bromine on the dibenzofuran backbone actually increased the potency of the mixed 
halogenated compounds. One suggestion for this would be that the dibenzofuran backbone is 
slightly smaller than the dibenzo-p-dioxin backbone as it only has one oxygen atom. 
Increasing the size of the molecule slightly by substituting a chlorine atom for bromine 
appears to provide a better fit for the AhR ligand binding domain.  
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TEF = 1 
 
REP = 2.01 
 
TEF = 0.03 
  
REP = 0.14 
 
REP = 0.22 
Figure 4.3: The space fill structure of 2,3,7,8-substituted dibenzo-p-dioxins and 1,2,3,7,8-substituted dibenzofurans - 
A) TCDD, B) 2-B-3,7,8-TriCDD, C) 1,2,3,7,8-PeCDF D) 1-B-2,3,7,8-TetraCDF and E) 1,3-DiB-2,7,8-TriCDF. TEFs were 
taken from Van den Berg et al. (2006) and REPs were calculated in this study.  
Figure 4.3C, D and E shows the structures of 1,2,3,7,8-substituted dibenzofurans (see also 
section 1.3.2). Based on the TEF of 1-B-2,3,7,8-TetraCDF (0.03; Van den Berg et al., 2006), 
1,2,3,7,8-PeCDF was found to be 3-fold more potent and 1,3-B-2,7,8-TriCDF was found to 
be 10-fold more potent. Therefore the potency of the compounds employs the following 
order: 1,2,3,7,8-PeCDF<1-B-2,3,7,8-TetraCDF<1,3-DiB-2,7,8-TriCDF. The substitution of a 
bromine at position 1 (Table 3.2) increases the potency of the dibenzofuran by 3-fold then a 
bromine substitution at position 3 increases the potency by a further 3-fold. Further work 
A B 
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would investigate 3-B-1,2,7,8-TetraCDF to see if a single substitution at position 2 or 3 also 
increases the potency of the compound (by increasing the longitudinal size of the compound). 
This also appears to be the same for the mixed halogenated PXB 126 congeners, with the 
bromine making the molecule bigger and thus potentially a better fit for the AhR binding 
domain. Risk assessment calculation of PBB 126 uses the TEF for PCB 126 however PBB 
126 was found to be 3-fold less potent than PCB 126 suggesting a reduced TEF for the 
compound. The mono-ortho-substituted PXBs were generally more potent than their 
chlorinated congeners showing that the increased size of the compound allows it to bind more 
effectively to the AhR binding site. PXB 105 was 10-fold and PXB 118 was 100-fold more 
potent than their purely chlorinated congeners showing than an increase in the size of the 
compound increases the potency. There are many more mixed halogenated compounds which 
may also be of similar abundance and potency as their chlorinated counterparts. The main 
issue there would be what to include and not include in the TEQ calculation. The use of the 
chlorinated TEFs for the mixed halogenated compounds tested in this work would not be 
appropriate as in a lot of cases the TEF was 10-fold different from the REP calculated 
experimentally. Therefore a new range of TEFs are required for these compounds. Further to 
this it would be interesting to do affinity measurements for all of the mixed halogenated 
compounds to explore any patterns between the different congeners. 
4.4.4 Antagonistic effects of mono-ortho-substituted PCBs and PXBs 
4.4.4.1 Structure of partial agonists 
Several mono-ortho-substituted PCBs and PXBs were tested in rat and human cell lines and 
showed that all six of the compounds investigated were partial agonists in rat H4IIE cells 
with the exception of PCB 156 which was shown to be a pure agonist. There were significant 
discrepancies between the REPs calculated for PCB 105, PCB 118 and PCB 156 in this paper 
and those calculated by the WHO consortium. This work suggests that PCB 105 and PCB 
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118 were 10-fold less potent than previously estimated whereas PCB 156 was 10-fold more 
potent. In human MCF-7 cells, PCB 118 and PCB 156 were shown to be partial agonists 
whereas PCB 105 was shown to be a relatively potent antagonist when treated 
simultaneously with TCDD (although higher concentrations of PCB 105 may have elicited an 
agonist response in human if tested). A concentration of 3 µM PCB 105 in rat and 10 µM 
PCB 105 in human reduced the potency of TCDD by 30-fold. Further to this, a concentration 
of 3 µM PCB 118 in rat and 10 µM PCB 118 in human reduced the potency of TCDD by 10-
25-fold. This suggests that the potency of a mixture containing these compounds could be 
reduced due to competition for binding to the AhR. However binding data and the Kd for 
these compounds is required to fully characterise their antagonistic properties. Chu et al. 
(2001) assayed TCDD in the presence of a mixture of 13 different PCBs including PCB 118, 
156, 105 and 126, which has since been shown by other authors (Chen and Bunce, 2004; 
Clemons et al., 1998; Suh et al., 2003; Hestermann et al., 2000) to be a mixture of agonists, 
putative partial agonists and antagonists. They found that when assaying TCDD in the 
presence of a low concentration of this mixture, the mixture has partial agonistic properties 
although the data is not conclusive (Chu et al., 2001). 
Substitution of one of the chlorine atoms for bromine (either meta- or para-substituted) 
increased the length of the compound, which appears to have a significantly large effect on 
the potency of the compound to activate the AhR (in rat H4IIE cells). This effect was seen for 
PXB 105/PCB 105 however this substitution appears to have less impact on PXB 156/PCB 
156. PCB 156 was shown to have very weak antagonistic properties in human and thus would 
have a very limited effect on the TEQ. All of the mono-ortho-substituted PXBs were shown 
to be partial antagonists in rat H4IIE cells. A concentration of 1 µM PXB 105 was shown to 
reduce the potency of TCDD by 200-fold showing that the compound is a more potent 
antagonist than PCB 105 as a lower concentration had a larger antagonistic effect. A 
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concentration of 300 nM PXB 118 was shown to reduce the potency of TCDD by 6-fold 
making it equivalent to PCB 118 in terms of antagonistic potential. PXB 156 was shown to 
have potent antagonistic properties as a concentration of 100 nM PXB 156 reduced the 
potency of TCDD by 90-fold showing that the substitution of chlorine for a bromine atom 
(on position 4’) had no effect on the agonistic properties of the compound but had significant 
effect on the antagonistic potential.  
 
TEF = 0.00003 
 
REP = 0.00001 
Figure 4.4: The space fill structures of two mono-ortho-substituted PXBs - A) PCB 105 and B) PXB 105. The TEF was 
taken from Van den Berg et al. (2006) and the REP was calculated in this study. 
Figure 4.4 shows the structures of PCB 105 and PXB 105. Papers that investigate the 
structure activity relationships of PCBs generally use the same bond lengths for all of the 
compounds thus removing it as a potential explanation for the partial agonistic properties 
(Andersson et al., 1997) therefore the only remaining variable is the energy required to rotate 
between the C-C (between benzene rings). Andersson et al. (1997) predicted the internal 
barrier of rotation (Erot) for all of the PCBs including the ones used in this study. The results 
showed that only a low Erot was required for the non-ortho-substituted PCBs obviously due to 
the lack of chlorine atoms in the ortho positions. On the other hand the mono-ortho-
substituted PCBs required nearly 3-times as much Erot to rotate in the same way due to the 
effect of the ortho substituted chlorines. This extra energy required to rotate may mean that 
the molecule is not planar in its most relaxed state but is rather twisted as shown in Figure 
4.4. The effect of this twisting of the C-C (between benzene rings) appears be the reason that 
A B 
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these compounds have partial agonistic properties. To fully characterise the mono-ortho-
substituted PCBs, several different antagonising concentrations of the compounds would be 
required to do a schild analysis to calculate their Kd.  
4.4.4.2 Effect of partial agonists on the TEQ 
The TEQ system assumes that all of the compounds undergo additivity whereby all of the 
TEFs can be added together based on the exposure and potency of that particular compound. 
However the method does not take into consideration the antagonistic effects of these 
compounds which may actually reduce the potency of other pure agonists as shown in the 
antagonism studies in this project (Figure 3.17; Brown et al., 1994; Safe, 1994; Toyoshiba et 
al., 2004; Walker et al., 2005). As discussed in section 1.4.2.3, several authors recommend 
adjusted methods which take into consideration these partial agonistic (antagonistic) 
properties (Howard and Webster, 2009; Howard et al., 2010; Pohjanvirta et al., 1995; 
Toyoshiba et al., 2004; Walker et al., 2005). 
4.5 Species differences 
4.5.1 Comparing rat and human AhR 
The potency of a variety of AhR agonists was measured in rat and human cells to compare 
their potency across species. A general finding from this work and from previous literature 
(Budinsky et al., 2010; Xu et al., 2000) is that these compounds are approximately 10-fold 
less potent in human cells compared with in rat cells. Figure 4.5 shows the direct comparison 
of the EC50s calculated in rat and human. TCDD, 2-B-3,7,8-TriCDD and PCB 126 were all 
found to be ~10-fold more potent in rat than in human however PXB 126B was only ~7-fold 
more potent in rat, producing a high REP in human cells. The differing potencies are most 
likely associated with subtle differences in ligand binding domain of the two AhRs (Denison 
et al., 2002). Comparison of the amino acid composition of the whole AhR amino acid 
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sequence show some significant differences between the two proteins however it also shows 
only minor differences in the structure of the ligand binding domains which is not surprising 
considering the receptors are exposed to the same xenobiotics. A direct comparison of the 
amino acids making up the ligand binding domains of several species including rat and 
human has been published previously (Figure 1.3; Burbach et al., 1992; Crews et al., 1988; 
Hahn et al., 1997). One of the aims of this study was to understand the differences in AhR 
ligand potency between rat and human. This was investigated by attempting to directly 
compare between the two AhR proteins as these differences may be due to a variety of 
reasons such as AhR affinity or be dictated by chaperone proteins. 
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Figure 4.5: Comparison of a variety of AhR agonists in rat and human – Rat and human cells were treated with various 
concentrations of a variety of compounds to calculate their EC50s. The EC50s were then compared. The slope = 1.04 and the 
r2 = 0.993. Points are the EC50s ± Standard error. The compounds (left to right) are Chr-19, PCB 156, PCB 126, PCB 126B, 
TCDD, 2-B-,3,7,8-TriCDD and AZ1. 
Figure 4.5 shows that the human EC50 was on average 15-fold (7.2-fold – 29.4-fold) more 
potent than rat for all the compounds shown (based on the equation). The slope was 1.04 and 
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the r2 was 0.993 showing that all the compounds shown conform to this conclusion. Even 
comparing a variety of different compounds, with varying magnitudes of EC50, shows there is 
a relationship between the potency of the compounds at rat and human AhR.  
It is very difficult to compare levels of proteins between rat and human because they may not 
have same levels of normalisation genes. The levels of CYP1A1 or CYP1A2, which bind to 
dioxin-like compounds, may have an impact on the overall potency of these compounds in 
different species. Accurate comparison of these proteins between species may identify a 
contributing factor of species differences. One possible way of identifying these differences 
is by measuring the mRNA of these proteins against a large number of normalisation genes 
as it is difficult even to compare intra-species/inter-tissue levels of normalisation genes as the 
mRNA/genomic DNA levels can be different. 
4.5.2 Expression of AhR in mouse BpRc1 cells 
4.5.2.1 Construction of BpRc1 cells 
One of the aims of this project was to investigate the species differences of the mechanism of 
AhR activation between rat and human cell lines. In order to directly compare between the 
AhR proteins of rat and human it was necessary to measure them without the effects of the 
different (rat or human) mechanisms of action. For an accurate comparison of the two 
proteins they would need to be measured with the same back ground mechanism of action to 
allow direct comparison. There were no issues related to the production of the AhR 
containing pRevTRE vectors however transfection of the genes into the PT67 cells and 
infection of the virus into BpRc1 cells gave considerable problems and required several 
attempts over many months (resulting in only transient expression of AhR in cells). The main 
issue was that although colonies were selected after antibiotic treatment, the colonies turned 
out not to contain the vector of interest. This may be due to the vector not fully integrating 
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into the genomic DNA or simply that the antibiotic was not at a high enough concentration to 
kill all of the cells which did not contain the vector (resistance gene).  
Another consideration was that the His-tag could have been left on as an additional measure 
of gene translation. There are antibodies available for AhR but they are not specific enough 
to distinguish between the different species. A His-tag antibody was available and could have 
been used to identify the infected AhR using western blotting. Alternatively a GFP tag could 
have been used but this is quite large and may have interfered with the protein folding of the 
AhR. The 7500fast software uses a threshold to calculate the Ct to compare between samples. 
The mRNA comparison in Figure 3.36E assumes that the primers and probes for the three 
AhR genes work at 100% efficiency. The threshold was then set to the same level for all 
three genes (mouse, rat and human AhR). 
4.5.2.2 Comparison of controls for the infected BpRc1 cells  
Both Clemons et al. (1998) and De Hann et al. (1996) calculated an EC50 of 140 pM ± 130 
for Hepa1c1c7 cells treated with TCDD. Miller et al. (1983), who created the BpRc1 cell 
line, found that the basal and induced levels of CYP1A1 (AHH) were 10% and 20%, 
respectively, when treating the cells with 1 nM TCDD for 24 hours. In this study an EC50 of 
1.65 nM (95% CI = 1.12 nM – 2.44 nM) was calculated which was approximately 10-fold 
more than literature values in wild-type Hepa1c1c7 cells. 5F 203 was previously measured in 
rat H4IIE cells by Bazzi et al. (2009) who calculated an EC50 of 3 µM (95% CI = 1.3 µM – 
7.7 µM) in rat H4IIE cells, which was significantly higher than the value calculated in this 
study (wild-type rat H4IIE cells; 675 nM; 95% CI = 524 nM – 869 nM), and 2 nM (95% CI = 
0.9 nM - 5 nM) in human MCF-7 cells which was just higher than the value calculated in this 
study (wild-type human MCF-7 cells; 1.18 nM; 95% CI = 818 pM – 1.72 nM). The more 
interesting conclusion of this comparison of 5F 203 between rat and human is that the 
compound is a relatively weak agonist in rat H4IIE cells but very potent in human MCF-7 
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cells (almost equal to TCDD). This shows that this compound is a very useful tool when 
investigating AhR differences between rat and human. 
4.5.2.3 BpRc1 rAhR 
BpRc1 wild-type cells were infected with a vector containing the rat AhR gene. Although 
initial infection to produce a double stable cell line was unsuccessful, it was possible to infect 
cells for use in producing a cell line that transiently expressed rat AhR. Figure 3.34 and 
Figure 3.35A show that the pRevTRE vector, along with the rat AhR gene, was successfully 
infected into the cell nucleus. A separate experiment was conducted to show that the rat AhR 
gene was transcribed. Figure 3.36 shows that there are low levels of rat AhR mRNA, but 4-
fold less than the mouse AhR mRNA, which itself was at very low levels compared to wild-
type mouse AhR mRNA from Hepa1c1c7 cells. The BpRc1 rAhR cells treated with TCDD 
did not produce a statistically different EC50 from the wild-type BpRc1 cell line. However 
BpRc1 rAhR cells treated with 5F 203 did produce a response which was not seen in the 
wild-type cells. This would be substantial proof (three biological replicates with 10 nM 
TCDD) that the experiment has worked but that the expression of rat AhR was only very low 
compared with rat H4IIE wild-type cells. Confirmatory AhR protein evidence would be 
needed to substantiate this. 
4.5.2.4 BpRc1 hAhR 
BpRc1 cells were also infected with pRevTRE containing the human AhR. As with rat, 
creation of a stably expressing cell line failed but it was possible to infect the cells to produce 
a cell line that transiently expressed human AhR. Figure 3.34 and Figure 3.35B show that the 
pRevTRE vector, along with the human AhR gene, was successfully infected into the cell 
nucleus. To confirm that the human AhR gene was transcribed by the pRevTet-Off vector, 
measurement of CYP1A1 mRNA was conducted using qRT-PCR (Figure 3.36). The 
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experiment shows that human AhR was transcribed but only at very low levels (~1%) 
compared with mouse AhR (which was also at very low levels) and human AhR mRNA from 
MCF-7 wild-type cells. The BpRc1 hAhR cells were treated with TCDD and 5F 203 but the 
EC50 values for TCDD were the same as for BpRc1 wild-type cells (5F 203 gave no response 
in either cell line) which shows that the levels of human AhR were not sufficient to have an 
effect or is non-responsive under these conditions.  
4.5.3 Comparison of AhR-related proteins 
Although the most likely reason for the experiment not working was that there was not 
enough rat or human AhR expression in the cell lines, the ability of the mouse chaperone 
proteins to interact with the rat or human AhR may also have had an impact in the ability of 
the exogenous AhR to interact with the host mechanism. The similarities of the AhR and 
Arnt as well as the three chaperone proteins; Hsp90, p23 and XAP2 were compared between 
rat, human and mouse to see how closely related the proteins were. Table 4.6 shows the 
similarities between the three species. The values are only estimates based on a direct 
alignment of the three amino acid sequences. 
 AhR LBD Arnt Hsp90 p23 XAP2 
       Human vs. Mouse 68.7% 86.7% 91.7% 98.8% 98.7% 94.2% 
Rat vs. Mouse 86.1% 97.0% 94.1% 99.6% 100% 97.0% 
       
Rat vs. Human 71.2% 85.5% 90.0% 98.9% 98.7% 94.0% 
       
Table 4.6: Amino acid comparison – Comparison of similarities between proteins associated with the AhR activating 
mechanism based on direct comparison of their amino acid sequences. Gene Ids are shown in Table 2.2. LBD: AhR ligand 
binding domain, estimated from mouse AhR LBD (Fukunaga et al., 1995). 
The similarities between the full AhR amino acid sequences of rat and human were compared 
against mouse. Human and mouse had only a 68.7% idenity compared with rat and mouse 
which had an 86.1% identity. Comparison of the mouse LBD with the two other species 
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showed an even higher homology with 86.7% and 97.0%, for human and rat, respectively. 
However another important issue was the similarity between the chaperone proteins of rat 
and human compared with mouse. The Arnt proteins were relatively similar between all three 
species (90.0 - 94.1% similarity) as were the XAP2 proteins which had a very close 
homology between all the species (94.0 - 97.0% similarity). Hsp90 was highly conserved 
between all three species (>98.8%). p23 was also highly conserved between the three species. 
Rat and mouse shared a 100% similarity compared with human and mouse which had 98.7% 
similarity. Several researchers have shown the importance of p23 for enhancing the AhR 
complex (Cox et al., 2004; Kazlauskas et al., 2001; Shetty et al., 2002) however more recent 
research from Flaveny et al. (2009) used p23 null models to show that p23 was not crucial for 
ligand binding or AhR-related gene expression. It was therefore concluded that none of these 
chaperone proteins would have an unusually higher effect on the BpRc1 hAhR cell line 
compared with the rat version. Based on this comparison, the most likely explanation for the 
failure of this experiment was the lack of DNA successfully transfected into the cell resulting 
in low human AhR expression. In order to compare the AhRs between rat and human, a new 
method of comparison is required. The host cell line needs to be AhR null not just AhR 
deficient to remove background interference.  
4.5.4 Alternative method of comparing AhR 
Unfortunately the stable infection of BpRc1 cells was unsuccessful, most likely due to the 
low viral concentrations used in the experiment. Also an issue may be that the gene did not 
integrate properly with the nucleic DNA. An alternative method could have produced an AhR 
knockout or even better a gene exchange (Doetschman et al., 1987; Tarutani et al., 1997; 
Uren et al., 2000; Weiss and Green, 1967). A full knock-out would remove the background 
levels of AhR activation to allow a higher signal to noise ratio. A gene exchange (knock-out) 
could be produced by using recombination which would exchange the mouse AhR gene with 
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an antibiotic resistance gene along with either the rat or human AhR. Recombination would 
need to occur on both chromosomes to produce a gene exchange. 
 
 
Figure 4.6: Basic example of recombination – gene of interest is cloned into a vector containing the 5’ and 3’ flanking 
regions of the gene to be replaced. The vector also contains a selectable marker. Recombination takes place and the gene of 
interest is integrated into the genome of the mouse cell line and is then selected producing a pure stock. 
This would have used a similar method to the one used in this project. Selection would have 
left mouse cell lines with no mouse AhR, replaced instead with rat or human AhR. There are 
AhR null mice available (Fernandez-Salguero et al., 1995, 1996; Gonzalez et al., 1995; 
Lahvis and Bradfield, 1998; Vasquez et al., 2003) so a primary culture could have been 
conducted as a replacement for the AhR-deficient Tao BpRc1 cell line.  
5. Conclusion 
A method of quantifying the agonistic and antagonistic properties of various AhR ligands 
was optimised and applied to a family of potent AhR agonists (AZFMHCs) and a known 
antagonist, CH223191. This study identified the highest known affinity, high potency ligand 
of the AhR, AZ1. The compound has been shown to be 5-10-fold more potent than TCDD at 
inducing CYP1A1 in two species and over several AhR-mediated genes. AZ1 is a synthetic 
AhR agonist and thus is not of environmental concern (although there is the possibility of 
occupational exposure; Mackenzie and Brooks, 1998) however it could be a very useful 
compound to help advance our understanding of the mechanism of AhR activation and 
provide further insight into the structure-activity relationships. This study also successfully 
TARGETING CONSTRUCT 
GENOME 
3’ flanking region 5’ flanking region 
Rat/human AhR gene Selectable marker 
Mouse AhR gene 
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used Schild regression to characterise the AhR antagonist, CH223191 showing that it is a 
potent AhR antagonist.  
The structure-activity relationships of several families of compounds were investigated to 
improve our understanding of the requirements for binding and of an AhR ligand to be an 
agonist or antagonist. Many of the novel 2-amino-isoflavones described in this study were 
not only active ligands (agonists/antagonists) of the AhR, but they also produce unusual 
species differences in response. These analyses have shown that even the slightest 
substitutions in chemical structure can significantly alter not only the potency of the 
compound but also its antagonistic potential. Both Chr-13 and Chr-19 could be useful tools 
when investigating the mechanism responsible for ligand-dependent species differences in 
the activation of the AhR. Perhaps more relevant to risk assessment, the PXDDs investigated 
in this study were found to have a lower potency than their fully chlorinated congeners 
whereas the PXDFs and PXBs tested were shown to be of higher potency. Several 
compounds of notable interest were identified such as 2-B-3,7,8-TriCDD which was found to 
be 2-fold more potent than TCDD at activating rat and human AhR. 2-B-1,3,7,8-TetraCDD 
and 2,3-DiB-7,8-DiCDF were also found to be under 2-fold less potent than TCDD 
demonstrating the potential impact these compounds could have on the total toxicity of a 
mixture. 
This data can now be used for the next generation of TEQ measurement and estimation 
although further work will be required to decide which compounds should be included in the 
TEQ as there are several thousand congeners of dioxin-like compounds when including the 
various mixed halogenated compounds. The potency data, together with occurrence data, 
should help inform regulators which compounds should be measured in environmental and 
food samples for purposes of risk assessment which should result in better estimate of our 
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overall exposure to AhR agonists. With regards to the current WHO TEFs, this study has 
shown that PCB 105 and PCB 118 are essentially antagonists at all but the highest of 
concentrations and therefore suggests their TEFs should be decreased. Consideration should 
be taken regarding the antagonistic properties of the PCBs and PXBs in relation to their 
ability to reduce the potency of other more potent AhR agonists. The TEF of PCB 156 should 
be increased to take account of the increased potency (based on previous literature) but care 
must be taken to measure for any contamination in the stocks of these compounds which may 
impact the overall potency, before including them in the TEF meta-analysis. 
In terms of species differences between rat and human, an estimated 15-fold reduction in the 
potency of these compounds to activate human AhR was observed in all of the compounds 
tested in this study. Unfortunately attempts to directly compare between the two AhRs did 
not fully succeed but the study did demonstrate the potential of the virus-based experiment to 
work, if the levels of infected exogenous AhR are high enough to have an impact on the 
cellular response. The study also identified a more promising alternative method which 
should eliminate the background mouse AhR response allowing a more accurate comparison 
of the infected AhRs. During this study, 5F 203, was once again shown to be significantly 
more potent in human (equal to TCDD) than in rat highlighting its usefulness in species 
comparison. 
In conclusion, the data derived in this study will help to improve our overall understanding of 
the mechanism of AhR activation by environmental pollutants and allow more focused risk 
assessment on these compounds. 
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